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The cornea is the front part of the eye and its clarity depends on both ocular surface 
health and tear film integrity. In many common ocular diseases such as dry eye and 
recurrent corneal erosion, wound healing is deranged. Transglutaminase (TG)-2 is a 
ubiquitous multi-functional protein known to affect skin wound healing but has not been 
evaluated on cornea surface. This work aims to evaluate the functions of TG-2 in 
mitochondrial mediated apoptosis, protein interactions and trafficking, as well as corneal 
epithelial wound closure.  
 
Increase in tear osmolarity has been associated with dry eye and ocular surface disorders. 
Hyperosmolar stimulation in cultured human corneal epithelial (HCE-T) cells induced a 
significant increase in mitochondrial potential, accompanied by reduced proliferation. 
Transient overexpression of TG-2 increased cellular transamidase activity and reduced 
viability. Importantly, in contrast to vector alone transfection, TG-2 overexpression has a 
higher proportion of mitochondrial depolarisation, accompanied by increased caspase 3/7 
and 9 activity. About 48% of hyperosmolar-induced mitochondrial depolarisation is TG-2 
dependent in HCE-T cells. 
 
Several TG-2 binding proteins with known wound healing functions were identified and 
their distribution was evaluated using novel centricollation technology. The binding 
partners’ concentrations were studied in human corneal epithelial cells expressing short 
hairpin RNA against TG-2 (shTG) and scrambled sequence shRNA (control shRNA). 
TG-2 deficiency decreased the expression levels of specific organelle markers, such as 
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late endosomes (RAB7), recycling endosomes (RAB11A) and secretory vesicles 
(RAB27A), as well as the expression of some binding proteins such as Golgi-associated 
protein (GOLGA2), which may cause preferential accumulation in other subcellular 
compartments. TG-2 levels may indirectly regulate cell adhesion and migration via the 
trafficking of these proteins and alteration of organelle functions. 
 
Cell migration, proliferation and adhesion are crucial components of epithelial wound 
closure. shTG cells have reduced impedance compared to control cells. There was no 
significant difference between shTG and control cells in spreading areas on non-
fibronectin substrate, the proportion of proliferating cells and cell cycles. shTG cells 
detached faster, showed decreased Rho protein activities and migrated significantly 
slower compared to control cells. Consistent with in vivo findings, TG-2 deficiency 
delayed the closure of the scratched wound. ShTG showed reduced phosphorylation of 
adhesion proteins at specific residues; the reduction of phosphorylation at S178 paxillin 
was the most notable since it was previously discovered to be crucial for adhesion and 
migration in human corneal epithelial cells. TG-2 cannot directly phosphorylate paxillin, 
and JNK1 was found to be the possible kinase candidate. However, TG-2 cannot directly 
recruit JNK1, and contrary to previous reports on human neuroblastoma cells, TG-2 
cannot indirectly recuit JNK1 through DLK in human corneal epithelial cells. Hence, 
JNK1 may mediate serine phosphorylation of paxillin through an unknown kinase in a 




In conclusion, these studies suggest that TG-2 is important in the modulation of cell 
stress, protein trafficking, cell adhesion and migration in corneal epithelial cells. 
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CHAPTER 1. INTRODUCTION 
1.1 The Ocular Surface  
1.1.1 Structure and Functions of Corneal Epithelium and Tear Film 
The cornea is the transparent front part of the eye and its clarity is important for vision. A 
healthy cornea and an overlaying tear film form the major anterior refractive surface of 
the eye, accounting for 75% of the total refractive power [1, 2]. The outermost surface of 
the cornea consists of 4 to 5 layers of stratified, non-keratinising squamous epithelium, 
which functions as a protective barrier to the external environment [1]. This corneal 
epithelium is around 50µm in thickness and is morphologically divided into three layers: 
bottom basal cell layer, middle wing layer, and outermost superficial or squamous cell 
layer [3]. Basal cells are the germinative layer of the epithelium which migrate anteriorly 
and differentiate into wing cells and superﬁcial cells [3, 4]. The outermost superficial 
cells have microscopic projections which can increase the contact area and adherence 
between the overlaying tear film and the cells [5]. Like the rest of the epithelial cells in 
the body, the corneal epithelium is in a constant state of turnover, which is approximately 
every 7 days [4]. Superficial epithelial cells are continually shed into the tear pool, with 
the deeper cells slowly replenishing the desquamating superficial cells [1, 3]. This rapid 
turnover of cells is crucial to maintain a healthy and intact corneal epithelium structure, 
so that worn, injured or infected epithelial cells can be discarded within a short period of 




The tight junction between laterally adjacent superficial cells contributes to the corneal 
epithelium’s barrier function, preventing potentially harmful substances from entering the 
eye [6]. Corneal epithelial barrier function is disrupted in majority of the ocular surface 
disorders which affect vision, such as dry eye [3], corneal infection [7], corneal ulceration 
[8], and scarring or melting of the corneal stroma [9]. Untreated dry eye patients showed 
2.7-3 times more corneal epithelial permeability compared to patients with normal tear 
function [10]. The integrity of the barrier function in dry eye patients can be clinically 
measured by the increased permeability of the corneal epithelial to fluorescein dye [10]. 
Besides tight junction, corneal epithelial barrier function is also dependent on the 
integrity of the ocular surface tear film [1]. 
 
Ocular surface and tear secreting glands work together as a functional unit to maintain the 
clarity of the cornea [10]. The surface of the cornea must be kept lubricated to prevent 
damage to the underlying epithelium. This is achieved by the spreading of a thin layer 
(7µm thick) of tear film over the epithelium through blinking to smoothen and lubricate 
the cornea [4]. The tear film, composed of lipid, aqueous and mucin layers, functions as a 
mechanical and antimicrobial barrier [11, 12]. Lipid layer secreted by the meibumian 
gland stabilises and retards evaporation of the aqueous layer, thus prevents drying of the 
corneal epithelium between blinks [11]. The mucin in the tear film lubricates the ocular 
surface, hence minimising the friction exerted by the eye lid during blinking as well as 
ocular rotational movements [11, 12]. Tear film supplies nutrients, oxygen, 
immunological and growth factors essential for the growth, proliferation and repair of the 
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epithelial cells. It also helps to maintain a smooth anterior surface for light refraction [2, 
11].  
 
1.1.2 Ocular Surface Diseases 
The clarity of the cornea depends on both the health of the ocular surface and the 
integrity of the tear film [10]. Ocular surface diseases are disorders affecting the surface 
of the cornea. The ocular surface is densely innervated with sensory nerves; patients 
suffering from ocular surface diseases often display a variety of symptoms, such as 
dryness, discomfort, infection, erosion, ulceration and scarring [6]. In severe cases, vision 
can be affected. Common ocular surface diseases include dry eye, blepharitis, pterygium, 
recurrent corneal erosion, chemical and thermal injuries, scarring and immunological 
conditions such as Sjogren’s Syndrome. In many of these ocular diseases, wound healing 
is deranged. 
 
Altered tear production associated with dysfunction of the lacrimal functional unit can 
show an unstable, proinflammatory tear film, and may promote ocular surface 
inflammation and apoptosis [10]. This can lead to a common ocular surface epithelial 
disease known as lacrimal keratoconjunctivitis (LKC), or commonly known as dry eye 
disease. Dry eye is a multi-factorial disease affecting tear film and ocular surface through 
increased osmolarity of tear film and inflammation of the ocular surface [13]. 
Evaporative dry eyes and aqueous deficient dry eyes are two major classes of dry eye 
disease; with evaporative dry eye being the more prevalent form of dry eye in Asia [13]. 
Dry eye disease affects millions of people with an estimated prevalence as high as 11–
20 
 
22% in the population [14]. It is characterised by symptoms ranging from mild 
discomfort to dryness, grittiness, foreign body sensation and visual disturbance [15]. Dry 
eye disease also lowers the patients’ quality of life by adversely affecting their daily 
activities.  
 
Patients who suffer from dry eye syndromes are more likely to develop recurrent corneal 
erosions (RCE) in the corneal epithelium [16]. RCE is a condition characterised by 
repeated epithelium breakdown due to defective adhesion of epithelial cells to the 
underlying membrane [17]. This kind of corneal epithelial defect must be rapidly restored 
to avoid infection and further damage to the corneal tissue. The migration of the corneal 
epithelial cells underpins the early phase of corneal wound healing as well as other ocular 
diseases [18, 19]. 
 
1.1.3 Current Treatment Options for Ocular Surface Diseases 
Ocular surface disorders such as dry eye, persistent epithelial defects, recurrent corneal 
errosions et cetera can cause great discomfort to the patients. If these conditions are left 
untreated, patients usually develop corneal opacification caused by fibrosis, which 
eventually lead to irreversible loss of vision. Corneal transplantation would have to be 
performed as a last resort to restore vision. Vision corrective surgeries such as LASIK 
(laser in situ keratomileusis) are very popular nowadays. Hence, the importance of 
corneal wound healing has also gained attention. Due to the unique requirement for 
transparency in the cornea, the understanding of wound healing responses to restore 
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visual acuity without causing scarring continues to remain a key challenge. This 





1.2 Transglutaminase-2  
1.2.1 TG-2 Expression and Its Regulation of Activities 
Transglutaminase (TG)-2, also known as tissue TG, is a 76-85kDa monomeric protein 
with distinct and reciprocally regulated transamidation function [20]. TG-2 is a 
ubiquitous protein, with almost all mammalian cells expressing this enzyme to varying 
extent [21]. This wide spread occurrence is due to its constitutive expression in 
ubiquitous cell types: endothelial cells, smooth muscle cells and other organ specific cells 
such as mesangial, colonic pericryptal fibroblasts and renomedullary interstitial cells [21, 
22]; whereas in other cell types such as human peripheral blood monocytes, TG-2 
expression can be induced by a variety of stimuli such as treatment with retinoic acid [23, 
24].  
 
Human TG-2 has four distinct domains, which are evolutionary conserved among all the 
other TGs: an N-terminal β-sandwich, an α/β catalytic core and two C-terminal β-barrel 
domains [25]. In the presence of Ca
2+
, TG-2 catalyses post-translational modification of 
protein by forming isopeptide bond between the γ-carboxyamide group of protein bound 
glutamine residues and the primary amine group of either protein-bound lysine residue or 
a polyamine [26]. The resulting cross-linked proteins form stable complexes thus 
increasing their resistance to degradation [23]. The presence of Ca
2+
 is essential for the 
TG-2 transamidase activity as its binding changes the TG-2 conformation and exposes 




Human TG-2 gene (designated as TGM-2) is mapped on chromosome 20q12. TGM-2 
comprises of 13 exons and 12 introns spanning across 32.5 kilobases [28]. TG-2 is 
perhaps the most intriguing member in the mammalian TG superfamily which consists of 
TG-1 to 7, factor XIII and band 4.2. What distinguishes TG-2 from other family members 
are its non-transamidation functions. These include intracellular G-protein signalling, 
protein kinase activity, integrin binding co-receptor for fibronectin, extracellular protein 
disulphide isomerase (PDI) activity and other non-enzymatic functions [29]. TG-2 has 
been reported to participate in important biological processes such as wound healing [30], 
apoptosis [31], inflammation [32], cancer progression and metastasis [33, 34]. 
 
TG-2 is predominantly a cytosolic protein with 70-80% of its cellular pool present in the 
cytoplasm, while a small fraction is localised in the nucleus and mitochondria; no TG-2 is 
detected in endoplasmic reticulum (ER) and golgi apparatus [35]. Depending on cell 
types, around 10-20% of TG-2 is secreted extracellularly and localised to plasma 
membrane and extracellular matrix (ECM) [36]. Interestingly, TG-2 lacks an amino-
terminal hydrophobic leader sequence and therefore cannot be externalised through the 
classical ER/golgi dependent secretory pathway [23]. The exact mechanism by which 
TG-2 is secreted remains elusive, however a recent study suggested that cytosolic TG-2 is 
recruited into perinuclear recycling endosomes prior to externalisation [37].  Another 
study reported that in renal tubular epithelial cells, a specific sequence in the TG-2 N-




TG-2 is the only member among the TG family that can bind and hydrolyse guanosine-5'-
triphosphate (GTP), acting as a classic G-protein which regulates signal transduction 
[39]. The enzymatic activity of TG-2 is reciprocally regulated by the binding of Ca
2+
 and 
GTP, which causes conformational changes in TG-2 and inhibits its GTPase or 
transamidation functions respectively [23, 40]. Inside the cells, the Ca
2+
 concentration is 
low in the cytoplasm, hence TG-2’s transamidating activity remains dormant and it 
functions as a GTPase [40]. However, this latent form of cytosolic TG-2 activity can be 
activated by increasing the intracellular Ca
2+
 concentration, either from intracellular 
stores or influx of extracellular Ca
2+
 [27, 41].  
 
1.2.2 TG-2 Plasmids 
Obtaining cDNA clone for a particular protein is vital for the expression of this specific 
desired protein in genetic engineering. The physiological functions of TG-2 can be 
studied through introduction of a constitutively expressed TG-2 plasmid in cultured cells. 
Ikura et al had first cloned TG-2 from guinea pig liver, followed by the successful 
isolation of full-length cDNA clones for human TG-2 by Gentile’s group [42, 43]. They 
reported that the isolated human TG-2 cDNA clone consisted of 5’untranslated sequence, 
coding domain, 1058 nucleotides of 3’untranslated sequence, but lacked a consensus 
polyadenylation sequence [42]. This clone was 3.3kb and had a molecular weight of 
77,253. Gentile et al then constructed an expression vector of human TG-2 by inserting 
the TG-2 cDNA into pSG5 eukaryotic expression vector containing a SV-40 early gene 
promoter and polyadenylation signal sequence (Appendix A, Figure A3) [44]. The 
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successful isolation and characterisation of human TG-2 cDNA clone opened the 
pathway to study the physiological functions of human TG-2.  
 
1.2.3 Animal Models 
To study the in vivo functions of TG-2, two different strains of TGM-2 knockout mouse 
models had been established by independent groups. Melino group replaced part of exon 
5 and all of exon 6 in the catalytic core domain of TGM-2 with a neomycin resistance 
gene [45]. The other mouse model generated by Graham’s laboratory inserted loxP sites 
into introns 5 and 8, flanking exons 6-8, which would inactivate both TGM2 alleles after 
cross-breeding with animals expressing Cre-recombinase [46]. The homozygote 
progenies of both mouse models showed no expression of TG-2 protein. Since TG-2 is 
ubiquitously expressed with diverse functions, it was surprising that the homozygous 
knockout of TGM-2 gene did not produce an embryonic-lethal phenotype [45]. The 
homozygous null animals of TG-2 were phenotypically normal at birth and born with 
expected Mendelian ratios. This lack of serious phenotypes may be explained by the 
compensation of other TGs present in the mammalian tissue [47]. However, alterations 
were expected in these TG-2
-/-
 mice since the other mammalian TGs did not bind 
GDP/GTP and they were absent on the cell surface (except FXIIIa). Preliminary 
evidences reported that these TG-2 null mice, especially under certain pathological 
conditions and stresses, showed altered fibroblast function in attachment and motility, 
impaired wound healing, defective phogocytosis clearance of apoptotic cells, as well as 
mild glucose intolerance and hyperglycaemia, consistent with the suggested functions of 
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TG-2 [44, 48, 49]. To date, no confirmed TG-2 deficiency has been reported in humans, 










1.3 Transglutaminase-2 and Cornea 
1.3.1 TG-2 Localisation in Cornea  
TG-2 activities are present in almost all human ocular tissues with different degree of 
expression [30]. Immunohistochemistry has shown that in the human cornea, TG-2 is 
expressed in the corneal epithelium, keratocytes and the corneal endothelium [30]. In the 
corneal epithelium, biotin-labelled cadaverine incorporation and immunohistochemistry 
has shown that TG-2 is predominantly found along the basement membranes, and also 
within the intercellular spaces and in the cytoplasm of the epithelial cells [50, 51]. In 
vitro, western blotting also showed that TG-2 was present in immortalised human corneal 
epithelial cells [52].  
 
1.3.2 The Role of TG-2 in Ocular Surface Diseases 
TG-2 has been reported to play an important role in various ocular surface inflammation 
and wound healing diseases such as allergic conjunctivitis [53], glaucoma [54] and 
pterygium [55]. These eye conditions not only cause morbidity such as pain and 
discomfort, but also affects the transparency of the cornea, leading to permanent loss of 
sight thus affecting the quality of life [56]. The involvement of TG-2 in ocular surface 
inflammation has been demonstrated by the success of using TG-2 inhibitor in the 
treatment of allergic conjunctivitis in guinea pigs [53]. In glaucoma, the role of TG-2 is 
supported by both in vitro and in vivo studies. Wordinger’s group reported that there were 
more TG-2 proteins and enzyme activity detected in cultured human glaucomatous cells 
compared to the normal control cells [57]. This was further supported by another study 
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which showed the presence of functionally active TG-2 in the scarring bleb of failed 
glaucoma filtration surgery patients [54]. Moreover, our group showed that there are 
aberrant DNA methylations on TG-2 promoter of excised pterygium tissues, compared to 





1.4 Transglutaminase-2 and Wound Healing 
1.4.1 TG-2 Binding Partners and Adhesion Signalling 
Extracellular TG-2 is known to interact with the ubiquitous and abundant ECM proteins, 
including fibronectin, collagen, vitronectin, osteopontin, et cetera. Among these ECM 
substrates, the binding of TG-2 to fibronectin (Fn) is characterised best. During wound 
repair, Fn provides a provisional matrix prior to collagen deposition for cell adhesion, 
migration and proliferation [18].  It has been reported that in normal rabbit cornea, 
fibronectin was only detected at decemet’s membrane, but soon after wounding, 
fibronectin was detected on the denuded corneal surface. This deposited fibronectin 
helped the migration of the epithelium to cover the denuded area [59]. Most of the 
extracellular roles of TG-2 that affect early wound repair involves its interaction with Fn 
[60]. TG-2 binds to the 42-kD gelatin-binding domain of Fn which lacks both the 
integrin-binding sites and RGD motif (Arginine-glycine-aspartate) [61, 62]. This binding 
occurs in a stochiometric ratio of 2:1 with high affinity (Kd 8-10nM) and does not require 
its transamidase crosslinking activity [63, 64]. The high affinity interaction between 
extracellular TG-2 and Fn mediates cell-matrix adhesions and enhances other adhesion-
related phenomena such as cell migration, ECM assembly and remodelling [65, 66]. 
Studies have showed that Fn protects cell surface TG-2 from proteolytic degradation, 
hence supporting cell adhesion and migration [67]. On the contrary, there are numerous 
studies which suggest that the crosslinking and polymerisation of Fn with cell surface 
TG-2 is linked to cell adhesion. In osteoblasts and human umbilical vein endothelial 
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cells, it has been demonstrated that the crosslinking of Fn by extracellular TG-2 
significantly promotes cell adhesion and increases β1 integrin clustering [68, 69].  
 
Besides binding to Fn, extracellular TG-2 non-covalently interacts with β1, β3 and β5-
subunits of the integrin family [70-72]. It is estimated that up to 40% of β1 integrins on 
the cell surface are associated with TG-2 and all extracellular TG-2 are complexed with 
integrins in a 1:1 ratio [29]. The precise mapping of the interaction site of TG-2 and 
integrin remains elusive. TG-2-integrins interaction is a direct interaction not mediated by 
Fn and is independent from the TG-2 transamidase activity [40]. It is well known that Fn 
can interact with integrin α5β1 through its 29-kD Fn domain containing RGD motif [73]. 
However, integrins have low affinity for ECM proteins, even for the ubiquitous Fn [29]. 
This relatively weak affinity of integrin-Fn association together with the stable 
interaction of TG-2-integrins and TG-2-Fn suggest that extracellular TG-2 may act as an 
integrin-associated adhesion co-receptor for Fn [29, 74]. All the three proteins in this 
ternary complex are able to interact with each other thus contributing to increased cell 
adhesion and spreading. Since both extracellular TG-2 and integrin can independently 
bind to different domains of Fn (42-kD and 29-kD respectively), therefore they are more 
collaborating in cell adhesion rather than acting as competitors.  
 
Apart from strengthening the cell-ECM adhesion, cell surface TG-2 can potentiate 
outside-in signalling by promoting integrin clustering on the cell surface, even in the 
absence of Fn [75]. The TG-2-integrin complexes have been shown to activate multiple 
downstream intracellular pathways and signalling targets, such as focal adhesion kinase 
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(FAK) and PI3K/Akt survival pathway, RhoA GTPase and its downstream target Rho-
associated coiled-coil containing serine/threonine protein kinase  (ROCK), leading to the 
formation of focal adhesions, actin stress fibers and increased actomyosin contractility 
[35, 75].  
 
Heparan sulphate proteoglycan (HSPG) syndecan-4 is a recently discovered binding 
partner of extracellular TG-2. Among the four mammalian syndecans, only syndecan-4 is 
ubiquitously expressed and present in focal adhesions [76]. Syndecan-4 interacts with the 
heparin binding domains of Fn and supports the formation of actin cytoskeleton [77]. A 
report by Telci et al in 2008 revealed that the interaction between syndecan-4 and 
extracellular TG-2 could be important during tissue injury or wound healing [77]. They 
found that syndecan-4 interacted with Fn-associated TG-2 and activated protein kinase 
Cα (PKCα), followed by the binding of β1 integrin [77]. These initiated a cascade of 
signalling events leading to the formation of focal adhesion, actin cytoskeleton 
reorganisation and the activation of survival kinase pathway. This TG-2-mediated RGD- 
independent cell adhesion may be significant in wound healing, where the presence of 
RGD peptides due to ECM breakdown may act as a competitive inhibitor, causing loss of 
cell adhesion and anoikis [76, 77]. Under these circumstances, Fn bound TG-2 would be 
able to rescue cell adhesion and facilitate wound repair by binding to cell surface heparin 




Figure 1.1. Diagram showing functions of transglutaminase (TG)-2 in cell matrix 
adhesion. (A) In the extracellular matrix environment, TG-2 non-covalently binds to 
fibronectin (green bars). Using its heparin sulfate chain, syndecan-4 helps to bring TG-2-
bound fibronectin close together, thus TG-2 is able to cross-link with more neighboring 
fibronectin molecules, increasing the matrix stiffness. (B) There are multiple domains on 
fibronectin (not shown) which can interact with either TG-2 or integrin. As a co-receptor 
of β1 or β3 integrins, TG-2 can bind non-covalently to fibronectin, recruiting downstream 
focal adhesion proteins, leading to cytoskeleton reorganization and/or downstream 
signaling. (C) TG-2 functions as a G protein. GDP bound TG-2 is inactive. The binding 
of agonist (red sphere) activates the transmembrane α1B-adrenergic receptor (α1B), 
which then regulates the activation of phospholipase Cδ1 (PLCδ1), which can hydrolyse 
phosphatidylinositol diphosphate (PIP2) to produce inositol-1,4,5- trisphosphate (IP3) 
and diacylglycerol (DAG), which have important role in cell signalling pathway through 




1.4.2 TG-2 in Wound Healing  
The significance of extracellular TG-2 goes beyond cell adhesion and spreading; TG-2 is 
involved in wound healing. Wound healing is an intricate and dynamic process that aims 
to restore the function and integrity of the damaged tissues after injury [78]. Wound 
healing processes involve 3 major components: cell migration, cell proliferation and cell 
adhesion [18]. It includes continuous interaction of multiple cell types and an array of 
signalling peptides, proceeding in overlapping stages which consist of inflammation, 
proliferation and remodelling [78]. However, wound healing is never perfect. TG-2 
activities are found to increase with the formation of scar tissue [79]. The formation of 
non-functional scar tissue may have functional or aesthetic consequences [80]. 
 
Accumulating evidences have reported the involvement and importance of TG-2 in 
wound healing processes, particularly in dermal wound healing [81, 82]. An early dermal 
wound repair study in rats by Bowness et al reported the increase in transglutaminase 
activity at the wound healing sites [81]. Another study reported that TG-2
–/–
 mice showed 
delayed skin wound healing compared to their wild type counterparts [82]. At cellular 
level, Upchurch et al reported that TG-2 was found to localise in ECM after the 
wounding of embryonic human lung fibroblast cells, and these TG-2 persisted around the 
wound site for many hours [83]. TG-2 has been implicated in different phases of dermal 
wound repair. Haroon et al reported that early in the skin wound healing process, TG-2 
was elevated in migrating keratinocytes, infiltrating macrophages and skeletal muscles 
cells [84]. Raghunath et al discovered that TG-2 was expressed in dermo-epidermal 
junctions [85]. In this study, TG-2 was found to cross-link the anchoring fibrils and may 
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have a role in maintaining the stability of the dermo-epidermal junctions. They even 
suggested that TG-2 might play a role in attaching the epidermal layer to the dermo-
epithelial junction [84, 85]. The migration of endothelial and inflammatory cells into 
fibrin is an indispensable part of the skin wound repair process. It has been demonstrated 
that the macrophages expressing TG-2 invade the fibrin clot to stabilise the fibrin 
network. This ability of TG-2 to stabilise the provisional fibrin and resist proteolytic 
degradation may play an important role in orchestrating the tissue repair. A definitive role 
of TG-2 in tissue repair has been shown by the impaired skin wound healing in TG-2 
knockout mice. This delayed wound closure can be rescued by external application of 
TG-2 to the wound site [82].     
 
In fact, the kinetics and distribution of TG-2 in ocular surfaces are not that dissimilar to 
those in the skin [51]. This similarity is crucial because the role of TG-2 in in vivo dermal 
wound healing has been extensively studied, and may provide insights to the role of TG-2 
in corneal epithelial wound healing. Cornea, like skin and other tissues in the body, is 
susceptible to frequent insult and wounding encountered in daily life. Most corneal 
epithelial wounds are repaired promptly and healed within 2 days from an injury [30]. 
TG-2 helps to stabilise the ECM at the wound site to promote corneal epithelial wound 
healing.   
 
Zhang et al reported that TG-2 was strongly up-regulated in the early wound healing 
process in rat cornea, especially in actively migrating corneal epithelial cells and stromal 
fibroblasts [30]. The ability of TG-2 to stabilise the fibrin network in skin inspired Zhang 
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et al to suggest that corneal keratocytes or inflammatory cells may produce TG-2 to 
create a provisional matrix in the stroma for the migration of cells [30]. Recently, this 
hypothesis has been confirmed by another study which showed that TG-2 was indeed 
required for the crosslinking of the fibrillar collagen in the stroma [86]. The common 
phenomenon of scarring, which is frequently present during tissue wound healing, is to 
be avoided in corneal wound healing. This is because scarring and edema can affect the 
clarity and transparency of the cornea, leading to loss of sight. Irreversible crosslinking 





1.5 Focal Adhesion Proteins and TG-2 
Focal adhesions (FA) are multi-protein structures that provide the mechanical link 
between actin cytoskeleton and underlying extracellular matrix. This interaction enables 
cells to interact with their surrounding environment and to regulate various cell 
behaviours such as cell adhesion, proliferation, survival, differentiation and migration 
[88].  
 
The initiation of FA formation occurs upon the binding of ECM ligands to integrin, 
followed by subsequent integrin clustering [89]. This leads to the sequential recruitment 
of various adaptor and signalling proteins such as talin, paxillin, vinculin, focal adhesion 
kinase (FAK) et cetera, forming large intracellular protein complexes at the integrin tails 
[90]. FA acts as a structural link between the ECM and the actin cytoskeleton which 
coordinates the transmission of downstream signals [91]. The assembly of FA is 
regulated by the Rho GTPase family of GTP-binding proteins such as RhoA, Rac1 and 
Cdc42 [91]. They regulate actin organization, cell contractility, lamellipodia and 
filopodia formation, membrane ruffling  as well as cell polarity [92]. Several literatures 
have shown that TG-2 was involved either directly or indirectly in the regulation, 
activation or signalling of several adhesion proteins [29, 71, 75].  
 
1.5.1 TG-2 and Paxillin  
Paxillin is a 68 kDa adaptor protein containing several protein-binding sites important for 
the coordinated recruitment of a diverse range of adaptor and signalling molecules, 
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leading to the sequential activation of other proteins [89]. Paxillin is indispensable as 
research has shown that the deletion of paxillin gene in mice is lethal in early embryonic 
development stage [89]. This early termination in embryonic development might be due 
to defective cell migration and cell spreading, as demonstrated by the paxillin-deficient 
fibroblasts cells [93].  
 
Paxillin has multiple phosphorylation sites at serine, threonine and tyrosine [94-96]. 
These phosphorylation sites are targeted by various kinases activated by wide array of 
stimuli such as growth factors and cell adhesion signalling. The phosphorylation of 
paxillin at specific amino acids has been associated with the recruitment of other 
signalling molecules into the complex, thus mediating the formation of focal adhesion 
and stress fibers, leading to cell adhesion and migration [95].  
 
Paxillin consists of two main structural domains: the amino (N) terminus and the 
carboxyl (C) terminus. The paxillin’s C-terminal contains four LIM (Lin-11, Isl-1, Mec-
3) domains (LIM1–4), which are zinc-finger motifs that can mediate protein-protein 
interactions [89]. It has been reported that phosphorylation on serine and tyrosine 
residues in paxillin LIM2 and LIM3 domains localises paxillin to the focal adhesions, 
regulating maturation and turnover of the focal adhesions [94]. On the other hand, the N-
terminus of paxillin consists of a leucine-rich motif with the consensus sequence 
LDXLLXXL, known as LD motifs (LD1-5) [93]. These LD motifs play an important role 
in the recruitment of signaling molecules as well as to function as binding sites for other 
proteins such as vinculin, FAK and E6 oncoprotein from papilomavirus [97, 98]. Hence, 
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it is not surprising that the phosphorylation of these LD motifs is related to the 
recruitment of downstream signalling molecules. For example, Nayal et al reported that 
the phosphorylation of paxillin on serine273, which lies within the LD4 domain, could 
regulate Rho GTPase signaling, thus controlling downstream signalling to the 
cytoskeletons [93, 99].  
 
Although the phosphorylation of paxillin is commonly studied on its tyrosine residues; 
paxillin is also heavily phosphorylated on its serine residues during cell adhesion [100].  
Serine178 is one of the key serine residues located within LD2 and LD3 motifs of 
paxillin [100], and may have an important role in signalling. Kimura et al reported that 
when Ser178 in paxillin was mutated to Ala178, an amino acid that could not be 
phosphorylated, they observed disrupted cytoskeletal remodeling, cell migration and 
adhesion in cultured human corneal epithelial cells [101]. This showed that the 
phosphorylation of Ser178 paxillin was important for cell adhesion and migration. 
Currently, there is no known interaction between TG-2 and paxillin. Furthermore, our 
laboratory reported a novel observation that lesser phosphorylated Ser178 paxillin were 
detected at the advancing edge of wounded corneal epithelium in TG-2 knockout mouse 
(TG-2
-/-
) compared to the wild type mouse (TG-2
+/+
). This in vivo data suggested that 
TG-2 may be involved in the phosphorylation of Ser178 paxillin in mouse corneal 












cornea 4 hours and 120 hours after scratching. Immunofluorescence staining was 
performed using antibody against phosphorylated Ser178 paxillin, followed by FITC-
conjugated secondary antibody (green). Nuclei were stained with DAPI (blue). Red 
arrows indicate the corneal epithelium wound edge; white arrows indicate the margin 





1.5.2 TG-2 and Other Focal Adhesion Proteins 
As mentioned earlier in this introduction chapter, extracellular TG-2 can interact non-
covalently with β-integrin which is important in cell-ECM adhesion [29]. The TG-2-
integrin complexes were shown to activate multiple downstream intracellular pathways 
and signalling targets, leading to the formation of focal adhesions, actin stress fibers and 
increased actomyosin contractility [35, 75]. This functional collaboration between TG-2 
and integrins was illustrated by a study, whereby the deficiency of TG-2
-/-
 macrophages 
in phagocytosis was due to impaired signalling and the inability of integrin β3 to 
accumulate in the phagocytic cup [102]. Also, Janiak et al showed that TG-2 promoted 
RhoA activation through β-1 integrin signaling and reduction of phosphorylation on src 
kinase [75]. In another study, Verma et al reported that TG-2 expression inhibited the 
phosphorylation of tumor suppressor phosphatase PTEN, causing its degradation and 
subsequently increased the phosphorylation of FAK at Tyr397 in 
pancreatic adenocarcinoma cell line [74]. Contradictory to this result, Stephens et al 
reported that human foreskin fibroblast cells transfected with TG-2-antisense showed an 
increase in phosphorylation of FAK at Tyr397 compared to mock transfected or TG-2 
overexpressing cells [103]. These studies showed that TG-2 expression in the cells could 
affect the activation of some of the focal adhesion proteins. However, the effect of TG-2 





1.6 Unanswered Questions and Specific Aims 
TG-2 is the protein of interest in this work. The focus of this work is on common 
biological processes such as apoptosis, cell adhesion and migration. TG-2 potentially 
links these biological processes to several in vivo human diseases such as evaporative dry 
eye, ocular surface damage and wound healing defects (Figure 1.3). Three chapters have 
been allocated to discuss the role of TG-2 in hyperosmolarity induced mitochondrial cell 
death (Chapter 2), the interacting proteins partners of TG-2 (Chapter 3) and the functional 
















Figure 1.3. Schematic showing TG-2 as the focus of this work. TG-2 potentially links 
these biological processes to several in vivo human diseases such as evaporative dry eye, 
ocular surface damage and wound healing defects. 
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Evaporative dry eye is a more prevalent form of dry eye in Asia, including in Singapore 
[13]. One of the central mechanisms of dry eye is tear hyperosmolarity, which involves 
apoptotic cell death, causing ocular surface damage [13]. The damaged ocular surface can 
release inflammatory cytokines which will further aggravate dry eye and cause more 
apoptosis [10]. Although hyperosmolarity is known to activate the mitochondrial 
apoptotic pathway [104], it is not known if TG-2 is involved in this process in human 
corneal epithelial cells. Also, is TG-2 an inducer of mitochondrial damage in 
hyperosmolar stimulated cells? Chapter 2 investigates whether cell death induced by 
hyperosmolarity in human corneal epithelial cells is dependent on TG-2.  
 
Cornea wound healing deserves to be evaluated as a unique scenario, as defective wound 
healing will reduce cornea transparency and affect visual function. Corneal epithelial 
wound healing consists of 3 major components: cell migration, proliferation and adhesion 
[18]. During the wound healing process, adhesion complex proteins and cytoskeletal 
proteins are transported/recycled continuously from one compartment to another. These 
transported proteins may contribute to crucial cell migration processes such as 
rearrangement of actin filaments, formation of lamellipodia and filopodia, as well as the 
assembly and disassembly of molecular motors. This study was thus extended to identify 
the interacting proteins partners of TG-2 and their protein transport which may affect cell 
adhesion and migration. In the cell, proteins that are involved in cell adhesion and 
migration are transported continuously from one compartment of the cells to another 
compartment. TG-2 which is present abundantly in the cells during this transport process 
is likely to interact with these transported proteins. What are the proteins that interact 
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with TG-2 that may affect cell adhesion and migration? How are these proteins 
transported? More specifically, which fragments of TG-2 are these proteins interacting 
with? These will be studied in Chapter 3 of this thesis.  
 
In Chapter 4, I further extended my study to elucidate the functional role of TG-2 in 
wound healing which also involves epithelial cell adhesion and migration. Under normal 
circumstances, ocular surface damage usually heals within 2-3 days [67]. However, some 
of these wounds have defects in healing. They heal very slowly or do not heal at all. Cell 
adhesion and migration may be involved in this process since they are the main 
components of wound healing. Most literatures have chosen to use fibroblast or cancer 
cells to investigate the role of TG-2 in the wound healing process [68, 105, 106].  Little 
or no work has been done to study the role of TG-2 in corneal epithelial wound closure. 
Although cell surface TG-2 is known to activate downstream signalling pathways [75], it 





1. To investigate the role of TG-2 in hyperosmolarity mediated mitochondrial cell death 
(Chapter 2). 
a. To elucidate whether hyperosmolar treatment can mediate cell death in cultured 
human corneal epithelial cells by checking cell proliferation, viability and cell 
death. 
b. To study whether mitochondria is involved in hyperomolar-induced cell death 
using flow cytometry analysis. 
c. To determine the presence of TG-2 in mitochondria; and whether TG-2 can 
induce mitochondrial damage in hyperosmolarity-stimulated cells.  
d. To study the effect of overexpressing TG-2 on cell proliferation and viability in 
cultured human corneal epithelial cells. 
2. To discover and characterise cell adhesion or migration related proteins which 
interact with TG-2 (Chapter 3). 
a. To characterise the proteins that interact with different TG-2 fragments using 
immunoprecipitation, LC/MS and MASCOT database search. 
b. To understand how these proteins are trafficked between cell compartments using 
centricollation and immunoblotting of potential binding partners in cells in 
combination with RNA interference of TG-2.  
c. To determine whether TG-2 level can affect the relative concentration of cell-
adhesion proteins in sub-cellular fractions using western blotting. 
3. To study the functional significance of TG-2 on cell adhesion and migration in 
corneal epithelial wound closure (Chapter 4). 
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a. To investigate the role of TG-2 in cell migration, adhesion and proliferation 
using in vitro techniques such as cell scratching assay, cell migration assay, 
immunofluorescence staining and trypsinisation assay. 
b. To evaluate the possible interaction of TG-2 and focal adhesion proteins in 
cultured human corneal epithelial cells by performing western blot against 
focal adhesion proteins. 
c. To determine if TG-2 affects paxillin incorporation in adhesion complexes 
by checking its in vitro kinase activity. 






CHAPTER 2. HYPEROSMOLARITY-MEDIATED MITOCHONDRIAL 
DYSFUNCTION REQUIRES TRANSGLUTAMINASE-2 IN HUMAN CORNEAL 
EPITHELIAL CELLS 
2.1  Tear Osmolarity and Dry Eye Diseases 
The human corneal epithelium is covered by a layer of tear film which provides 
mechanical and antimicrobial barrier, lubrication and nutrients to the underlying 
conjunctiva and cornea, to ensure a smooth surface for light refraction [11]. The 
osmolarity of the tear film is important for normal functioning of the ocular surface and 
any changes to the tear osmolarity may cause cell death or induce inflammatory response 
in the cornea epithelial cells [104, 107]. Tear osmolarity in normal eyes has been reported 
to range from approximately 300 to 310 mOsm/L [108, 109]. The increase in tear 
osmolarity has been associated with dry eye and ocular surface disorders [110]. This rise 
in tear osmolarity has been correlated with pathological changes of the ocular surface, as 
well as increased epithelial cell death, leading to the loss of barrier function and reduced 
cornea transparency [59, 111]. Hence, the effect of hyperosmolarity on corneal epithelial 
cells, especially its effects in the downstream death signalling pathway, deserves 
evaluation. It is important to note that most of the in vitro and animal dry eye studies 
require long-term and high levels of hyperosmolar treatment (400-600 mOsM/L) in order 




2.2  TG-2 and Cellular Stress 
TG-2 can be regulated by cellular stress. It has been reported that oxidative stress 
promotes in situ activation of TG-2. For instance, Shin et al reported that human lens 
epithelial cells treated with hydrogen peroxide promoted oxidative stress, leading to 
increase in in situ TG-2 activity [112]. Similarly, an increase in TG-2 activity was 
observed when apoptotic cell death was induced in human peripheral blood mononuclear 
cells using a ROS (reactive oxygen species) generating enzyme xanthine oxidoreductase 
[113]. Also, TG-2 is involved in stimulating corneal epithelial cell death after UV 
irradiation [114]. It has been shown that hyperosmolarity and increased intracellular 
calcium levels can induce cell death in various cell types [115, 116]. In addition, previous 
studies also reported that osmotic stress such as increased concentration of sorbitol and 










2.3  TG-2 and Mitochondria 
Mitochondria are known as the powerhouse of the cell as it plays a key role in adenosine 
triphosphate (ATP) synthesis for energy production [118]. Mitochondria are also 
important in regulating caspase activity and apoptosis [119]. In intrinsic or mitochondria-
dependent apoptosis triggered by different types of intracellular stress, the 
permeabilisation of mitochondrial membrane leads to the release of crucial apoptotic 
molecules such as cytochrome c and caspases, thereby causing apoptosis [119, 120]. The 
integrity of the outer mitochondrial membrane depends on the interactions of both pro- 
and anti-apoptotic members of the Bcl-2 family proteins [119].  
The involvement of mitochondria in human corneal epithelial cell death pathway has 
been implicated through the release of cytochrome c [104]. Although most of the TG-2 
are cytosolic, TG-2 can also be found in mitochondria [121]. TG-2 has been associated to 
mitochondria-induced cell death in non-ocular context [122, 123]. For example, 
Piacentini et al reported that TG-2 overexpression increased mitochondrial membrane 
potential and sensitised the neuronal cells to apoptosis [122]. Another study reported that 
the impairment of mitochondrial function in neuroblastoma cells significantly promoted 
the in situ TG-2 activity [123]. It has been proposed that TG-2 is a novel member of a 
multifunctional BH3-only pro-apoptotic protein whereby it shares 70% similarity with 
the BH3 domain of Bcl-2 family [124]. Besides its involvement in mitochondria-
dependent apoptosis, other evidences also showed that TG-2 may participate in other 
mitochondrial functions such as mitochondrial energy production and regulation of 




Currently, there are limited studies done to evaluate the role of TG-2 in hyperosmolar-
induced cell death. Also, it is uncertain whether mitochondria are involved in TG-2-




2.4  Hypothesis and Specific Aims 
It is hypothesised that osmotic stress induced cell death in human corneal epithelial cells 
is TG-2 dependent. 
 
The aim of this study is to determine whether cell death induced by hyperosmolarity in 
human corneal epithelial (HCE-T) cells is dependent on TG-2. If this dependence exists, 
we aim to ascertain the role of the mitochondria in this death process.  
 
Specific Aims 
To investigate the role of TG-2 in hyperosmolarity mediated mitochondrial cell death.  
a. To elucidate whether hyperosmolar treatment can mediate cell death in cultured 
human corneal epithelial cells by checking cell proliferation, viability and cell 
death. 
b. To study whether mitochondria is involved in hyperomolar-induced cell death 
using flow cytometry analysis. 
c. To determine the presence of TG-2 in mitochondria; and whether TG-2 can 
induce mitochondrial damage in hyperosmolarity-stimulated cells.  
d. To study the effect of overexpressing TG-2 on cell proliferation and viability in 




















Figure 2.1. Schematic showing the focus of this chapter, as depicted by the blue square. 
The main objective of this chapter is to elucidate the role of TG-2 in hyperosmolar 
induced mitochondrial depolarisation.  
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2.5  Methodology 
 
The materials and methods will be presented in flow chart in every chapter. The overall 
methodology of this chapter is presented as Methodology Flow Chart 1. Due to space 




Methodology Flow Chart 1. Flow chart showing general methodology to study the 
effects of hyperosmolarity induced mitochondrial depolarisation in cultured human 
corneal epithelial cells. The detailed protocol for each technique was described in 
Appendix A.  
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2.5.1 Immortalised Human Corneal Epithelial Cells 
In vitro experiments in my projects were performed using immortalised human corneal 
epithelial (HCE-T) cells due to various factors such as high requirement of cells numbers 
in various experiments, changes of phenotypes in primary cells upon passaging, high cost 
of primary cell culture medium and the translational medical implications of using human 
cells.  
 
To study the effects of TG-2 deprivation in human corneal epithelial cells, HCE-T cells 
were stably transfected with shRNA targeting TG-2 to generate TG-2 knock-down cells, 
known as shTG cells in this thesis; or with scrambled shRNA to produce a control cell 
line, known as control shRNA cells (See methods at Appendix A1.2). The specificity of 
this shRNA targeting TG-2 sequence was confirmed by the following experiments: 
firstly, the reduction of TG-2 transcript and protein in HCE-T cells (Figure 2.2), 
secondly, the reduction of TG-2 expression on cell surface (Figure 2.3), and thirdly, the 
overexpression of wild type TG-2 overcoming the functional effect of TG-2 deficiency 

























Figure 2.2. Results from different experiments to determine the amount of TG-2 in 
control shRNA and shTG cells. (A) Real-time Quantitative RT-PCR result of shRNA and 
shTG cells. GAPDH was used as a control.  (B) Western blot showed the expression of 
TG-2 protein in shRNA and shTG cells. (C) Bar chart showing densitometry for the 











Figure 2.3. Flow cytometry result showing differential expression of cell surface TG-2 in 
shTG and control shRNA cells. Scrambled shRNA (control) and shTG cells were 
trypsinised and incubated with primary antibody against transglutaminase (TG)-2 and 
Alexa Fluor 488 secondary antibody. The proportion (%) of cells stained positive for TG-
2 was calculated and shown for each of the cell types. Bottom row: Graph shows the 






Figure 2.4. Table showing reverse transcription real-time PCR result of transglutaminase 
(TG)-2 transcript levels, normalised to GAPDH. Cultured human corneal epithelial cells 
(HCE-T) stably expressing scrambled shRNA (shRNA) and shRNA targeting 
transglutaminase (TG)-2 (shTG) were used. These cells were transiently transfected with 
either pSG5 plasmid (control) or pSG5 TG-2 plasmid (over-expression of TG-2). Total 
RNA was then extracted from these transfected cells. The fluorescence of amplified 
products was measured at 483-533nm.   
Treatment
TG-2 fold change 
normalised to GAPDH SEM
shRNA pSG5 1 0.01
shTG pSG5 0.45 0.06
shRNA pSG5 TG-2 444.69 0.02
shTG pSG5 TG-2 533.74 0.04
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2.6  Hyperosmolar Stimulation Induced Mitochondrial Depolarisation 
A series of sodium chloride concentration with different osmolarity was tested on 
cultured human corneal epithelial (HCE-T) cells over a period of 24 hours (Figure 2.5A). 
Based on the amount of mitochondrial depolarisation as well as references from previous 
literature [103], 460mOsM was chosen as a suitable hyperosmolar treatment for the 
experiment. This osmolarity of 460mOsm is applicable to clinical situation as a 
keratoconjunctivitis sicca patient has recorded a hyperosmotic tear film of approximately 
450 mOsm [109]. 
 
Consistent to the 24 hour MTS cell proliferation assay (Figure 2.5A), cell impedance 
assay also showed that HCE-T cells treated in hyperosmolar condition at 460mOsM has 
reduced proliferation/ viability compared to those grown in normal osmolarity (Figure 
2.5B). When the cells were incubated for extended hours (12 and 24 hours) in 
hyperosmolar medium with (Top, Figure 2.5C) or without serum (Bottom, Figure 2.5C), 
there was a gradual increase in cytochrome c protein level in the cell cytosol/total protein 
lysate. Flow cytometry results showed that after the cells were treated with hyperosmolar 
medium at 460mOsM for 24 hour, 14.5% more cells (27.3% minus 12.8%) showed 
mitochondrial depolarisation, compared to the control untreated cells at 300mOsM. As a 
positive control, cells treated with Carbonyl Cyanide m-Chlorophenylhydrazone (CCCP), 
a known mitochondrial oxidative phosphorylation uncoupler, caused 99.8% of the cells to 
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Figure 2.5. Figures showing the effects of basal osmolarity and hyperosmolarity on cell 
proliferation/viability. (A) MTS cell proliferation assay was performed to evaluate the 
proliferation/ viability of human corneal epithelial cell treated to media of various 
osmolarity (300, 450, 540mOsM) for 24 hour. Cell viability was calculated by 
normalising the absorbance values of the cells in various osmolarity to control 
(300mOsm). Three independent experiments were performed. P value was calculated 
with anova followed by the 3 post hoc multiple comparisons. *: p < 0.05. (B) A real-time 
cellular impedance based assay (Xcelligence) was performed to monitor the proliferation 
of cultured human corneal epithelial cells (HCE-T). Cell index provides information 
regarding cell viability, number, morphology, and adhesion degree. In this experiment, an 
equal number of cells was seeded in each well and the cells were treated with 
hyperosmolar medium (460mOsm) or control (300mOsm). Quadruplicates were done for 
each condition. (C) Sub-confluent HCE-T cells were exposed to either 5% fetal bovine 
serum-containing media (Top) or serum-free media (Bottom) for various time points. 
Western blots were then performed on the total cell lysates using primary antibodies 
against cytochrome (Cyt) c or β-actin. (D) Flow cytometry scatterplot shows the 
percentage of cells with mitochondrial depolarisation. Sub-confluent HCE-T cells were 
exposed to control medium (Left: 300mOsm) and hyperosmolar medium (Middle: 
460mOsm) for 24 hours, prior to trypsin detachment and staining with JC-1, a membrane 
permeant dye which indicates mitochondrial membrane potential. JC-1 dye shows 
mitochondrial potential-dependent accumulation which is demonstrated by a green (~529 
nm) to red (~590 nm) fluorescence emission shift. Hence, mitochondrial depolarisation is 
measured by a reduction in the red/green fluorescence intensity ratio.  In this scatterplot, 
an ellipse was drawn around the cells with no mitochondrial depolarisation; the 
percentage of cells outside the delineated ellipse was shown. As a positive control, cells 
were incubated with carbonyl cyanide m-chlorophenylhydrazone (CCCP), a known 
mitochondrial depolariser (0.1M), 30 minutes before the flow cytometry (Right: CCCP).  




2.7  Effects of TG-2 Overexpression  
To study the effect of TG-2 overexpression, one can compare the effects of cells 
expressing control plasmid versus cells expressing TG-2 plasmid. TG-2 overexpression 
was achieved by electroporating cells with 1ug of pSG5 TG-2 plasmid, while control 
cells were generated by electroporation with same the amount of pSG5 plasmid (See 
Methods at Appendix A2.5). Reverse transcription real-time PCR was performed against 
different exons of TG-2 in order to confirm that the TG-2 sequence in the plasmid was 
expressed in full length (Figure 2.6). The electroporation conditions and the control 
vector used in the overexpression experiments were also checked in HCE-T cells to 









Figure 2.6. Figures showing semi-quantitative reverse transcription-polymerase chain 
reaction (RT-PCR) against different exons of TG-2 and western blot images of 
transfected cells against TG-2 primary antibody (A) Human corneal epithelial (HCE-T) 
cells were transfected with either pSG5 or pSG5 TG-2 plasmids, followed by 24 hours of 
incubation. Total RNA extraction and reverse transcription was then carried out to obtain 
cDNA. GAPDH was used as a housekeeping gene. Semi-quantitative reverse 
transcription-polymerase chain reaction (RT-PCR) against different exons of TG-2 was 
performed. Bottom right: Diagram showing position of primers on various TG-2 exons. 
Primers that are intron-spanning pairs were used. (B) Western blot showing cell lysate of 
pSG5 or pSG5 TG-2 transfected HCE-T cells blotting against TG-2 primary antibody. β-





Figure 2.7. Microscopy images showing HCE-T cells 24 hours after various 
electroporation conditions in serum free condition. 1x10
6
 cells were seeded into each well 
of 6-well plate. Cell were electroporated with (Right) or without plasmid DNA (Middle). 
Cells without electroporation are shown on the Left. The percentages indicate cell 






Compared to HCE-T cells expressing control plasmid (HCE-T pSG5), there was two-fold 
increase in transamidase activity in HCE-T cells overexpressing TG-2 (HCET pSG5 TG-
2) (Figure 2.8A). To confirm that TG-2 could localise in the mitochondria of cultured 
HCE-T cells, western blot was performed and TG-2 was successfully detected in the 
mitochondrial extract (Figure 2.8B). The integrity of the mitochondrial extract was 
shown by immunoreactivity to mitochondrial antioxidant manganese superoxide 
dismutase (MnSOD). shRNA and shTG cells transfected with control plasmid pSG5 
(shRNA pSG5 and shTG pSG5) showed similar cell index; however, the cell index 
dropped when they overexpressed TG-2 (shRNA pSG5 TG-2 and shTG pSG5 TG-2), 
suggesting a decrease in cell proliferation (Figure 2.8C). This reduction in proliferation 
due to overexpression of TG-2 was confirmed by crystal violet cell proliferation assay 
(Figure 2.8D). Also, the overexpression of TG-2 (pSG5 TG-2) in HCE-T cells increased 
caspase-3/7 and -9 activities (Figure 2.8E, F). As a negative control, ZVAD-FMK, a pan- 
caspase inhibitor, significantly reduced (p< 0.05) the caspase-3/7 and -9 activities in both 
TG-2 overexpressing cells (pSG5 TG-2) and control cells (pSG5). The concentration of 































Figure 2.8. Figures showing effects of transfecting cells with pSG or pSG5 TG-2 
plasmids on transamidase activity, cell proliferation and caspases activities. (A) In the 
transamidase activity assay, the transgluatminase crosslinking activity was calibrated to 
the commercially available purified guinea pig liver transglutaminase-2 activity. *: p < 
0.05. Height of bars: mean, error bars: SD. (B) Western blot showing the presence of TG-
2 protein in the cytoplasmic fraction and mitochondrial extract of HCE-T cells, as well as 
in rat liver mitochondrial extract. The integrity of mitochondria was determined by 
manganese superoxide dismutase (MnSOD). (C) Line graph showing result of cell 
impedance assay (see Appendix A14.1), whereby cell index was plotted against time for 
four types of cells. (D) Barchart showing the results of cell proliferation using crystal 
violet assay. The effect of TG-2 overexpression on cell densities was shown in cells 
transfected with pSG5 TG-2 plasmids. Three independent experiments were performed. *: 
p < 0.05. Height of bars: mean, error bars: SD. (E), (F) Barcharts showing the results of 
cell-based caspase 3/7 and 9 activity assays, 24 hours after transfection. Negative control, 
Z-VAD-FMK, a cell permeable pan-caspase inhibitor, was added at a concentration of 
20mM. Three independent experiments were performed. *p < 0.05. Height of bars: mean; 



















Figure 2.9. Figures showing crystal violet cell proliferation assay of cells incubated with 
or without Z-VAD-FMK (A) Human corneal epithelial (HCE-T) cells, HCE-T 
transfected with pSG5 or pSG5 TG-2 were treated with or without Z-VAD-FMK for 24 
hours. Cell density was proportional to absorbance measured at 595nm. (B) Bar graph 
showing comparison between HCE-T cells treated with Z-VAD-FMK (mean of HCE-T, 
HCE-T pSG5 and HCE-T pSG5 TG-2) versus mean of untreated cells. Paired T test 
revealed that there was no significant difference between treatment and no treatment (p = 





2.8  Hyperosmolarity Induced Mitochondrial Depolarisation is TG-2 Dependent  
Under basal osmolarity of 300mOsm, there was no significant mitochondrial 
depolarisation in untransfected cells, shRNA, shTG, mock transfected cells and cells 
transfected with pSG5 plasmids (Figure 2.10).  
 
 
In 300mOsm medium, 14.6% of shRNA cells transfected with control plasmid pSG5 
showed mitochondrial depolarisation; the percentage increased to 27.1% when the cells 
were exposed to hyperosmolar medium of 460mOsm (Figure 2.11A, top row). This 12.5% 
difference (27.1% minus 14.6%) represented a 1.86-fold change (27.1% / 14.6%) in 
mitochondrial depolarisation (Figure 2.11A, top row). Under the same condition, 6.2% 
(23.9% minus 17.7%) or 1.35-fold (23.9% / 17.7%) of shTG cells transfected with 
control plasmid pSG5 showed mitochondrial depolarisation (Figure 2.11A, bottom row). 
Hence, shRNA pSG5 cells showed that greater proportion of cells underwent 
hyperosmolar-induced mitochondrial depolarisation compared to shTG pSG5 cells (1.86 
versus 1.35-fold change), suggesting that hyperosmolar-induced mitochondrial 
depolarisation was partly dependent on TG-2.  
 
When cells were transfected with pSG5 TG-2 plasmids in 300mOsm, the proportion of 
cells undergoing mitochondrial depolarisation in shRNA pSG5 TG-2 cells were similar to 
that of shTG pSG5 TG-2, either under normal osmolarity (Figure 2.11B, left column: 
23.5% / 23% = 1.02-fold change) or in 460mOsM (Figure 2.11B, right column:  33.5% / 
33.3% = 1.0-fold change). This was probably because the overexpression of TG-2 by 
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transfection increased transcript levels over a few 100-fold (Table 1), suggesting that TG-
2 was already saturated in the transfected cells. Hence, it was not surprising that cells 
overexpressing TG-2 responded in a similar fashion to hyperosmolar stimulation. 
Comparing hyperosmolar treated and untreated conditions, shRNA pSG5 TG-2 showed 
1.45-fold change in mitochondrial depolarisation, similar to the 1.43-fold change in shTG 
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Figure 2.10. Flow cytometry analysis showing percentages of cells with mitochondrial 
depolarisation under basal osmolarity (300mOsM) condition. Human corneal epithelial 
cells (HCE-T no electroporation), HCE-T expressing scrambled RNA (shRNA no 
electroporation), HCE-T expressing shRNA targeting TG-2 (shTG no electroporation), 
HCE-T cells transfected without plasmid DNA (HCE-T mock electroporation) and HCE-
T transfected with control plasmid pSG5 (Electroporated HCE-T: pSG5) were incubated 
for 24 hours. Sub-confluent adherent cells were trypsinised and non-adherent cells in the 
medium were collected. Both the trypsinised adherent cells and non-adherent cells were 
combined and stained with mitochondrial dye JC-1. Each point represents a single cell. 
An ellipse was drawn to delineate the population of cells with healthy mitochondria. The 
percentage of cells outside of the ellipse, which were cells with depolarised mitochondria, 











Basal Osmolarity (300mOsM) 
12.9 ± 0.9% 12.9 ± 0.9% 
9.6 ± 0.8% 10.5 ± 0.09% 10.1 ± 1.3% 
11.5 ± 1.3% 
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300 460 mOsm 
14.6 ± 1.14% 27.1 ± 2.28% 
23.9 ± 2.38% 17.7 ± 4.46% 
Fold Change of 
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Figure 2.11. Flow cytometry analysis showing percentages of cells with mitochondrial 
depolarisation in normal (300mOsM) and hyperosmolar (460mOsm) conditions. Sub-
confluent adherent cells were trypsinised and non-adherent cells in the medium were 
collected. Both the trypsinised adherent cells and non-adherent cells were combined and 
stained with mitochondrial dye JC-1 (Methods see Appendix D, A12.2). An ellipse was 
drawn to delineate the population of cells with healthy mitochondria. The percentage of 
cells outside of the ellipse, which were cells with depolarised mitochondria, was 
calculated (mean of three experiments). The fold change of hyperosmolar-induced 
mitochondrial depolarised cells for each cell type was shown on the right by dividing the 
percentage in the “460mOsM” by that in the “300 mOsM”. Control shRNA and shTG 
cells under 360mOsM and 460mOsM were transfected with either (A) PSG5 plasmids or 





















300 460 mOsm 
33.5 ± 4.80% 23.5 ± 7.60% 
23.0 ± 2.50% 33.3 ±4.38% 
Fold Change of 






TG-2 fold change 
normalised to GAPDH SEM
shRNA pSG5 1.00 0.01
shTG pSG5 0.45 0.06
shRNA pSG5 TG-2 444.69 0.02





Table 1. Table showing reverse transcription real-time PCR result of transglutaminase 
(TG)-2 transcript levels, normalised to GAPDH. Cultured human corneal epithelial cells 
(HCE-T) stably expressing scrambled shRNA (shRNA) and shRNA targeting TG-2 
(shTG) were used. These cells were transiently transfected with either pSG5 plasmid 
(control) or pSG5 TG-2 plasmid (over-expression of TG-2). Total RNA was then 
extracted from these transfected cells. The fluorescence of amplified products was 





Why was the mitochondrial depolarisation in cells overexpressing TG-2 not as high as in 
the cells expressing the control plasmid (1.86-fold change)? One of the reasons was that 
at 300 mOsm, the pSG5 plasmid transfected cells had lower basal TG-2 compared to the 
saturated levels of TG-2 in pSG5 TG-2 expressing cells. The fold increase in pSG5 TG-2 
cells in Figure 2.11B may not be due to TG-2 mechanisms. Hence, one could interpret 
that 1.45-fold (Figure 2.11B, top row) out of the 1.86-fold (Figure 2.11A, top row) 
increase in the hyperosmolar-induced mitochondrial depolarisation was due to non-TG-2 
mechanism. Thus the hyperosmolar-induced mitochondrial depolarisation that was TG-2-
dependent would be 1.41-fold (1.86-fold minus 1.45-fold). In terms of percentages, this 
meant that about 48% (41/86 x 100%) out of the total amount of hyperosmolar-induced 











Figure 2.12. Schematic showing that basal cells exposed to hyperosmolar condition can 
induce mitochondrial depolarisation through transglutaminase-2 dependent or non-
transglutaminase-2- dependent mechanisms. 
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2.9  Discussion 
HCE-T cells exposed to hyperosmolar medium have reduced proliferation/viability 
through mitochondria and caspase-dependent mechanism which is partially dependent on 
TG-2 function. Dry eye is a multi-factorial disease that is accompanied by hyperosmolar 
tears and ocular surface inflammation [13]. This clinical condition was simulated by 
hyperosmolar culture medium in cultured HCE-T cells. The tear osmolarity in normal 
eyes is around 300 to 310mOsM [108, 109], while dry eye patients have an osmolarity of 
343 ± 32 (306 to 441) mOsM [109]. A keratoconjunctivitis sicca patient has even 
recorded a hyperosmotic tear film of approximately 450 mOsm [109, 126]. The increase 
in extracellular osmolarity has been reported to affect cell functions in various tissues 
such as human bronchial epithelial cells [127], peripheral blood mononuclear cells [128], 
as well as the corneal epithelium [104]. Results in this study agree with previous 
literatures that hyperosmolarity induced apoptosis in primary corneal epithelial cells 
through cytochrome c-mediated pathway [104, 122].  
 
Around 70% of TG-2 is localised to the cytosol; however, some of them are also 
localised to other organelles such as mitochondria [129]. In this study, TG-2 was found to 
be present in the mitochondria extract from both the cultured HCE-T cells and rat liver. It 
has been suggested that TG-2 may act as a protein disulphide isomerase (PDI) in 
mitochondria, contributing to the correct assembly and homeostasis of respiratory chain 
complexes [125]. TG-2 plays an important role in mitochondria physiology. Aberrant 
TG-2 has been reported to cause mitochondrial dysfunction both in vitro and in vivo 
[122]. For example TG-2 knockout mice showed mitochondrial energy production 
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impairment as evidenced by decreased ATP levels after physical stress, suggesting a role 
of TG-2 in regulating ATP synthesis [125, 130]. Also, after mitochondrial-mediated 
apoptosis by staurosporine, TG-2 overexpressed cells showed rapid loss of mitochondrial 
membrane potential compared to control cells [122]. However, the relationship between 
TG-2 and mitochondria in human cornea has not been evaluated.  
 
The link between TG-2 and apoptotic cell death has been reported both in vitro [131] and 
in vivo [31]. Overexpression of TG-2 sensitises the cells to apoptosis or makes them more 
susceptible to apoptotic-inducing stimuli [44, 122]. For instance, Chen et al reported that 
the expression of TG-2 sensitised drug resistant breast carcinoma cells to apoptosis [132]. 
However, the direct link between TG-2 and apoptosis has not been established on the 
ocular surface. An earlier paper reported that the intracellular delivery of exogenous 
transglutaminase by a peptide delivery system into cornea epithelial cells significantly 
increased caspase-3 activity compared to vehicle control, suggesting that TG-2 may be 
linked to cell death in primary cultured HCE-T cells [114]. In addition, the expression of 
TG-2 in drug-resistant breast carcinoma cells rendered the cells more sensitive to 
apoptotic stimuli accompanied by activation of caspase-3 -7 and -9 [132]. Hence, the 
overexpression of TG-2 in HCE-T cells which induced higher caspase-3, -7, and -9 
activity compared to the control cells in this project correlated well with the previously 
mentioned publications [114, 132]. Pan-caspase inhibitor Z-VAD-FMK was added as a 




Compared to previous literatures, the current methodology is different whereby TG-2 was 
overexpressed in cultured HCE-T cells and the caspase activities were quantified [114, 
132]. TG-2 has been reported to be involved in several types of stress-induced apoptosis. 
The differences in the experimental outcomes were likely due to the choices of different 
apoptotic stress, or different cell types. Chen et al reported that higher cell death was 
induced by staurosporine treatment to TG-2 overexpressed neuroblastoma cells as 
compared to similarly stressed cells with endogenous TG-2 [132]. Literatures also 
reported that TG-2 played a role in apoptosis due to oxidative stress in lens tissues [133] 
and alcohol-induced stress in hepatic cells [134]. On the contrary, hyperosmolar 
stimulation did not further increase the mitochondrial depolarisation in TG-2 
overexpressing cells (Figure 2.11B, 1.45 and 1,43-fold) compared to cells with 
endogenous TG-2 (Figure 2.11A, top panel, 1.86-fold), suggesting that the endogenous 
TG-2 already saturated the requirement for TG-2. From Figure 2.12, around 48% of the 










2.10  Conclusion 
This study concludes that hyperosmolar stimulation induced apoptosis in corneal 
epithelial cells via caspase-dependent mitochondrial dysfunction is dependent on TG-2. 
Protection against mitochondrial stress in the ocular surface through targeting TG-2 may 
have important implications in the treatment of inflammatory eye diseases. 
 
Key Findings 
a. Hyperosmolar treatment mediated cell death and reduced cell viability in cultured 
human corneal epithelial cells.  
b. Hyperosmolar stimulation caused the release of cytochrome-c and mitochondrial 
depolarisation.  
c. TG-2 was present in mitochondrial extract. Hyperosmolar stimulation did not 
further increase the mitochondrial depolarisation in TG-2 overexpressing cells 
compared to cells with endogenous TG-2; while in TG-2 deficient cells, 
hyperosmolar conditions induced less amount of mitochondrial depolarisation, 
indicating a partial dependence on TG-2 function. 
d. TG-2 overexpression increased transamidase activity, reduced cornea epithelial cell 






CHAPTER 3. TRANSGLUTAMINASE-2 AND BINDING PARTNERS   
3.1 Subcellular Compartmentalisation of Proteins  
TG-2 in subcellular compartments can affect physiological functions differently since its 
Ca
2+
 -dependent transglutaminase cross-linking activity and GTPase activity are known 
to be modulated by the local environment [23]. Previously Milakovic et al reported that 
cytosolic TG-2 was pro-apoptotic whereas nuclear TG-2 was anti-apoptotic [135]. Lesort 
et al also demonstrated that different subsets of proteins were modified by nuclear TG-2 
compared to the cytosolic TG-2 [136]. It is important to understand the binding partners 
which interact with different domains of TG-2 in the cell, as it may impact the cell 
migration or adhesion signaling pathways. For example, the interaction of TG-2 with 
endocytic receptor LRP-1 (low-density lipoprotein receptor-related protein 1) at different 
locations, either in vitro and on the cell surface, may affect endocytosis and other 
physiological functions [35].  
 
The protein-binding partners of TG-2, apart from integrins and ECM proteins such as 
fibronectin, have yet to be investigated. Also, proteins that interact with specific domains 
of TG-2 are not known. Moreover, the roles of TG-2 in cell trafficking and 
compartmental localisation have not been studied in cornea epithelial cells. The cellular 
proteins need to be separated efficiently in order to fully understand the function of TG-2. 
Previously, TG-2 binding partners, such as Bcl-2-associated X protein (Bax), were 
discovered by immunoprecipitation [124]. In this study, a mass spectrometry-based 
method was employed to elucidate the protein binding partners of TG-2. Fragments of 
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3.2  Subcellular Trafficking and Corneal Wound Healing 
Several literatures have examined the relationship between corneal wound healing and 
sub-cellular trafficking [137-139]. Kucerova et al found that heterozygous deficiency in 
Pax6, which was associated with congenital ocular surface diseases, disrupted 
glycoprotein trafficking, thus it affected wound healing response in corneal epithelial 
cells [137]. Meanwhile, McClintock and Ceresa studied the effects of two growth factors: 
transforming growth factor-α (TGF-α) and epidermal growth factor (EGF), on endocytic 
trafficking of growth factor receptor (EGFR) protein which could influence EGFR-
mediated corneal wound healing [138]. Shankardas et al studied the expression and 
distribution of 14-3-3 proteins in human cornea and conjunctiva, and suggested that the 
proteins may be involved in epithelia specific signalling and trafficking pathways [139, 
140]. These literatures evaluated the significance of protein trafficking in corneal wound 
healing. However, they did not study the sub-cellular localisation of the trafficked 
proteins through fractionation. Also, the mechanism by which proteins were trafficked 
between sub-cellular compartments was not elucidated. Moreover, the link between TG-2 







3.3 High-speed Cellular Protein Separation  
Ultracentrifugation is a pelleting process that has been used in several studies examining 
subcellular trafficking. However, conventional ultracentrifugation has drawbacks such as 
requiring long extraction times and not preserving the sample integrity very efficiently, as 
the sample remains at high centrifugal force for a longer time. 
 
Centricollation is a novel method of protein separation based on a stepwise density 
extraction or flotation principle. It provides uniform and specific separations by applying 
equal centrifugal force to the entire sample. The hallmark of this technique is that the 
sample stays at high centrifugal force for only 2 to 3 min for each fraction. The 
centricollated samples can rapidly accelerate to 125,000g within a very short time of 45 
seconds instead of multiple hours, allowing multiple extractions in a relatively short time. 
This technique uses sucrose solution with increasing density and produces sucrose 
fractions ranging from 8.5-40%. Other advantages of using centricollation technique 
include the possible usage of small samples with extraction volumes as low as 50μL up 
till 3mL, usage of predefined density extracting media with a range of increasing 
densities, non-denaturing separation conditions and high recovery yield of more than 
90%. The fractionation conditions are also non-denaturing to the sample. Moreover, the 
sucrose fractions generated are compatible with all downstream analyses, including gel 





3.4 Hypothesis and Specific Aims 
It is hypothesised that specific TG-2-protein and protein-protein interactions in cell 
compartments are important in the understanding of corneal epithelium wound healing 
and may suggest new treatment options for ocular surface diseases.  
 
Specific Aims 
To discover and characterise cell adhesion or migration related proteins which interact 
with TG-2.  
a. To characterise the proteins that interact with different TG-2 fragments using 
immunoprecipitation, LC/MS and MASCOT database search. 
b. To understand how these proteins are trafficked between cell compartments using 
centricollation and immunoblotting of potential binding partners in cells in 
combination with RNA interference of TG-2.  
c. To determine whether TG-2 level can affect the relative concentration of cell-












Figure 3.1. Schematic showing the focus of this chapter, as depicted by the blue square. 









Methodology Flow Chart 2. Flow chart shows general methodology to study the 
protein-protein interactions in cultured human corneal epithelial cells. The detailed 








Methodology Flow Chart 3. Flow chart showing general methodology to study the 
protein trafficking in cultured human corneal epithelial cells. The detailed protocol for 





3.6 Identification of Potential TG-2 Binding Partners 
Fifteen TG-2 interacting proteins that bind to different TG-2 fragments (Figure 3.2, 
Figure 3.3) were identified using mass spectrometry and MASCOT protein database 
search (Appendix A8, A10).  Table 2 shows examples of TG-2 binding partners 
identified by mass spectrometry and MASCOT protein database search. One example of 
potential binding peptide was shown for each TG-2 fragment (Table 2). Individual mass 
spectrometry experiments were done using independent and repeated co-
immunoprecipitation experiments (Methods at Appendix A7.1) which successfully pulled 
down the same 15 TG-2 interacting proteins, thereby increasing the confidence of the 
interaction. In addition, the same co-immunoprecipitation elute that was used to run the 
mass spectrometry was used to perform immunoblotting. The same TG-2 ligands 
discovered in MASCOT were successfully identified using commercially available 
antibodies (Appendix B). Moreover, these proteins had been shown to be indirectly 





Figure 3.2. Western blots showing the TG-2 ligands identified using commercially 
available antibodies. Immortalised human corneal epithelial cells were transfected with 
FLAG-tagged plasmids expressing TG-2 fragments (denoted as FLAG-T1, FLAG-T2, 
FLAG-N, FLAG-C). Co-immunoprecipitation was performed to pull down proteins with 
FLAG-tagged. Western blotting successfully identified 11 out of 15 of the TG-2 ligands 












Figure 3.3. Schematic showing proteins interacting with different domains of TG-2 and 










Table 2. Examples of TG-2 binding partners identified by mass spectrometry and 
MASCOT protein database search. One example of potential binding peptide was shown 
for each TG-2 fragment.  
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Figure 3.4. Molecular network showing the interactions of TG-2 and its potential binding 
partners. Yellow entities: Mass spectrometry and MASCOT database showed that these 
interacting proteins had some relationship with TG-2 through indirect pathways. Red 







Where were these TG-2 ligands located in the cells? Using centricollation technique to 
separate cell lysate through stepwise density extraction (Appendix A5), the sub-cellular 
localisation of these potential TG-2 binding partners could then be determined by 
referring to an approximate organelle localisation chart provided by Prospect Biosystems 
(Figure 3.5). The chart showed sucrose density (%) corresponding to a known organelle 
based on particle diameter (µm). Most of the organelles fell within the sucrose density of 
14 - 50%. Hence, gross centricollation was first carried out at sucrose density of 8.5%, 
20%, 30% and 40% (Figure 3.6). From the gross centricollation result, most of the 
potential TG-2 ligands were found in the 8.5% and 20% sucrose fractions (SF); thus 










Figure 3.5. Figure showing the approximate distribution of organelles at different 
sucrose density (%) versus particle diameter (µm). Red arrows indicate pre-defined 

















Figure 3.6. Western blotting images showing TG-2 ligands expression levels in 
centricollated control shRNA and shTG cell lysates. Gross sucrose fractions of 8.5%, 
20%, 30%, and 40% were used. Most of the proteins of interest were found in the 8.5% 




3.7 Grouping of TG-2 Binding Partners 
As mentioned in Section 3.6, since most of the TG-2 ligands fell between 8.5% to 20% 
SFs, hence immunoblotting was performed against the 15 TG-2 interacting proteins in 
this range of SFs. Using commercially available antibodies, western blotting consistently 
detected 7 out of the total 15 TG-2 binding proteins. The TG-2 interacting proteins were 
categorised into three groups according to how TG-2 (control scrambled shRNA vs shTG 
cells) affected the pattern of localisation in various SFs (Figure 3.7). The relative 
intensity for each individual western blot band was also quantitatively measured (Figure 
3.7B). 
 
Group 1 consisted of desmin (DES), presenilin associated, rhomboid-like protein 
(PARL), neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), and serine protease 
(PRSS3). Proteins falling into this group had lower expression of proteins in shTG 
compared to control shRNA cells in all (DES and PARL) or in specific fractions (NTRK3 
and PRSS3). The ratio of relative intensities between control and shTG cells was around 
3:1.  
 
Group 2 consisted of proteins which were lower in shTG cells in one SF, but showed a 
reversal trend in other SFs. This group included Golgi-associated protein (GOLGA2) and 
integrin beta-4 (ITGB4). For example in GOLGA2, shTG had higher protein 
concentration than control cells in 8.5% SF, but it had lower concentration of protein than 
control in 10%, 15% and 20% SFs. The ratio of relative intensities between control and 
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shTG cells corresponding to each SF was approximately 1:3, 3:2, 3:2, 2:1 in GOLGA2; 
and 1:2, 3:2, 2:2, 2:1 in ITGB4 
 
Protein in Group 3, such as Syntaxin binding protein (STXBP2), expressed similar 
concentration in both control and shTG cells in all the 4 SFs. STXBP2 had relative 
intensity ratios of 1:1,1:2,1:2, 1:1 in control and shTG cells for each SF. The band 
intensities in the 10% and 15% SFs were slightly higher in shTG cells compared to 
control. However, when compared to repeated experiments, STXBP2 had consistently 




































Figure 3.7. Representative western blot images showing TG-2 ligands expression levels 
in centricollated cell lysates. (A) Sucrose fractions of 8.5%, 10%, 15%, and 20% were 
used. Group 1 ligands: These were characterised by lower expression of proteins in shTG 
compared to control (scrambled shRNA) in all (DES and PARL) or in specific fractions 
(NTRK3 and PRSS3). Group 2 ligands: These were characterised by their reduced 
expression in one of the SFs, but showed an increased expression in other SFs. Group 3 
ligand: syntaxin binding protein (STXBP2), which was characterised by the similar 
expression patterns between shTG and control in all the fractions tested. Three 
independent experiments were performed. (B) Densitometry showing relative intensity 
levels of various TG-2 ligands according to different density sucrose fractions from 
western blot results. Group 1: This group consistently showed a lower protein expression 
in shTG cells compared to control shRNA cells in all the sucrose fractions. The members 
of this category include DES, PARL, NTRK3 and PRSS3. Group 2: Comparing the 
expression level in shTG and shRNA cells, this group consisted of proteins that showed 
higher expression in shTG in one sucrose fraction, but showed lower expression level in 
shTG in another fraction. GOLGA2 and ITGB4 fell into this category. Group 3: shTG 
and shRNA cells were found to have relatively similar expression patterns in all sucrose 
fractions. This group consisted of the protein STXBP2.   
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3.8  Characterisation of Organelles in Different Sucrose Fractions 
The characterisation for known organelles in different SFs from 8.5%, 10%, 15%, to 20% 
is shown in Figure 3.8. Organelles such as recycling endosomes, endoplasmic reticulum, 
and mitochondria were only found in particular SFs. Recycling endosomes were 
predominantly found in the 8.5-15% SFs. Endoplasmic reticulum were only present in the 
8.5% SF. Mitochondria were only found in the 10% SF.  
 
All the other organelles, for example early endosomes, late endosomes, secretory vesicles 
and lysosomes, showed different immunoreactivities intensities in 8.5-20% SFs. Early 
endosomes were predominantly expressed in the range of 8.5%-15% SFs. The 
expressions of late endosomes (RAB7), recycling endosomes (RAB11A) and the 
secretory vesicles (RAB27A) were lower in shTG cells compared to control. On the other 
hand, the reduction of TG-2 did not affect the immunoreactivity against lysosomes 








Figure 3.8. Western blots showing expression levels of organelle markers according to 
various densities of sucrose fractions in centricollated control and shTG cells. Late 
endosome (RAB7), recycling endosome (RAB11A) and the secretory vesicle (RAB27A) 
showed decreased expressions in shTG compared to control cells. The expression level of 
early endosome (EEA1), lysosomal (LAMP1), mitochondria (RAB3D) and endoplasmic 
reticulum (PDI) expressions were not affected by the status of TG-2. Early endosomes, 
late endosomes, secretory vesicles and lysosomes were present in all sucrose fractions. 
Recycling endosome, endoplasmic reticulum and mitochondria were not present in all 
fractions, for example recycling endosomes were mostly found in the 8.5%-15% range, 
while endoplasmic reticulum and mitochondria were mostly found in the 8.5% and 15% 
sucrose fractions respectively.  




3.9 Discussion  
Depending on sub-cellular localisation, TG-2 proteins in different locations had different 
functions; for example cell surface TG-2 had different functions from intracellular TG-2 
[60, 61]. These were previously studied using non-ocular cell types such as 
neuroblastoma cells [135], human and mouse fibroblasts [141], Swiss 3T3 murine 
fibroblasts and primary vascular endothelial cells [61]. In this study, proteins binding to 
TG-2 had different protein concentrations and were present in different cell fractions. 
TG-2 was predominantly present in the lower density sucrose fractions (SF) as 
immunoreactivity against TG-2 was found in 8.5%, 10%, 15% and 20% fractions. This 
suggested that TG-2 may have a role in protein trafficking in these SFs.  
 
TG-2 binding proteins were categorised into 3 groups according to the way TG-2 status 
affected the protein distribution. Group 1 had lower expression of binding proteins in 
shTG compared to control in all or specific SFs. This group consisted of Desmin (DES), 
presenilin associated, rhomboid-like protein (PARL), neurotrophic tyrosine kinase, 
receptor, type 3 (NTRK3) and serine protease (PRSS3). Group 2 included two members: 
integrin β4 protein (ITGB4) and Golgi associated protein, golgin-A2 (GOLGA2). 
Binding proteins that fell in this group had lower expression in shTG cells in one SF, but 
showed a reversal trend in other SFs. Group 3 was made up of Syntaxin binding protein 
(STXBP2), which expressed similar concentration in both control and shTG cells in all 
the four SF. Recycling endosomes, endoplasmic reticulum, and mitochondria were found 
in specific SFs. Meanwhile, early endosomes, late endosomes, secretory vesicles and 
lysosomes were present in all the SFs tested. 
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The current study differs from previous literatures, all of which examined sub-cellular 
trafficking and cell adhesion, in the use of high-speed centricollation to fractionate cell 
lysates. There are few or no reports that employ this relatively new centricollation 
technology to study sub-cellular trafficking. Instead, most studies had chosen to use 
ultracentifugation as a tool for protein isolation to evaluate sub-cellular trafficking in 
various cell types [142, 143].  These studies predominantly evaluated the sub-cellular 
localisation of specific proteins but did not study in the context of cell motility processes 
or wound healing.  
 
This work shares some similarities with a study by Zemskov et al whereby they 
investigated TG-2-regulated trafficking of low-density lipoprotein receptor-related 
protein 1 (LRP1) from cell surface to inside of the cells and other sub-cellular 
compartments using methods similar to this current study [141]. Similar to this work, 
Zemskov’s study used fractionation to analyse the membrane distribution of various 
proteins. Unlike the current study that first carried out gross fractionations over a wider 
range of SFs (8.5% - 40%), followed by greater resolution at finer range from 8.5%, 10%, 
15% to 20% SFs, Zemskov’s study only included SFs at 5%, 35% and 45%. In addition, 
instead of centricollation, fractionation by ultracentrifugation was performed in 
Zemskov’s study. Both studies had evaluated a wide range of organelles, except that 
there was no systemic characterisation of the SFs in Zemskov et al’s report. Apart from 
the distribution of LRP1, Zemskov et al did not examine how TG-2 affected the 
trafficking of other proteins; whereas in the current study, TG-2 binding proteins were 




The localisation of late endosomes and lysosomes using RAB7 and LAMP1 respectively 
was consistent with published literature [144]. In the current study, RAB7 was detected 
in 8.5% and 10% SFs; while de Araujo et al detected RAB7 in 6-11% SFs. LAMP1 was 
detected in 8.5%, 10%, and 20% SFs in this study; while it was detected in 6-16% SFs in 
de Araujo et al’s data. 
 
3.9.1  Possible Roles of TG-2 Binding Proteins  
A group of TG-2 interacting proteins which may have important roles in wound healing 
response was discovered in the current study. The possible roles of these seven TG-2 
interacting proteins are discussed below.  
 
The binding of integrin β4 (ITGB4) with plectin was shown to be important for the 
formation and stability of hemidesmosomes (HDs) [145-147].  With the formation of β4-
plectin complex, HDs could mediate the adhesion of epithelial cell to the underlying 
basement membrane [145]. The removal of integrin β4 genes in mice resulted in the lack 
of hemidesmosomes, causing the fragile attachment of the tissue to the basal lamina 
[146]. The loss of integrin β4 was not compensated by the other integrins in the tissues. 
Hence, patients expressing a null mutated integrin β4 suffered from epidermal blistering 
due to poor epidermis adhesion to the basement membrane [148]. Apart from its 
structural adhesive role, integrin β4 also acted as a signalling component involved in cell 
migration [149-151]. Joly et al reported that integrin β4 interacted with Laminin-5 and 
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influenced epithelial cell adhesion, signalling and migration properties [151]. Another 
study showed that the phosphorylation of integrin β4 at specific site was important for 
HD disassembly at the trailing edge of cells during cell migration [150]. Pullar et al 
demonstrated that integrin β4 could coordinate with epidermal growth factor to initiate 
and maintain cathodal migration, with Rac1 as a common downstream target [149]. From 
these findings, it is evident that integrin β4 may have a crucial role in cell adhesion and 
migration possibly in wound healing as well. 
 
Desmin (DES) is a type III intermediate filament that may have an important role in 
strengthening and maintaining the integrity of the myofibroblasts and the corneal stroma 
[152]. Injury in the cornea was reported to increase the desmin expression in the stromal 
cells, which then enhanced the stromal strength and helped in the contraction of the 
wound in incisional injuries [152]. Capetanaki et al reported that skeletal muscle cells in 
desmin null mice had poor cell adhesion and showed increased intercellular space [153]. 
Another study showed that desmin could bind to alpha-crystallin, a heat-shock protein, in 
the leading edge of the migrating lens epithelial cells [154]. Hence, desmin may play an 
important role in cell adhesion and migration, which is essential in wound healing and to 
maintain normal cell metabolism. 
 
Golgin subfamily A member 2 (GOLGA2) is a cis-Golgi matrix protein that plays an 
important role in the stacking of Golgi cisternae, maintenance of Golgi structure and 
glycosylation. GOLGA2 was reported to be involved in subcellular vesicle trafficking of 
proteins to various cellular compartments [155, 156]. Cordell et al implicated that 
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GOLGA2 and its binding protein were involved in the delivery of non-classically 
secreted proteins to the plasma membrane [157]. Another study by Diao et al reported 
that knocking down GOLGA2 significantly inhibited the transport from endoplasmic 
reticulum to golgi [158]. They suggested that GOLGA2 was involved in membrane 
tethering at the endoplasmic reticulum to the Golgi intermediate compartment and cis-
Golgi [158].  Meanwhile, Kodani et al found that GOLGA2 regulated centrosome 
organization and function through the Rho GTPase Cdc42 and Tuba [159]. During cell 
migration, Cdc42 would control polarisation at the leading edge of the cell and the re-
orientation of the Golgi apparatus. These evidences suggested that GOLGA2 was 
involved in protein trafficking and may have an important role in cell migration.  
 
Protein serine 3 or mesotrypsin (PRSS3) is an enigmatic trypsin isoform resistant to 
natural trypsin inhibitors and was reported to be involved in the metastasis of various 
cancer cells [160-162]. A study in early-stage non-small lung cancer cells found that 
overexpression of PRSS3 significantly increased transendothelial migration and a similar 
phenomenon in pancreatic cancer cells showed increased proliferation, invasion and 
metastasis,  suggesting a potential role for mesotrypsin in metastasis [160, 163]. Another 
paper by Hockla et al reported that up-regulation of PRSS3 in breast cancer cells 
increased malignant tumour growth [161]. They also suggested that mesotrypsin could 
act through proteolysis of extracellular or cell surface targets to promote malignant 
growth [161].  Since proteolysis of extracellular matrix is known to be essential for cell 




Neutrotrophic tyrosine kinase, receptor, type 3 protein (NTRK3) is a cell surface receptor 
responsible for the proliferation and differentiation of neurally derived cells. Studies by 
Yamauchi et al reported that NTRK3 could enhance the migration of premyelinating 
Schwann cells via activation of Rho GTPases Rac1 and Cdc42 as well as the downstream 
c-Jun N Terminal kinase cascade (JNK)  [164, 165]. The ability of NTRK3 to regulate 
cell motility through Rho GTPase pathways suggests that its interaction with TG-2 may 
enhance the cell migratory response.  
 
Presenilin-associated rhomboid-like protein (PARL) is a mitochondrial resident rhomboid 
serine protease which encodes mitochondrial integral membrane proteins. PARL knock-
out mice would have impaired mitochondrial cristae junctional sealing and woulddie 
postnatally due to massive apoptosis [166].  Currently no literature has directly related 
the function of PARL to cell adhesion and migration. Mitochondrial fission and fusion 
events were linked to T lymphocytes polarisation and movements as well as to cancer cell 
migration and invasion [167]. Since PARL is involved in mitochondria expression, 
PARL may indirectly influence cell migration and adhesion through mitochondria and 
other mitochondrial interacting proteins.  
 
Syntaxin binding protein 2 (STXBP2, also known as MUNC18-2) is important for 
regulating intracellular granule trafficking. STXBP2 was also reported to control the 
assembly of SNARE complex [168, 169]. Skalski et al have reported that inhibition of 
SNARE mediated trafficking pathway affected cell spreading and cell adhesion [170, 
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171]. Hence, the interaction between STXBP2 and TG-2 may influence cell spreading 
and adhesion.  
 
3.9.2  Proposed Hypothesis 
The following hypotheses on the role of TG-2 and the trafficking of its interacting 
proteins are proposed based on existing literatures and known protein functions: Group 1 
proteins consisted of DES, PARL, NTRK3, and PRSS3; these had higher protein 
expression in control compared to shTG. In this case, TG-2 is proposed to either act as an 
adaptor protein, or as an upstream regulator for the transcription of interacting protein. 
TG-2 acting as an adaptor protein may bind and sequester its interacting protein in 
particular cellular compartments. Hence, TG-2 deficiency may cause non-differential 
accumulation of interacting partners in other cell compartments. TG-2 was reported to act 
as an adaptor protein for β1 and β3 integrins in subcellular compartments [29]. 
Alternatively, TG-2 may also act as an upstream regulator that modulated the 
transcription of the binding proteins. The increase in TG-2 expression would therefore 
increase the interacting protein expression in all the cell compartments.  
 
Group 2 members GOLGA2 and ITGB4 showed a reversal pattern of protein expression 
from 8.5% to 10% SFs between control and shTG. In the 8.5% SF, an accumulation of 
TG-2 interacting proteins were observed in shTG, but not in the 10% and higher SFs. On 
the contrary, the control cells showed a higher protein expression in the 10% SF. TG-2 is 
proposed to act as a carrier protein which can translocate GOLGA2 and ITGB4 from one 
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compartment (8.5% SF) to another cellular compartment (10% and higher SFs). Hence, 
deficiency in TG-2 may hinder the removal of its interacting proteins from 8.5% SF 
causing an accumulation in that compartment. It was reported that fibronectin could act 
as a carrier protein for extracellular TG-2 [64]. Thus, it would not be surprising if 
intracellular TG-2 exhibits a similar type of relationship with its ligands.  
 
Subcellular TG-2 status most likely did not affect the trafficking of group 3 proteins. This 
was because similar immunoreactivities were observed against STXBP2 between control 
and shTG cells in all tested SFs, suggesting that STXBP2 was probably unaffected by 
TG-2 concentration. In Chapter 4 of this thesis, TG-2 was found to regulate wound 
closure rate. In combination with the current findings, TG-2 is hypothesised to affect 













The current study employed a novel density based protein separation technique known as 
centricollation to elucidate the biological function of specific molecules; it is particularly 
powerful when combined with traditional cell biology techniques. This was not done 
before and hence, this current study may provide an idea of how to fully utilise this 
technology in the future. In this study, centricollation was used to explore the sub-cellular 
localisation of TG-2 and its interacting partners. TG-2 was found to be involved in the 
trafficking of sub-cellular proteins which may regulate the biological and cellular 
functions relevant to wound healing processes. The current study provided an insight on 
TG-2’s mechanism, its trafficking pathway and associated ligands. This may help in the 
future development of therapies for corneal epithelial wound healing. 
 
Key Findings 
a. Seven proteins that interacted with different TG-2 fragments were identified.  
b. TG-2 binding proteins were categorized into 3 groups according to the way TG-2 
status affected the protein distribution. 
c. TG-2 status could affect some of the sub-cellular concentrations of its binding 
proteins such as DES, PARL, NTRK3, PRSS3, ITGB4 and GOLGA2; and 





CHAPTER 4. TRANSGLUTAMINASE-2 IN CORNEAL EPITHELIAL 
MIGRATION AND ADHESION 
4.1 TG-2 in Cell Adhesion and Migration 
It was recently reported in literature that cell adhesion and migration may be affected by 
the involvement of cell surface TG-2 in cell-matrix interactions [36, 65]. Gentile et al 
first showed that overexpression of TG-2 increased fibroblast cell adhesion to the 
substratum, together with increased resistance to trypsin detachment [44]. Gaudry et al 
confirmed the involvement of cell surface TG-2 in cell adhesion by reporting that cell 
adhesion points had higher concentrations of TG-2 [172]. Endothelial cells with reduced 
expression of TG-2 were shown to decrease cell adhesion, spreading and stabilisation of 
melanoma adhesion under laminar flow [173, 174]. In addition, TG-2
–/–
 mouse 
embryonic fibroblasts were reported to migrate slower compared to the fibroblasts 
derived from wild-type mice [82]. A similar observation was reported in human retinal 
pigment epithelial (RPE) cells whereby the blocking of TG-2 reduced cell adhesion and 
migration [175]. 
 
The in vivo wound healing experiment previously done by our laboratory reported that 
mice with homozygous TG-2 deletion (TG-2
−/−
) showed delayed corneal wound closure in 
contrast to their wild type (TG-2
+/+
) counterparts (Figure 4.1A). From day 3 onwards, the 
remaining unclosed epithelial defects were significantly different (p< 0.05) (Figure 4.1B). 
Immunofluorescence staining showed that TG-2 was present in the corneal epithelial 
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layers and basement membrane of TG-2
+/+
 mice, but absent in the TG-2
-/-









Figure 4.1. The corneal epithelial layers and the basement membrane of homozygous 
transglutaminase (TG)-2 deleted (TG-2−
/−) mice showed delayed corneal wound closure 
compared to wild type (TG-2
+/+
) mice. (A) Representative microscopy images showing 
corneal epithelial wound stained with topical fluorescein dye (green) after the corneal 




 mice. Scale bar = 100 μm. (B) 
Line graph showing the percentages of unclosed wound (vertical axis) over time 




mice, 5 mice were used for each genotype and 3 
independent experiments were done. *: p < 0.05. (C) Picture showing 





mouse. Primary antibody against TG-2, FITC conjugated secondary antibody (green) and 






4.2 Hypothesis and Specific Aims 
Since TG-2 is ubiquitously present in human corneal epithelium and TG-2 is known to be 
related to cell surface integrins and matrix proteins, we hypothesised that TG-2 affects 
wound healing processes through cell adhesion, migration and interaction with focal 




To study the functional significance of TG-2 on cell adhesion and migration in corneal 
epithelial wound closure. 
a. To investigate the role of TG-2 in cell migration, adhesion and proliferation using 
in vitro techniques such as cell scratching assay, cell migration assay, 
immunofluorescence staining and trypsinisation assay. 
b. To evaluate the possible interaction of TG-2 and focal adhesion proteins in 
cultured human corneal epithelial cells by performing western blot against focal 
adhesion proteins. 
c. To determine if TG-2 affects paxillin incorporation in adhesion complexes by 
checking its in vitro kinase activity. 







Figure 4.2. Schematic showing the focus of this chapter, as depicted by the blue square. 





Methodology Flow Chart 4. Flow chart showing general methodology to study the role 
of TG-2 on cornea epithelial wound healing and relevant wound healing processes consist 
of cell adhesion, spreading and migration. The detailed protocol for each technique is 
described in the Appendix.   
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4.4 Delayed Wound Closure in TG-2 Deficient Cells  
As mentioned in Figure 4.1, our in vivo mouse cornea wound healing experiment showed 
that TG-2 knockout mice had slower wound closure compared to their wild type 
counterparts. The same phenomenon was observed in in vitro scratch test assay using 
immortalised human corneal epithelial cells. The closure of a uniformly scratched wound 
took 12 hours in control shRNA cells, whereas the wound closure was delayed and not 
evident in shTG cells after 48 hours (Figure 4.3). Since TG-2 could interact with 
extracellular matrix fibronectin during cell adhesion and migration [65], the experiment 
was performed on both uncoated and fibronectin-coated surfaces (fibronectin coating 
methods at Appendix A3.3). The result was independent of the presence of the 
fibronectin coating on the culture vessel. This was because control cells always closed 
their scratched wounds more rapidly than the shTG cells regardless of the presence of 
fibronectin (Figure 4.3B). From 6 hours post scratching onwards, there were significant 
differences in the width of the residual wound between shTG and control cells (p < 0.05) 
(Figure 4.3B).  
 
Statistical analysis (General Linear Model, Appendix A18) was performed from 2 to 14 
hours after scratching. The analysis reported that the ‘within subject’ factor (time) was 
significant (p < 0.001) whereas the TG-2 status and fibronectin coating were significant 
for the ‘between subject’ factors (p < 0.001). Upon post-hoc analysis, the wound in 
control cells grown on fibronectin coated surfaces closed significantly faster than shTG 
cells, regardless of whether shTG cells were grown on fibronectin coated (p = 0.001) or 
uncoated surfaces (p = 0.005). On the other hand, on uncoated surfaces, the wound of 
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control cells closed faster than shTG cells, again regardless of whether shTG cells were 
grown on fibronectin coated (p = 0.001) or uncoated surfaces (p = 0.004). There was no 
significant difference in wound width between shTG cells grown on plates with or 
without the coating of fibronectin (p = 0.885). Hence, fibronectin coating did not affect 






Figure 4.3. TG-2 knockdown in human corneal epithelial cells caused delayed wound 
closure. (A) Phase contrast microscopy images at different time points. A uniform width 
scratched strip was created on confluent layer of control or shTG cells. The cells were 
grown on either uncoated or fibronectin-coated surfaces. Scale bar = 50 μm. (B) Line 
graph showing the percentages of defect remaining (vertical axis) over time post-
scratching (horizontal axis) in control and shTG cells, n = 6 independent experiments. *: 
















4.5 In vitro Study of TG-2 Deficiency in Cell Migration and Adhesion  
4.5.1  TG-2 Deficiency Reduced Cell Migration Speed 
A 2-D in vitro cell migration assay was performed to study whether the speed of cell 
migration at the wound edge affected the duration of wound closure. Fifty random cells 
were selected at the advancing edge and their centroids were recorded at 10 minute 
intervals for around 16 hours with time-lapse microscopy (Figure 4.4A). On uncoated 
culture surfaces, control shRNA cells migrated at significantly higher speed (p < 0.0001) 
(uncoated: 0.42 ± 0.05 μm/min) compared to shTG cells (uncoated: 0.31 ± 0.03 μm/min); 
with the migration speed difference of 0.11 μm/min (Figure 4.4B, top). Similarly, control 
shRNA cells also migrated faster on fibronectin-coated plates, with 0.12 μm/min 
difference of migration speed between control (0.66 ± 0.05 μm/min) and shTG cells (0.54 
± 0.05 μm/min) (Figure 4.4B, bottom).  
 
Statistical analysis with dependent variable consisting of cell speed at different time 
period showed that the ‘between subject’ factors (fibronectin status, TG-2 status) were 
significant (p = 0.001). The significance in the time factor (p < 0.001) may indicate the 
increase in speed for the first 25 time points (first 4 hours) (Figure 4.4C). Post hoc testing 
showed that control cells migrated faster on fibronectin coated surfaces compared to the 
other three setups (all p < 0.001). On uncoated plates, control cells migrated significantly 
faster than shTG cells (p < 0.001); shTG cells grown on fibronectin coated surfaces 
migrated faster compared to shTG cells grown on uncoated plates (p < 0.001). The cell 
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migration speed between control cells cultured on uncoated plates and shTG cells grown 
on fibronectin-coated plates (p = 1.0) was no different. 
 
To evaluate whether the reduction in shTG cells’ migration speed was due to a delay in 
the initiation of cell movement, the data was analysed in segments of 6 hours (Figure 
4.4C). ShTG cells did not show a delay in the initiation of cell movement in the first hour 
compared to the control shRNA cells. In the first 6 hours, all four conditions showed an 
increase in free-space movement, subsequently reaching a more stable level, followed by 
a decline in velocity. The migration velocity was significantly lower in shTG compared 
to the control cells (P < 0.001), whether on uncoated (Figure 4.4D) or fibronectin-coated 
polystyrene surfaces (Figure 4.4E). This trend continued for the next 6 hours, but in later 
phases (>12 hours). 
 
Using in-house developed software, the effects of TG-2 on cell directionality was 
evaluated (Method see Appendix A18.3). The data was analysed in segments of 4 hours. 
For every segment, shTG cells had higher population of cells at higher oscillation mean 
range compared to the control cells. By measuring the lateral deviation of individual cells 
during migration, shTG cells showed higher amplitude of cell movement, suggesting 









Polystyrene surface with no fibronectin coating 


























Polystyrene surface with fibronectin coating 
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shRNA shTG shRNA shTG shRNA shTG
Uncoated 0.46±0.09 0.29±0.06 0.44±0.08 0.38±0.07 0.40±0.04 0.29±0.08
Fib coated 0.70±0.04 0.55±0.08 0.69±0.07 0.58±0.04 0.58±0.06 0.44±0.06
1-6hr 6-12hr 12-18hr
















Figure 4.4. Figures showed results of non-traumatic cell migration assay. Fifty adjacent 
cells were randomly selected at the advancing edge of the confluent cell sheet. Migration 
of cells was recorded every 10 min over 16 hours using live cell time-lapse microscopy. 
The centroid positions of the cells, consisting of either scrambled shRNA (control) or 
shTG cells, were tracked using ImageJ software. (A) Phase contrast microscopy images 
at 0, 7 and 14 hours after removal of culture cylinder. Blue and red lines represented the 
migratory tracks of the cells. Scale bar = 50 μm. (B) Line plots showing cell migration 
and mean velocity of 50 adjacent cells randomly selected at the advancing edge for each 
condition, whereby the initial cell positions were normalised to the plot origin. Top: Cell 
migration using cells cultured on polystyrene surface without fibronectin coating. 
Bottom: Cell migration with cells cultured on polystyrene surface coated with human 
fibronectin. (C) General linear model (GLM) analysis showing the mean velocity of 50 
contiguous shRNA or shTG cells on uncoated plates, recorded every 10 minutes over a 
period of 16 hours. (n = 2 independent experiments).  (D) Line plots showing segments of 
cell migration in period of 6 hours. Mean velocity of each time period was calculated. (E) 
Table showing the mean velocity of 50 randomly selected control shRNA or shTG cells 
at the advancing edge for each condition, on either uncoated or fibronectin-coated plates, 
recorded every 10 minutes and analysed in segments of every 6 hours. Mean velocity of 













Figure 4.5. Histograms showing the distribution of numbers of cells (y-aixs) against the 
oscillation of cells in micrometre (x-axis) over time between control shRNA and shTG 
cells on fibronectin coated surfaces.  
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4.5.2  TG-2 Deficiency Reduced Cell Adhesion/Spreading 
During the in vitro scratch test, shTG cells had the tendency to fold back on themselves at 
the advancing edge, which indicated signs of reduced adherence to the underlying culture 
surface. By measuring and analysing the change of impedance, cellular behaviors such as 
cell attachment, proliferation and cellular responses to pharmacological stimuli could be 
quantified. shTG cells showed significant reduction in cell impedance compared to its 
control counterpart (p < 0.001)  from 1 to 6 hours after initial seeding on polystyrene 
surfaces (Figure 4.6A).  Factors that potentially caused the decreased impedance in shTG 
cells were assessed individually. The MTS cell proliferation assay performed on non-
confluent monolayer cells showed no difference in proliferation rate between shTG and 
control cells (Figure 4.6B). This was supported by steady state cell cycle analysis (Figure 
4.6C) which also indicated no difference in proliferation rates between the two cell types. 
Consistent with the findings, there was a low proportion of Ki-67 positive cells at 6 hours 
after scratching and there was no significant difference (p = 0.59) between shTG [14/581 
(95%CI: 0.0136– 0.0415)] and control shRNA [11/368 (95%CI: 0.0156–0.0550)] (Figure 
4.6D).  
 
The mean cell area between phalloidin-stained shTG (555 ± 161 μm2) and control shRNA 
cells (682 ± 218 μm2), measured 24 hours after seeding on fibronectin-coated surfaces, 
was significantly different (p < 0.0001) (Figure 4.6E). Interestingly, in the absence of 
fibronectin coating, there was no significant difference in the cell area between control 
and shTG cells (Figure 4.6E, Left). There was no significant difference between groups 
in their nuclei area (p > 0.05 ANOVA in Figure 4.6E, Right). Time-lapse microscopy 
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showed that shTG cells detached faster than control shRNA cells after diluted trypsin was 
added to the uncoated polystyrene plates (Figure 4.6F).  
 
In summary, the delay of wound closure in shTG cells compared to control may be due to 


































Figure 4.6. The reduced cell impedance in TG-2 knockdown corneal epithelial cells was 
due to the decrease in cell adhesion and spreading, but not cell proliferation. (A) Five 
million each of control shRNA or shTG cells were seeded on polystyrene surfaces in 
triplicate. Cell impedance value (cell index) was recorded over time. (B) Bar graph 
showing MTS assay which measured the cell proliferation rate of control shRNA and 
shTG cells grown on polystyrene surfaces. Y-axis denotes the cell proliferation measured 
at A490. (C) Cell cycle analysis showed the percentage of cells in G0/G1, S, and G2/M 
phases in control shRNA and shTG cells. (D) Representative microscopy images of cells 
stained positively with Ki-67 (green). Control shRNA or shTG cells were seeded on 
polystyrene surfaces till confluent and a single uniform width scratched wound was 
administered. Six hours after scratching, cell proliferation (red arrows) was determined 
by Ki-67 stains. Cell nuclei were counterstained with DAPI (blue). Scale bar = 50 μm. 
(E) Bar graph showing cell (left) and nuclei (right) area of control shRNA and shTG cells 
grown on either fibronectin-coated (+) or uncoated (−) polystyrene plates for 24 hours. 
The areas were calculated by randomly choosing more than 50 adhering cells. N= 3 
independent experiments.*: p < 0.001. (F) Time-lapse images of control shRNA and 
shTG cells after addition of diluted 0.005% Trysin-EDTA in PBS at 37°C, 5%CO2. 
Imaging was stopped when all cells had detached, which was after 25 minutes for shTG 




4.6 TG-2 Deficiency Disrupts Actin Cytoskeleton  
To evaluate the effects of TG-2 on actin cytoskeleton, filamentous (F)-actin was stained 
with phalloidin 3 hours after scratching in control shRNA and shTG cells (Figure 4.7). 
The cortex at the advancing edge and cell-cell junctions of control shRNA cells showed 
stronger staining of phalloidin compared to shTG cells, indicating condensation of F-
actin in the control cells. Also, majority of the control shRNA cells at the advancing edge 
formed lamellipodia in line with the direction of cell migration. On the other hand, shTG 
cells exhibited disrupted F-actin pattern. At the advancing edge of shTG cells, the 
presence of large gaps at the advancing edge showed signs of cells detachment. Also, 
lamellipodia at the advancing edge seemed to be extended in the direction of the wound 
and also perpendicularly to the wound (Figure 4.7, right: white arrows).  
 
Rho family of small GTPases such as RhoA, Rac and Cdc42 are known to regulate actin 
organisation, cell adhesion and migration [176, 177]. The Rho family proteins alternated 
between an active GTP-bound state and an inactive GDP-bound state and their activation 
could be quantified by performing G-Lisa activation assays (See methods at Appendix 
A12.4). The status of TG-2 in the cells did not affect the level of RhoA; whereas shTG 
cells showed significant reduction in activation of Rac and Cdc42 compared to control 

















Figure 4.7. Figures showing FITC-conjugated phalloidin staining and Rac, Cdc42, RhoA 
activation assays in control shRNA and shTG cells. (A) Representative images of FITC-
conjugated phalloidin staining (green) in control shRNA and shTG cells on uncoated 
polystyrene surfaces, 3 hours after in vitro scratching. Blue staining indicated nuclei 
stained with DAPI. White arrows show the directions of lamellipodia. Scale bar = 50 μm. 
(B) Activation assays for RAC (left), Cdc42 (middle) and RhoA (right). Subconfluent 
control shRNA and shTG cells were lysed and activation assays were performed. 
Absorbance was read at 490nm. Three independent experiments were performed. Height 





4.7   Interaction and Effects of TG-2 with Focal Adhesion Proteins 
4.7.1  TG-2 Deficiency Reduced Phosphorylation of Ser178 Paxillin 
Kimura et al reported that the phosphorylation of paxillin at Ser178 was important for 
cell migration in cultured human corneal epithelial cells [101], which were the same type 
of cells used in this project. They reported that when Ser178 paxillin was replaced with 
alanine, an amino acid which cannot be phosphorylated, wound closure rate was 
significantly decreased in human corneal epithelial cells expressing these mutant proteins 
[101].  Since Kimura et al had used the same cell types as this project, would TG-2 have 
any effect on the phosphorylation of paxillin at Ser178?  
 
To investigate TG-2’s role in phosphorylating integrins and focal adhesion complexes in 
control shRNA or shTG cells, control shRNA and shTG cells were seeded in serum-free 
medium and incubated overnight to reach a confluency of 60-70% on uncoated 
polystyrene surfaces (Figure 4.8A-E). To detect the phosphorylation of focal adhesion 
proteins, western blotting was performed on the lysate of control shRNA and shTG cells 
using specific antibodies targeting phosphorylated focal adhesion proteins. Total protein 
of each focal adhesion protein was also probed to show that the change in phosphorylated 
protein level was not due to the change in the total protein.  
 
Phosphorylation of paxillin at Ser178 was reduced in shTG cells compared to control 
cells (Figure 4.8A). This observation was consistent with the in vivo result in Figure 4.2, 





 mice cornea epithelium 4 hours after abrasion in contrast to wild type TG-2
 
mice. 
The amount of TG-2 in the cells did not affect the phosphorylation of β-1 integrin at 
Ser785 (Figure 4.8B). Some literatures reported that corneal epithelium did not have β-3 
integrin [178, 179]. However, β-3 integrin was successfully detected in the cultured 
corneal epithelial cells as shown in Figure 4.9C. There was a reduction in the 
phosphorylation of Tyr747 at β-3 integrin shTG cells in contrast to the control cells 
(Figure 4.8C). There was also reduced phosphorylation at Tyr822 of vinculin (Figure 
4.8D) and focal adhesion kinase (FAK) at Tyr925 in shTG cells compared to control 
cells, but there was no difference at Tyr576 of FAK (Figure 4.8E).  
 
Since shTG cells exhibited less cell spreading on fibronectin coated surfaces (Figure 
4.6E), the phosphorylation levels of some of these focal adhesion proteins (Ser178 
paxillin, Tyr747 β-3 integrin, Tyr822 Vinculin) were repeated in serum-free medium on 
uncoated surfaces. Similar results were observed when the same experiments were 













Figure 4.8. Figures showing western blot images of shTG and control shRNA cell lysate 
on primary antibodies against various adhesion proteins. (A) total paxillin and pS178 
paxillin, (B) total β1 integrins and pS785 β1 integrins, (C) total β3 integrins and pY747 
(D) total vinculin and pY822 vinculin (E) total focal adhesion kinase (FAK), pY925 FAK 
and pY576 FAK. β actin was used as loading control. (F) Densitometry analysis showing 






























Figure 4.9. Human corneal epithelial cells with TG-2 deficiency reduced the 
phosphorylation of several focal adhesion proteins. (A-C) Control shRNA or shTG cells 
were seeded on fibronectin-coated plates followed by 5 hours of serum starvation. 
Western blots were then performed using 50µg of total cell lysates using primary 
antibodies specific for phosphorylated and total (A) β3 integrin, (B) paxillin and (C) 
vinculin; β actin was used as loading control. (D) Bar chart showing densitometry of 
western blots. For each of the protein of interest, the phosphorylated protein intensities 
were normalised to the total protein intensities. The resulting value were expressed as 
fold change comparing to the intensity of control cells (n= 3 independent experiments). * 




4.7.2 TG-2 Interacts with Paxillin in In vitro 
In previous sections, it has been shown that TG-2 is crucial for corneal epithelial cell 
adhesion and migration. In addition, the phosphorylations of focal adhesion proteins such 
as integrin β-3, vinculin, paxillin and FAK at specific tyrosine/serine residues were 
associated with TG-2 status. However, there is no known relationship between TG-2 and 
the focal adhesion proteins, beyond the fact that TG-2 could interact with integrin β1 and 
β3 at cell surface to bind fibronectin [29, 180]. Hence, co-immunoprecipitation using 
anti-paxillin antibody was used to examine whether recombinant TG-2 could interact 
with vinculin, paxillin and FAK.  
 
Co-immunoprecipitation data showed that anti-paxillin antibody successfully pulled 
down TG-2 in both shTG and control shRNA cell lysates (Figure 4.10). Control shRNA 
cells had more TG-2 proteins compared to shTG (Figure 4.10, leftmost 2 columns, row 1) 
while similar amounts of paxillin were pulled down in the assay (Figure 4.10, leftmost 2 
columns, row 2). Vinculin and FAK were also co-immunoprecipitated by anti-paxillin 
antibody (Figure 4.10, leftmost 2 columns, rows 3, 4,), suggesting that these were bona 
fide mature focal adhesion complexes whose components separated under denaturing 
conditions. The amount of TG-2 did not affect the binding of FAK or vinculin to the 
paxillin-containing complex (Figure 4.10, leftmost 2 columns, rows 3, 4). Even when 
pre-clearing had been performed, TG-2 in the lysate may still be able to interact non-
specifically with the streptavidin agarose resin during incubation; this was why negative 
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control experiments without paxillin antibodies to pull down were performed. (Figure 


























Figure 4.10. Co-immunoprecipitation of shTG and control cell lysate against anti-
paxillin. (A) Total cell lyate from cell line shTG and control shRNA was 
immunoprecipitated with or whithout anti-paxillin. Elute and flow-through were used for 
western blotting with antibodies against TG-2 and focal adhesion proteins: paxillin, 
vinculin and FAK. Elute from plain streptavidin agarose beads without adhering antibody 
was used as negative control. (B) Bar chart showing the densitometric quantification of 
the proportion of proteins pulled down with paxilllin, using paxillin antibody, from shTG 
and shRNA cell lysate. Height of bars represents mean of ratios of 3 experiments, error 





The binding of TG-2 to paxillin was confirmed by an in vitro label-free assay which 
studied the interactions between TG-2 and focal adhesion proteins such as paxillin, 
vinculin and integrin (Methods at Appendix A16). This assay used an optic grating sensor 
technique, Enspire Multimode Plate Reader (Perkin Elmer, MA, USA), to evaluate in 
vitro protein interactions. The readout of this assay would measure changes in the index 
of refraction upon a binding event, indicated by a shift of wavelength of the incident 
light. The wells in the microplate were pre-coated and incubated overnight with 
recombinant paxillin protein. When different concentrations of TG-2 and αVβ3 integrin 
recombinant proteins were added to the immobilised paxillin protein, spectral shifts were 
detected after equilibrium (Figure 4.11A, B), suggesting both TG-2 and αVβ3 integrin 
could individually bind to the paxillin proteins. On the contrary, the addition of 
increasing concentration of recombinant vinculin to the immobilised paxillin showed 
minimal change in the spectral shift, hence the binding of vinculin to paxillin was not 
conclusive (Figure 4.11C).  
 
In the context where TG-2 had already interacted with paxillin, the addition of αVβ3 
integrin (Figure 4.11D left) or vinculin (Figure 4.11D right) caused additional 
interactions, which may be due to the binding of these two molecules to the pre-existing 
TG-2/paxillin complex, or that the two additional molecules enhanced the TG-2/paxillin 
interaction. When TG-2 was added to the integrin/paxillin complex (Figure 4.11E), there 
was a further increase in the spectral shift; implying that either the newly added TG-2 had 
bound to the integrin/paxillin complex, or that it had enhanced the binding of previously 
added integrin to the immobilised paxillin. Spectral shift occurred after the addition of 
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TG-2 to the solution containing vinculin (Figure 4.11F). This increase in spectral shift 
suggested that the newly added TG-2 had bound to the immobilised paxillin, implying 
that the interactions between TG-2 and paxillin were stronger than the vinculin paxillin 
interactions. These experiments were done in pH 7.0. Experiments repeated at pH 4.3 
















Figure 4.11. Graphs showing Enspire Label-free biochemical assay which showed a 
spectral shift after the addition of recombinant proteins to immobilised paxillin. Paxillin 
recombinant protein was first immobilised at a final concentration of 0.05µg/µL. After 
the immobilised paxillin was in equilibrium, the spectral shift was reset arbitrarily to 
zero picometres before adding a second recombinant protein, either TG-2, αVβ3 
Integrin or Vinculin, at the indicated concentrations. The spectral shift was then 
measured and recorded (Top row: A, B, C). These spectral shifts were again reset to 
zero before the addition of the next recombinant protein. The new shifts were then 







4.7.3  TG-2 Cannot Phosphorylate Paxillin Directly 
Since TG-2 deficiency reduced the phosphorylation of paxillin at Ser178, I would want to 
find out next how TG-2 would affect the phosphorylation of paxillin. Can TG-2 act as a 
kinase to phosphorylate paxillin?  
 
An in vitro autoradiographic kinase assay was performed to examine whether TG-2 itself 
could phosphorylate paxillin (Methods at Appendix A17.1). Strong bands were detected 
for the two positive controls at the expected molecular weight of paxillin in lane 9 (JNK 
is known to phosphorylate paxillin [101]), and Histone H1 in lane 10 (CDK2-CyclinE1 is 
known to phosphorylate Histone H1 [181]) (Figure 4.12A, Lane 9 and 10), indicating the 
reliability of the in vitro kinase assay with respect to the assay procedure.  
 
No bands could be detected for paxillin and TG-2 in Figure 4.12A from lanes 1 to 8, 
showing that TG-2 neither phosphorylated paxillin (Figure 4.12A, Lanes 3-8) nor auto-
phosphorylated itself (Figure 4.12A, Lane 1) in this experiment. Also, no protein auto-
phosphorylation activity could be found for the paxillin preparation alone (Figure 4.12A, 
Lane 2).     
 
Since TG-2 itself could not phosphorylate paxillin, could TG-2 recruit or activate another 
kinase to phosphorylate paxillin?  A panel of 190 known Serine/Threonine kinases was 
screened to identify the protein kinase that could phosphorylate paxillin. This 
phosphorylation profiling showed a differential ability of paxillin to act as a substrate for 
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the tested kinases. JNK1 was found to have the highest relative activities (Figure 4.12B). 
The full tested panel of the 190 Serine/Threonine kinases is shown in Appendix D, Figure 
A11. To confirm that JNK1 could act as a kinase to phosphorylate paxillin, a radioactive 
protein kinase filter-binding assay was performed (Methods at Appendix A17.2). Briefly, 
radioactive ATP was added together with a fixed concentration of JNK and increasing 
concentration of paxillin protein. The kinase activity dependent transfer of the radioactive 
phosphate was determined with a microplate scintillation counter. Figure 4.13 showed 
















Figure 4.12. Figures showing autoradiogram of in vitro kinase activities as well as a 
library of Serine/Threonine kinases to identify the protein kinase that phosphorylates 
paxillin. (A) Autoradiogram shows in vitro kinase activities of proteins. Samples were 
loaded on a 4-12% SDS-PAA gel and analysed by electrophoresis. The gel was dried and 
exposed to x-ray film for 60 min. Paxillin and different concentrations of TG-2 were 
loaded into lane 1-8. Lane 9 and 10 were positive controls with known kinase activities; 
which were phosphorylation of paxillin by JNK1, and phosphorylation of Histone H1 by 
CDK2-CyclinE1 respectively. (B) A library of 190 Serine/Threonine kinases was 
screened to identify the protein kinase that can phosphorylate paxillin. JNK1 was found 
to have the highest relative activities. The activity ratio value described the ratio between 
the activity of the particular kinase with and without sample protein. 
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JNK1 (Lot005) 3986 43 394 3592 84.34
PKA (Lot002) 7600 87 394 7206 82.43
MARK2 (Lot002) 24606 330 394 24212 73.30
DYRK1B (Lot001) 6317 81 394 5923 73.12
NEK7 (Lot002) 22181 304 394 21787 71.64
PRKX (Lot001) 5872 77 394 5478 71.14
GRK2 (Lot001) 16225 232 394 15831 68.17
MAPKAPK3 (Lot001) 1632 18 394 1238 67.28
TSSK1 (Lot001) 14094 204 394 13700 67.25
GRK3 (Lot001) 6065 112 394 5671 50.75
CDK5/p25NCK (Lot001) 13798 265 394 13404 50.62











Figure 4.13. Barchart showing activity value (in counts per minute, cpm) of JNK1 
with paxillin substrate. Reaction cocktails containing radioactive ATP and 5ng per 
well of JNK1 protein were added with different concentrations of paxillin protein 
(0ug, 2.5ug, 5.0ug and 10.0ug). Kinase activity dependent transfer of 33Pi was 
determined with a microplate scintillation counter. Error bars= standard deviation. 




4.7.4 Interaction of TG-2 and JNK 
Since the phosphorylation of Ser178 of paxillin in corneal epithelial cells was JNK-
mediated, I would be interested to determine if TG-2 could affect recruitment of JNK to 
the focal adhesion complex. First, immunoblots were done against recombinant TG-2, 
paxillin and JNK at various concentrations to ensure that these proteins could be detected. 
1µg of TG-2 and paxillin recombinant protein respectively could be pulled down by anti-
paxillin during co-immunoprecipitation, while 5µg of JNK was needed for anti-paxillin 
to successfully pull it down (Figure 4.14A).  
 
Co-immunoprecipitation with anti-paxillin antibody confirmed that recombinant TG-2 
protein can bind to paxillin complexes, which also bound JNK (Figure 4.14B). However, 
when TG-2 concentration was increased (1µg, 2.5µg, 5µg) in the presence of fixed 
concentrations (1µg) of paxillin and JNK, there was no corresponding increased in the 
intensity of JNK in the immunoblots, suggesting that the amount of JNK in the complex 
did not increase in a TG-2 dependent manner (Figure 4.14B, C). When recombinant 
proteins were mixed with the resin without the paxillin Ig, further washing of the resin 
would have removed any adhered proteins, showing that none of the adhesion proteins 
could bind directly to the streptavidin resin (Figure 4.14B, negative control in leftmost 
column). Further negative controls for the immunoblots performed without primary 




If JNK was the mediator that phosphorylated paxillin, what was the relationship between 
TG-2 and JNK? I have shown in Figure 4.14B that increasing TG-2 did not increase the 
JNK in the complex, which implied that TG-2 was not involved in recruiting JNK to the 
complex. Since Robitaille et al reported that TG-2 could crosslink and activate 
MAP3K12 (also known as DLK) and subsequently activate downstream JNK in human 
neuroblastoma cells [182], could TG-2 also recruit JNK via this mechanism in human 
corneal epithelial cells? Referring to co-immunoprecipitation in Figure 4.10, anti-paxillin 
successfully pulled down TG-2 and other focal adhesion proteins but failed to pull down 
MAP3K12. This showed that MAP3K12 was not part of the adhesion complex. If TG-2’s 
crosslinking function was involved in this context, it may be via unknown mechanisms 
such as an unidentified upstream kinase that was recruited to the complex. Alternatively, 
JNK could have been activated and phosphorylated by unknown TG-2 dependent 










Figure 4.14. Cell free in vitro immunoprecipitation and western blotting. 
Immunoprecipitation was performed using mixture of human recombinant proteins TG-2, 
JNK and paxillin. The recombinant proteins mixture was incubated at 4
o
C overnight 
followed by immunoprecipitation with anti-paxillin. Western blotting was then carried 
out on the pulled down proteins with anti-TG-2, anti-JNK and anti-paxillin. (A) 
Increasing concentration of recombinant JNK protein (0, 0.1, 1 and 5 µg) was added with 
fixed amount (1 µg) of TG-2 and paxillin proteins respectively in co-
immunoprecipitation. (B) Fixed concentration of JNK and paxillin at 5µg and 1µg 
respectively per 200 µl reaction volume was added, while increasing concentration of 
TG-2 at 1µg, 2.5µg and 5µg per reaction was added. Negative control consisted of 
recombinant proteins mixed with streptavidin agarose resin without paxillin Ig (negative 
control in leftmost column). (C) Bar graphs showing densitometry for the anti-paxillin 
pulled down TG-2 and JNK proteins.  
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4.8  Discussion 
Together with previous findings, this study demonstrated a novel mechanism of TG-2, 
i.e. TG-2 could bind and was required for the phosphorylation of adhesion molecules. 
More than one experimental approach was employed in this study such as cell scratching 
assay, cell migration assay, trypsinisation assay, western blotting and kinase assay; which 
were used to supplement the in vivo mouse corneal scratch wound data. 
 
An in vitro scratch wound of cultured human corneal epithelial cells with reduced TG-2 
(Figure 4.3), supported by an in vivo corneal abrasion experiment in TG-2 knockout and 
wild type mice (Figure 4.1), helped to provide evidence that TG-2 played an important 
role in corneal epithelial wound healing for the first time. The status of TG-2 did not 
affect cell cycle progression and cell proliferation (Figure 4.6A-D); while the presence of 
TG-2 increased cell adhesion, spreading (Figure 4.6E, F) and cell migration speed 
(Figure 4.4B).  
 
Cell adhesion and spreading are essential to cell movement. The involvement of TG-2 in 
cell adhesion and/or migration have been reported in various cell types such as retinal 
pigment epithelial cells [175], osteoblast cells [68], breast cancer [183], enthothelial cells 
[173], monocytes [65] and metastatic melanoma cells [174]. Interestingly, shTG cells had 
significantly smaller cell areas compared to control shRNA cells when cultured on 
fibronectin-coated surfaces, but had comparable cell area to control cells when grown on 
uncoated surfaces (Figure 4.6E). A similar observation was also reported by Jones et al 
whereby antisense TG-2 transfected human endothelial cells showed reduced cell 
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spreading [173]. This difference in cell area between control shRNA and shTG cells was 
possibly due to the interaction between fibronectin, TG-2 and integrin, likely because it 
was well known that TG-2 could act as an integrin-associated coreceptor for fibronectin 
[29]. Control shRNA cells had higher amount of TG-2 compared to shTG cells, hence 
they could interact better with the underlying fibronectin coating, contributing to the 
bigger cell area. 
 
Cytoskeleton is a structure that is responsible to maintain cell shape, to organise the 
organelles within cells, and to provide mechanical support for cells to carry out crucial 
biological activities such as motility and division [184]. When TG-2 was reduced in 
cultured human corneal epithelial cells (shTG cells), the cytoskeleton organisation was 
deranged (Figure 4.7A) and the cells showed slower migration velocity compared to the 
control cells (Figure 4.4B). This highlighted the importance of TG-2 in cell adhesion and 
migration.  
 
Literatures had reported that extracellular TG-2 induced integrin clustering, potentiating 
outside-in signalling leading to the stimulation of downstream Rho proteins [75]. Small 
GTP-binding proteins of the Rho family such as RhoA, Rac and Cdc42, were known for 
regulating actin dynamics essential for cell migration [177]. RhoA promoted actin 
filament assembly, mediated cell contractility and controlled the retraction of tail in 
migrating cells; while Rac and Cdc42 initiated the formation of lamellipodium and 
filopodia [185]. In addition, Rac and Cdc42 also mediated the formation of focal 
adhesion complexes, which were different from the focal adhesions induced by RhoA 
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[176, 177].  In cells with reduced TG-2, there was a reduction in Rac and Cdc42 activity 
relative to control cells (Figure 4.7B). Although the activity of RhoA was not 
significantly different in the experiment, literature had reported that extracellular TG-2 
elevated RhoA levels via clustering of β-1 integrin as well as down-regulation of the Src-
p190RhoGAP pathway [75]. However, the study of adhesion molecules clustering is not 
in the scope of this report.  
 
This was the first study to examine the interactions between TG-2 and focal adhesion 
proteins. Previous publications had only studied the interaction of extracellular TG-2 with 
integrin in the regulation of cell adhesion and migration [29, 186]. Previously, it was 
widely accepted that corneal epithelium had β-1 integrin, but not β-3 integrin. Here, by 
using specific antibodies targeting β-3 integrin and phosphorylated Tyr747 β-3 integrin, 
we showed that β-3 integrin was present and activated in a TG-2 dependent manner in 
human cornea epithelial cells (Figure 4.8C). The presence of β-3 integrin in human 
cornea epithelium was further supported by the expression of β-3 integrin transcript and 
protein in primary corneal epithelial cells derived from cadaveric limbal explant tissue 
(Appendix D, Figure A10). This was confirmed by another unrelated Gene Chip project 
from our laboratory which showed that β-3 integrin transcripts were present in both the 
corneal epithelial cell line and primary cultured corneal epithelial cells (Appendix D, 
Figure A10).  
 
It has been reported that phosphorylation of β-3 integrin at Tyr747 was crucial for both 
inside-out and outside-in signaling [187] and recruitment of signalling proteins [188] 
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during cell adhesion [189]. TG-2 status also affected the phosphorylation of vinculin at 
Tyr822 and FAK at Tyr925 (Figure 4.8D, E). The phosphorylation of vinculin at Tyr822 
has not yet been related to functions in control of cell shape and migration [190]. 
However, it was reported that since Tyr822 is located close to the flexible hinge region of 
vinculin, phosphorylation at this site maybe important to maintain its open conformation, 
which may affect the subsequent binding of talin [191]. In strain stimulated intestinal 
epithelial cell migration, the phosphorylation of FAK at Tyr925 was required for Rac1 
mediated downstream activation of PI3K/AKT pathway [192]. Also, it has been reported 
that in mouse embryonic fibroblasts, FAK phosphorylation at Tyr925 was required for 
cell migration and formation of cell edge protrusion [193].  
 
Immunoblotting using phosphoserine-specific antibody showed that shTG cells had 
reduced phosphorylation of paxillin at serine 178 relative to control cells (Figure 4.8A). 
This was a robust finding because it showed that TG-2 did not need specific extracellular 
ligands to phosphorylate paxillin. Previously, literatures had reported that TG-2 
dependent adhesion signaling required specific interaction with syndecan-4 and 
fibronectin [194]. The relationship between TG-2 and paxillin phosphorylation was also 
supported by our in vivo preliminary data (Figure 1.2), strongly suggesting that TG-2 
could mediate corneal epithelial wound closure through phosphorylation of paxillin at 
Ser178.  
 
The phosphorylation of paxillin at Ser178 leads to the downstream recruitment and 
activation of signalling molecules, thus mediating focal adhesion dynamics. Huang et al 
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reported that the phosphorylation of paxillin on Ser178 by c-Jun N-terminal kinase (JNK) 
was required for the association of FAK to paxillin [195]. This binding of FAK then 
promoted the phosphorylation of paxillin at Tyr 31 and Tyr 118, which then led to the 
subsequent recruitment of vinculin [196, 197]. This suggested that the phosphorylation of 
paxillin at Ser178 may be upstream of the phosphorylation of FAK and vinculin.  
 
The success of pulling down TG-2 protein using paxillin-bound agarose beads in shTG 
and control shRNA cell lysates suggested that TG-2 could interact directly with 
recombinant paxillin. This was supported by the Enspire cell free assay whereby the 
addition of increasing concentration of recombinant TG-2 to immobilise paxillin caused a 
spectral shift in Figure 4.11. Another piece of evidence was that paxillin was detected in 
shTG and control shRNA cell lysate by a specific anti-paxillin antibody (Figure 4.8A). 
 
Previous studies by Mishra et al had reported that TG-2 could act as a kinase and 
phosphorylate IGFBP-3, p53 and histones [198-200]. However, after performing kinase 
assay using increasing concentration of TG-2 against fixed concentration of paxillin, 
there were no bands observed on the blot upon X-ray exposure, indicating that TG-2 
itself could not act as a kinase to phosphorylate paxillin. After screening a library of 
known serine/threonine kinases, JNK1 was a more probable candidate to phosphorylate 
paxillin as a kinase. The kinase activity of JNK1 with its substrate paxillin was then 
confirmed using a radioactive protein kinase assay, which is the gold standard for the 
quantification of protein kinase activity involving the incorporation of γ-33P-labeled ATP 
into a substrate [107]. Consistent with this finding, Kimura et al reported that 
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phosphorylated JNK co-localised with paxillin at the wound margin through 
immunostaining [101]. They also found that when JNK inhibitor was added to the 
cultured human corneal epithelial cells, there was a reduction in phosphorylation of 
paxillin at Ser178, but not the paxillin expression level. This was supported by Huang et 
al who reported that overexpression of JNK1 enhanced the phosphorylation of paxillin in 
HEK-293 cells [201].  
 
If JNK was the kinase that phosphorylated paxillin, what was the relationship between 
TG-2 and JNK? The effects of TG-2 on JNK had been reported, for example, the 
silencing of TG-2 reduced the expression of pJNK [202, 203]. Also, several studies 
showed that JNK could modulate the phosphorylation of paxillin at Ser178 and the 
formation of focal adhesions in corneal epithelial cells [101, 195, 204]. Earlier in this 
chapter, I showed that increasing TG-2 did not increase JNK in the complex, implying 
that TG-2 was not involved directly in recruiting JNK to the complex. Since TG-2 could 
not directly recruit JNK, could TG-2 recruit JNK indirectly through other kinases? 
Robitaille et al reported that TG-2 could crosslink and activate dual leucine zipper kinase 
(DLK, otherwise known as MAP3K12), and subsequently activate downstream JNK in 
fibroblasts and human neuroblastoma cells [202, 205]. Could TG-2 also activate 
downstream JNK through MAP3K12 in human corneal epithelial cells? Unfortunately, 
this specific mechanism was probably not active in our cell context since MAP3K12 
could not be pulled down by paxillin antibody in our co-immunoprecipatation study. This 
showed that MAP3K12 was not part of the adhesion complex in human corneal epithelial 
cells. TG-2 may be involved in JNK activated paxillin pathway via unknown mechanisms 
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such as through an unidentified upstream kinase that is recruited to the focal adhesion 
complex. Alternatively, JNK could be activated by unknown TG-2 dependent 
mechanisms, followed by recruitment to the adhesion complex. 
Since TG-2 can bind directly to paxillin, it is important to know the specific domain of 
both TG-2 and paxillin that was involved in this interaction. The interaction between TG-
2 and paxillin may differ in various cell substrates and tissue origins. We suggest that 
TG-2 may interact with the LD domains in the amino terminal region of paxillin to affect 
the recruitment of other proteins, since LD domains are known to have various protein 







4.9  Conclusion 
In summary, this project proposed that TG-2 can improve wound closure in corneal 
epithelial cells through phosphorylation of fundamental focal adhesion proteins. Since 
serine phosphorylation of paxillin has been associated with cell adhesion and migration in 
fibroblasts and epithelial cells [96, 101], and TG-2 has been shown to mediate adhesion 
in different cell type [44, 65]; hence TG-2 dependent serine phosphorylation of paxillin 
may act as a signal transduction mechanism for cell adhesion and migration in stratified 
epithelium. Also, I have showed that TG-2 can interact with paxillin in human corneal 
epithelial cells. The interaction between paxillin and TG-2 may be important as a 
potential therapeutic target since wound healing is deranged in most ocular surface 
diseases. In disease conditions, cell adhesion and wound closures may be improved by 
increasing this paxillin-TG-2 interaction. Further studies also need to focus on the 
interaction of TG-2 with different focal adhesion proteins and identify the sequence of 
signaling. This can help to decipher TG-2’s role in ocular surface diseases such as 








a. TG-2 deficiency delayed wound closure, both in vitro and in vivo. The lack of TG-2 
reduced cell migration velocity and cell adhesion/spreading, exhibited deranged actin 
cytoskeleton and reduced in Rac and Cdc42 protein activities. 
b. TG-2 deficiency reduced phosphorylation of Tyr747 integrin β3, Tyr822 vinculin, 
Tyr925 FA, and most notably Ser178 paxillin. 
c. TG-2 bound to paxillin but TG-2 could not phosphorylate paxillin. JNK1 is the 
proposed kinase that could phosphorylate paxillin. 
d. TG-2 concentration did not affect JNK. TG-2 could not indirectly activate JNK 






CHAPTER 5.  CONCLUSION AND FUTURE DIRECTIONS 
 
Key Findings 
1. The role of TG-2 in hyperosmolarity-mediated mitochondrial cell death has been 
evaluated as follows (Chapter 2):  
a. Hyperosmolar treatment mediated cell death and reduced cell viability in 
cultured human corneal epithelial cells.  
b. Hyperosmolar stimulation caused the release of cytochrome-c and 
mitochondrial depolarisation.  
c. TG-2 was present in mitochondrial extract. Hyperosmolar stimulation did not 
further increase the mitochondrial depolarisation in TG-2 overexpressing cells 
compared to cells with endogenous TG-2; while in TG-2 deficient cells, 
hyperosmolar conditions induced less amount of mitochondrial depolarisation, 
indicating a partial dependence on TG-2 function. 
d. TG-2 overexpression increased transamidase activity, reduced cornea 
epithelial cell proliferation and increased caspase-3/7 and 9 activity.  
2. The interacting partners of TG-2 which are cell adhesion or cell migration related 
were discovered and characterised as follows (Chapter 3): 
a. Seven proteins that interacted with different TG-2 fragments were identified.  
b. TG-2 binding proteins were categorized into 3 groups according to the way 




c. TG-2 status could affect some of the sub-cellular concentrations of its binding 
proteins such as DES, PARL, NTRK3, PRSS3, ITGB4 and GOLGA2;  and 
organelles such as recycling endosomes, endoplasmic reticulum, and 
mitochondria.   
3. The functional significance of TG-2 on cell adhesion and migration in corneal 
epithelial wound closure was evaluated as follows (Chapter 4):  
a.  TG-2 deficiency delayed wound closure, both in vitro and in vivo. The lack of 
TG-2 reduced cell migration velocity and cell adhesion/spreading, exhibited 
deranged actin cytoskeleton and reduced  in Rac and Cdc42 protein activities. 
b. TG-2 deficiency reduced phosphorylation of Tyr747 integrin β3, Tyr822 
vinculin, Tyr925 FA, and most notably Ser178 paxillin. 
c. TG-2 bound to paxillin but TG-2 could not phosphorylate paxillin. JNK1 is 
the proposed kinase that could phosphorylate paxillin. 
d. TG-2 concentration did not affect JNK. TG-2 could not indirectly activate 





5.1  Summary and Discussion 
TG-2 is a ubiquitous, multi-functional protein that is expressed in corneal epithelial cells. 
In Chapter 1 of this thesis, it was demonstrated for the first time that hyperosmolar 
stimulation mediated mitochondrial depolarisation in human corneal epithelial cells is 
partially dependent on TG-2 function. Contrary to reports that TG-2 was not present in 
mitochondria [121, 207], TG-2 was successfully detected in the mitochondrial extract of 
cultured human corneal epithelial cells. Overexpression of TG-2 increased cellular 
transamidase activity and reduced cell proliferation. Importantly, when compared to 
pSG5 (vector alone) transfection, overexpression of TG-2 increased the proportion of 
mitochondrial depolarised cells. Our findings were supported by Piancentini et al’s work, 
which showed that TG-2 overexpression sensitised cells to apoptosis through the increase 
of mitochondrial membrane potential [122]. Hyperosmolar conditions caused a 
significant reduction in mitochondrial potential and decreased cell proliferation in HCE-
T. The fold change of mitochondrial depolarisation in TG-2 overexpressing cells was less 
than those in cells with endogenous TG-2, suggesting that the presence of endogenous 
TG-2 had already saturated the requirement for TG-2. 
 
Since defective wound healing reduces cornea transparency and affects visual function, in 
Chapter 2, this study was then extended to identify the interacting protein partners of TG-
2 and their protein transportation, which may affect cell adhesion and migration. TG-2 
was found to be involved in the trafficking of sub-cellular proteins relevant to wound 
healing processes. TG-2 deficiency reduced the expression of desmin, mitochondrial 
intramembrane cleaving protease (PARL), protein tyrosine kinase (NTRK3), and serine 
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protease (PRSS3) in all (8.5%, 10%, 15%, and 20%) the sucrose fractions (SF) tested. 
Integrin beta-4 protein and the Golgi associated protein (GOLGA2) showed a reverse 
expression pattern between subcellular compartments; whereby compared to control, both 
the proteins had higher expression levels in the 8% SF, but decreased in the subsequent 
10%, 15% and 20% SFs. On the other hand, syntaxin binding protein (STXBP2) had 
similar amounts of protein between shTG and control in all SFs tested. Furthermore, the 
decrease in TG-2 level reduced the expression of organelles markers for late endosomes, 
secretory vesicles and recycling endosomes, suggesting that TG-2 levels may mediate 
cell adhesion and migration through protein transport and alteration of organelle 
functions. What differed this study from a previous report [141], which both examined 
sub-cellular trafficking and cell adhesion, was the use of centricollation, a novel protein 
fractionation technology to separate cell lysates through stepwise density extraction.  
 
Since wound healing is deranged in many of the common ocular surface diseases, in 
Chapter 3, this work was further extended to elucidate the functions of TG-2 in wound 
healing which involved epithelial cell adhesion and migration. Cells with reduced TG-2 
showed lower cell impedance compared to control, due to differences either in cell 
proliferation, spreading or adhesion. There was no significant difference in cell cycle 
progression, and the proportion of proliferating (Ki-67 positive) cells between shTG and 
control cells. However, control cells required a longer time to detach after trypsinisation 
compared to shTG cells. When cultured on fibronectin coated surfaces, shTG cells 
showed smaller cell spreading areas, deranged cytoskeleton organization, slower 
migration velocity and reduced Rho protein activity compared to the control cells, 
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indicating the importance of TG-2 in cell adhesion and migration. Upon further 
investigation, cells with reduced TG-2 showed decreased phosphorylation of adhesion 
proteins at specific residues. Among them, the most notable residue was Serine 178 
paxillin, since it was previously reported, using the same cultured human corneal 
epithelial cells as in our experiment, to play an important role in adhesion and migration. 
However, TG-2 itself could not directly phosphorylate paxillin. After screening a library 
of kinases, JNK1 was found to be the highest possible kinase candidate to phosphorylate 
paxillin. The kinase activity of JNK1 with paxillin substrate was confirmed via 
radioactive kinase assay. TG-2 can bind to paxillin and JNK, hence we proposed that TG-
2 is present in the FA complex. However, TG-2 neither can directly recruit JNK nor 
indirectly through DLK (also known as MAP3K12) in HCE-T cells. Taken together with 
the previous findings, JNK mediated the serine phosphorylation of paxillin through 
unknown kinase in a TG-2 dependent fashion. This activated JNK or paxillin may then 
phosphorylate other adhesion proteins, leading to the maturation of the FA complex, thus 
regulating corneal epithelial cell adhesion and migration.  
 
Literatures had reported that C-jun N-terminal kinase (JNK), extracellular signal-
regulated kinase (ERK), and mitogen-activated protein kinase (MAPK) signalling 
pathways were involved in hyperosmolar-induced corneal epithelial apoptosis [99, 104, 
122]. However, these publications did not evaluate the role of TG-2 in the JNK, ERK, or 
MAPK signalling pathways. In addition, Kimura et al reported the JNK-dependent serine 
phosphorylation of paxillin in corneal epithelial cells, but did not study the role of TG-2 
in this pathway [101]. The current work is the first study to connect the missing links 
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between TG-2, apoptosis and wound closure related cell motility processes which 
involved cell adhesion and migration. We reported that JNK1 may act as a kinase in TG-
2-mediated corneal epithelial cell migration and adhesion by modulating the paxillin 
phosphorylation and the subsequent formation of focal adhesions.   
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5.2  Strengths 
More than one experimental approach was employed in these studies to elucidate the role 
of TG-2 in common biological processes.  
 
In Chapter 2, cell impedance assay allowed real time monitoring of cell viability, number, 
morphology, and adhesion degree in cell-based assays without the use of labels which 
may potentially affect cell functions. Quantitative assays such as TG-2 transamidase 
activity assay and cell-based caspase-3/7 and 9 assays were performed and they are 
different from other semi-quantitative techniques such as Western blot. For example, an 
optimised TG-2 transamidase activity assay could be used to accurately determine the 
transglutaminase activity in protein samples, since TG-2 concentration was proportional 
to detectable TG-2 crosslinking activity within a linear range. HCE-T overexpressing 
TG-2 showed at least 50% more of the transamidase activity than the cells transfected 
with pSG5 vector. Since it was reported that hyperosmolarity could increase transamidase 
activity in primary corneal epithelial cells [111], hence the current method of TG-2 
overexpression in corneal epithelial cells may be a suitable means to study the effect of 
hyperosmolar stimulation on TG-2. Instead of using TG-2 inhibitor, various approaches 
were employed in this study to alter the TG-2 function; for example, overexpression of 
TG-2 and RNA interference targeting TG-2 sequence, thus permitting the evaluation of 




In Chapter 3, a novel density based protein separation technique known as centricollation 
was employed to elucidate the biological function of TG-2 binding proteins. 
Centricollation is a stepwise protein separation technology where low volumes can be 
processed quickly under non-denaturing condition with high recovery yield. This 
technology is particularly powerful when used together with conventional cell biology 
methods. TG-2 protein interacting partners were listed based on an unbiased proteomics 
method (LC-LC/MS) followed by a detailed database search. Ligands bound to TG-2 
domains were then pulled down by immunoprecipitation and their identities were 
determined by western blotting using specific antibodies. The fact that the same 
molecules were discovered from repeated co-IP experiments increased the confidence of 
the interaction.  
 
In Chapter 4, the effect of TG-2 on cell migration was studied both in vitro via cultured 
human cornea epithelial cells in cell culture scratch test and non-traumatic cell migration 




 mice cornea scratch test. Cell migration speed 
was quantified in real time and cell directionality was analysed using ImageJ software as 
well as cell oscillation software developed by our collaborator. The effect of TG-2 on cell 
proliferation was studied using 3 different experimental approaches consisting of Ki-67 
staining, tetrazolium MTS assay and cell cycle progression assay. This was because both 
Ki-67 staining and tetrazolium MTS assay were not so specific but they could be 
performed on attached cells; on the other hand, cell cycle progression assay was specific 
but can only be done on trypsinised cells, which may have some cells lost during the 
trypsinisation stage.   
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5.3  Limitations 
There were several limitations in this work. Instead of primary human corneal epithelial 
cells, SV-40 immortalised corneal epithelial cells, which may not be representative of the 
native human corneal epithelial cells, were used. The use of immortalised cell lines was 
necessary due to several reasons: for example, primary corneal epithelial cell culture 
medium was relatively costly; different batches of primary cells had different phenotypes 
after passaging; the scarcity of human cornea tissues; the translational therapeutic 
implications of using human cells; as well as the high demand of cells for different types 
of experiments, such as mitochondrial extraction and overexpression by plasmid 
transfection.  
 
Since there were only cultured cells used in these experiments, it may be important to 
conduct experiments on mice with genetically modified TG-2 function in order to verify 
the in vivo relevance of the in vitro cell culture data. Another limitation was that only a 
single sequence of shRNA targeting TG-2 was employed, hence there was a chance of off 
target effects. 
 
The main limitation of centricollation technique was that particle size could not be used 
as a criterion to separate entities. Ideally, more purified fractions could be obtained, if 
centricollation was used together with a size exclusion method, or a technique based on 
particle diameter such as asymmetric field flow fractionation. Besides, the molecules 
discovered by mass spectrometry may not be definite ligands in living cells. This is 
because after cell lysis, TG-2 may non-specifically interact with other molecules. Also, 
168 
 
after cell lysis, molecules that were already sequestered and separated spatially may be 
brought into close proximity and interacte with TG-2.  
 
When the role of TG-2 in wound healing was evaluated, we tried to rescue TG-2 in the 
cell migration assay by either adding recombinant human TG-2 protein into the culture 
media, or by coating the culture surfaces with recombinant human TG-2 protein. 
However, the rescue effect was inconsistent. This outcome could be due to the inadequate 
amount of TG-2 added, the added TG-2 had low activity, or the failure of the added TG-2 
to localise at the right location. We did not over-express TG-2 in corneal epithelial cells 
to rescue cell migration because this technique caused cell apoptosis, hence it would 
require a large amount of cells to produce a confluent cell sheet for scratch test assays. 
 
The interaction between TG-2 and paxillin was not studied using living cells. In co-
immunoprecipitation, it was possible that the binding of TG-2 to paxillin may occur after 
cell lysis and this interaction may not occur within intact living cells. This limitation 
could be partially overcome by performing live cell imaging with fluorescence labeling 
of paxillin and TG-2 to check for colocalisation. However, imaging approaches may not 
work because TG-2 is ubiquitous in all parts of the cell and may colocalise with any other 
molecule that was expressed.  
 
Results of the kinase screening assays may not be totally relevant in our biological 
context because these were purely in vitro assays consisting of only cell free pure 
recombinant proteins. In cellular systems, more work could be performed in the future by 
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deleting or expressing inactive mutants of JNK1 to confirm the in vivo effects. However 
the main focus of this project is not the kinase activity of JNK1 but rather the relationship 

















5.4  Clinical Significance and Future Studies 
The findings in this study suggest that TG-2 plays an important role in ocular surface 
diseases, especially in cornea wound healing related diseases such as persistent corneal 
epithelial defects or recurrent corneal erosion in dry eye patients. Hence, TG-2 deserves 
to be evaluated as a potential therapeutic target. TG-2 related strategies may be used 
together with conventional therapy, or as an adjuvant therapy.  
 
Since TG-2 is involved in hyperosmolarity-mediated mitochondrial cell death in corneal 
epithelial cells, mitochondria protecting agents may be important in the treatment of dry 
eye, such as cyclosporine A (CsA). Literatures reported that CsA could inhibit 
mitochondrial permeability transition, which is the sudden increase of membrane 
permeability due to high concentrations of calcium ions causing swelling and uncoupling 
of the mitochondria, thereby reducing damage and preventing apoptosis [208, 209]. In 
addition, CsA is already a FDA approved ophthalmic drug commonly used for treatment 
of chronic dry eye condition to increase tear production [210]. Although topical CsA has 
shown beneficial effects in treating dry eye disease, many dry eye patients failed to show 
consistent therapeutic response to CsA [15]. Hence more work remains to be done to 
determine the effective and safe concentration of CsA for mitochondrial protection in 
ocular surface. Excitingly, SkQ1, a novel mitochondria-targeted antioxidant molecule 
aimed to reduce oxidative stress inside mitochondria, was recently reported to have 
attained positive results in US phase II clinical trial for treatment of dry eye disease, 




In addition, TG-2 inhibitors may also be used to protect cells from hyperosmolar stress. 
Various cell penetrating and non-cell penetrating TG-2 inhibitors such as 
dansylcadaverine, 3-halo-4,5-dihydroisoxazoles, LDN-27219 and cystamine have been 
developed [211, 212]. Out of these TG-2 inhibitors, cysteamine, a FDA-approved 
reduced form of cystamine, has currently entered phase II clinical trial to determine its 
effectiveness in treating Huntington’s disease, in which TG-2 is suspected of 
participating in its pathogenesis [213]. The development of new and better TG-2 
inhibitors remains an active area of research.  
  
This study has demonstrated the effects of TG-2 deficiency on protein transportation, cell 
adhesion, cell migration and wound closure. Since this work showed that TG-2 could 
interact with proteins that are involved in cell adhesion and migration, hence there is 
potential application of TG-2 in treating chronic corneal epithelial wounds that fail to 
heal within a predicted amount of time as most normal wounds would. TG-2 deficiency 
may be addressed by increasing TG-2 activity through an appropriate stimulus, such as 
increasing cytosolic calcium or by overexpressing TG-2 using a cDNA plasmid delivered 
via an eye drop formulation. Since some growth factors may affect specific cell types and 
wound healing pathways, it is suggested that combinations of growth factors may be 
better for complex wounds.  For example, topical applications of platelet-derived growth 
factor (PDGF) and insulin were reported to increase the wound healing rate [214, 215]. 
Hence, topical TG-2 may be used in conjunction with growth factors such as epidermal 
growth factor (EGF) and transforming growth factor (TGF)-β1 to improve the corneal 
wound healing process [216, 217].  
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Since wound healing is affected in most of the ocular surface diseases, the interaction 
between paxillin and TG-2 may be important as a potential therapeutic target. In disease 
conditions, wounds that fail to heal may be improved by increasing this paxillin-TG-2 
interaction, leading to the increase in cell adhesion and migration. On the other hand, 
disrupting this TG-2-paxillin interaction using TG-2 inhibitors may help to improve 
ocular surface diseases with aggressive cell migration that cause scarring. Since TG-2-
paxillin interactions occur inside the cells, it is important to find a TG-2 inhibitor that can 
effectively penetrate inside cells without causing toxicity.  
 
Cell migration, adhesion and proliferation are important aspects of malignant cancer cells 
metastasis. During this process of metastasis, cancer cells are dislodged from their 
primary tumour location, migrated, adhered and proliferated in a secondary environment. 
This metastasis process employs a similar pathway as wound healing, which also 
involves cell migration, adhesion and proliferation. As demonstrated by other cancer 
research, elevated expression of TG-2 has been associated with increased cancer 
metastasis and cell survival [218, 219]. Hence, strategies that inhibit TG-2 or its 
interacting proteins may be another direction in cancer research. For example, the 
identification of TG-2 interacting proteins related to cell migration and adhesion, as well 
as the discovery that TG-2 levels can affect phosphorylation of adhesion proteins, may 
have potential in targeting metastatic cancer, or as a new tool to study cell adhesion and 




The question of whether TG-2 function is indeed beneficial in clinical setup is still under 
debate. In vitro cell culture experiments showed that TG-2-mediated mitochondrial 
apoptosis appeared to be highly dependent on the nature of the stimulus [117]. Moreover, 
although there were reports that the ocular surface of dry eye patients have higher 
expression of TG-2 [220], TG-2 may or may not be directly linked to dry eye disease. 
Furthermore, in clinical context, dry eye is a multifactorial disease involving immune 
cells, which is much more complex than in vitro cell culture conditions. Also, the role of 















5.5  Conclusion  
In conclusion, this thesis showed that TG-2 is involved in mitochondrial-induced 
apoptosis, cell motility processes and corneal epithelial wound closure. More work needs 
to be done to better understand the roles and mechanisms of TG-2 in various biological 
processes. The understanding of these pathways would help to devise combinatorial 
strategies for inhibition of apoptosis and improvement in ocular wound healing.  
 
Application of TG-2 inhibitors to mouse models of some human diseases, such as 
Huntington’s disease, has shown promising therapeutic potential [211]. However, the 
safety, efficacy and cellular localisation of TG-2 inhibitors should be evaluated in the 
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Appendix A. List of Laboratory Techniques 
A1.  Cell Culture 
A1.1. Immortalised Human Corneal Epithelial Cells 
Primary human cornea epithelial cells were immortalised using recombinant simian virus 
40 (SV40)-adenovirus vector [221]. This cell line retains the properties of normal corneal 
epithelial cells and has well developed desmosomes at intracellular junctions. In this 
thesis, this cell line will be referred as HCE-T, as large T antigen was expressed in every 
immortalised cell. Studies used passages from 80 to 98. The cells were grown in 
Dulbeco’s modified Eagle’s medium (DMEM)-F12 supplemented with 5% fetal bovine 
serum (FBS). 
 
A1.2. Scrambled shRNA and shTG Cells 
In this thesis, shTG referred to HCE-T cells stably transduced with short hair pin RNA 
(shRNA) targeting TG-2; while scrambled shRNA cells referred to HCE-T cells stably 
transduced with non-specific scrambled shRNA.  
The sense and anti-sense sequences (5’ to 3’) of SiRNA against TG-2 were 
GGCCCGUUUUCCACUAAGAtt and UCUUAGUGGAAAACGGGCCtt respectively. 
This SiRNA targeted part of exon 3 of the TG-2 gene. 
1. To study the effect of TG-2 reduction, silencing short hairpin RNA targeting TG-2 
was subcloned into the pSM2 backbone.  
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2. Lipofectamine Plus reagent (Invitrogen, Grand Island, NY) was used to transfect the 
cloned vectors with retroviral packaging cell line PA317.  
3. Six hours later, the medium was changed to fresh DMEM supplemented with 10% 
FBS, streptomycin (100 g/ml), penicillin (100 U/ml), and 2mML-glutamine, and 
cultured at 37ºC in 5% CO2.  
4. Viral supernatants from transiently transfected PA317 cells were then filtered with 
0.45µm filters and stored at -80ºC.  
5. HCE-T cells were seeded and allowed to adhere.  
6. Twenty-four hours later, medium was replaced with the filtered viral supernatants.  
7. Polybrene was added at 8 g/ml and cultured for 3 days.  
8. Stably transduced cells were subsequently expanded in DMEM-F12 supplemented 
with 5% FBS and 0.15 g/ml of puromycin.  
 
A1.3. Trypsinizing, Counting and Passaging Cells  
1. Trypsin 0.05% (Invitrogen, Grand Island, NY) was warmed to 37ºC before use.  
2. Cells were washed once in sterile phosphate buffered saline (PBS).  
3. The volume of trypsin used should cover the surface of the cultured cells.  
4. After the addition of trypsin, cells were incubated at 37ºC, 5% CO2 for 5 to 10 
minutes. 
5. Gentle rocking was done to ensure complete detachment of cells from the dish.  
6. Complete media with 5% FBS was added to neutralize the trypsin. 
7. The cells were then centrifuged at 800-1000rpm for 5 minutes. 
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8. The supernatant was removed. The cell pellet was reconstituted with fresh complete 
media. 
9. To count the cells, 10µL of tryphan blue was added to 10µL cell suspension. 
10. 10µL of the tryphan blue/cell mixture was added into hemacytometer channel. 
11. Cells were counted at all the 4 quadrants. 
12. Desired amount of cells were seeded into new culture vessels. 
 
A1.4. Freezing and Thawing cells 
1. A freezing mixture of 70% complete media, 20% FBS and 10% DMSO was prepared. 
2. At least one million cells were added to the freezing mixture in a cryo tube. 
3. The cryo tubes were then placed into a freezing container containing isopropanol, and 
placed overnight at -80ºC.  
4. The cryo tubes were then transferred into liquid nitrogen for long term storage. 
5. Cells to be thawed in cryo vials were removed from liquid nitrogen and placed on ice. 
6. One milliliter of warm complete media was added into the cryo vial to thaw the cells. 
7. After complete thawing, the cells were spun down using similar centrifuge settings as 
passaging.  
8. After aspiration of the supernatant, fresh culture media were added to re-suspend the 
cells. 




A2.  Preparation of Plasmids and Transfection 
A2.1. Preparation of Luria-Bertani (LB) Broth and Agar Plate 
1. LB broth and agar was made by adding LB broth pellet or LB agar powder to distilled 
water, as recommended by manufacturer.  
2. The liquid broth and agar was then autoclaved. 
3. Antibiotics such as kanamycin or ampicillin were added into the LB broth just before 
any experiment to facilitate selection of bacteria. 
4. The LB broth was stored at room temperature. 
5. For the LB agar, antibiotics were added to the liquid agar after cooling to 55ºC. About 
20ml of agar was poured into each 10cm plate.  
6. The poured agar plates were then cooled down before stored at 4ºC.  
 
A2.2. Propagation of Plasmid DNA Expressing TG-2 Fragments 
1. Four TG-2 domains: C terminal 1 (T1), C terminal 2 (T2), catalytic core (C), and N 
terminal (N) fragments were cloned respectively into pIRES-hrGFP II plasmid vector 
expressing Flag-tagged peptides (Figure A1). These plasmid DNAs were cloned by 
GenScript, NJ, USA.  
2. The four TG-2 domains sequences were shown in Figure A2. These sequences were 
confirmed by DNA sequencing services (1
st
 Base, Singapore) using primer as follows: 

















Figure A1. Circular map and features of pIRES-hrGFP II expression vector (Agilent 
Technologies, CA, USA). The piRES-hrGFPII vector is 5.5kb, contains a CMV 
promoter, neomycin/kanamycin-resistance gene, SV40 early promoter providing G418 
resistance in mammalian cells and a bovine growth hormone polyadenylation sequence 
(BGHpA) for improved stability and translatability of mRNA. The gene of interest may 













TG-2 core (981 bp) ~37kD 
GCC ACC ATG GCA GCG GAT GCT GTG TAC CTG GAC TCG GAA GAG GAG CGG CAG GAG 
TAT GTC CTC ACC CAG CAG GGC TTT ATC TAC CAG GGC TCG GCC AAG TTC ATC AAG 
AAC ATA CCT TGG AAT TTT GGG CAG TTT GAA GAT GGG ATC CTA GAC ATC TGC CTG ATC 
CTT CTA GAT GTC AAC CCC AAG TTC CTG AAG AAC GCC GGC CGT GAC TGC TCC CGC 
CGC AGC AGC CCC GTC TAC GTG GGC CGG GTG GTG AGT GGC ATG GTC AAC TGC AAC 
GAT GAC CAG GGT GTG CTG CTG GGA CGC TGG GAC AAC AAC TAC GGG GAC GGC GTC 
AGC CCC ATG TCC TGG ATC GGC AGC GTG GAC ATC CTG CGG CGC TGG AAG AAC CAC 
GGC TGC CAG CGC GTC AAG TAT GGC CAG TGC TGG GTC TTC GCC GCC GTG GCC TGC 
ACA GTG CTG AGG TGC CTG GGC ATC CCT ACC CGC GTC GTG ACC AAC TAC AAC TCG 
GCC CAT GAC CAG AAC AGC AAC CTT CTC ATC GAG TAC TTC CGC AAT GAG TTT GGG 
GAG ATC CAG GGT GAC AAG AGC GAG ATG ATC TGG AAC TTC CAC TGC TGG GTG GAG 
TCG TGG ATG ACC AGG CCG GAC CTG CAG CCG GGG TAC GAG GGC TGG CAG GCC CTG 
GAC CCA ACG CCC CAG GAG AAG AGC GAA GGG ACG TAC TGC TGT GGC CCA GTT CCA 
GTT CGT GCC ATC AAG GAG GGC GAC CTG AGC ACC AAG TAC GAT GCG CCC TTT GTC 
TTT GCG GAG GTC AAT GCC GAC GTG GTA GAC TGG ATC CAG CAG GAC GAT GGG TCT 
GTG CAC AAA TCC ATC AAC CGT TCC CTG ATC GTT GGG CTG AAG ATC AGC ACT AAG 
AGC GTG GGC CGA GAC GAG CGG GAG GAT ATC ACC CAC ACC TAC AAA TAC CCA GAG 
GGG TCC TCA GAG GAG AGG GAG GCC TTC ACA AGG GCG AAC CAC CTG AAC AAA CTG 
GCC GAG 
 















Figure A2. Nucleotide sequences of human TG-2 four fragments: N terminal, catalytic 
core, N-Terminal 1 and N-Terminal 2. 
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A2.3. Plasmid DNA Over-Expressing TG-2 
1. Over-expression of TG-2 was achieved by a cDNA plasmid pSG5 coding for TG-2 
(referred to as pSG5 TG-2 in thesis).  

















Figure A3. Circular map and features of pSG5 vector (Agilent Technologies, CA, USA). 
The pSG5 vector is a eukaryotic expression vector which is 4.1kb in size. The gene of 
interest can be ligated into the vector via restriction sites EcoR I, BamH I, and Bgl II. The 
f1 origin can rescue ssDNA, the SV40 (simian virus 40) early promoter and origin allows 
overexpression of the recombinant gene, the T7 bacteriophage promoter mediates 




A2.4. Plasmid Propagation, DNA Extraction, Purification and Quantification 
1. The lyophilized plasmid DNA was dissolved in 20µL water and vortex diligently. 
2. A tube of DH5α competent cells was thawed on ice.  
3. The cells were gently mixed with pipette tip. 50μl of cells were aliquoted for each 
transformation reaction into a 1.5 ml microcentrifuge tube. 
4. Five nanogram of plasmid DNA was added to the cells followed by gentle mixing.  
5. The tubes were incubated on ice for 30 minutes. 
6. The competent cells were heat shocked in a 42°C water bath for 20 seconds without 
shaking. 
7. Tubes were then placed on ice for 2 minutes. 
8. Pre-warmed 950μl of DMEM-F12 media was added to each tube. 
9. The tubes were incubated at 37°C for 1 hour, shaking at 225 rpm. 
10. 20-100μl of media containing the cells from each transformation was spreaded on 
pre-warmed selective agar plates.  
11. The plates were incubated overnight at 37°C. 
12. Individual transformed clones were picked using sterile inoculation loop. The colony 
was immersed into a 15mL tube containing 2mL LB broth with appropriate antibiotic.  
13. The tube was then incubated 8 hours at 37ºC, shaking at 300rpm. 
14. The bacteria LB broth was then transferred into a conical flask containing fresh 
100mL LB with antibiotic. 
15. The conical flask was then incubated overnight at 37ºC, shaking at 300rpm. 
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16. The next day, 500µL was removed from the bacteria LB broth and mixed with an 
equal volume of glycerol. This was stored at -80ºC to serve as a stock for future 
plasmid propagation. 
17. DNA extraction was performed on the rest of the LB broth following instructions 
from the Qiagen Maxiprep kit. The cells were first harvested by centrifuging at 6000g 
for 15 mins at 4ºC.  
18. The cell pellet was resuspended in 10mL Buffer P1 in a 50mL tube until no cell 
clumps remain. 
19. Then 10mL of Buffer P2 was added. The solution was thoroughly mixed by 
vigorously inverting the tube 4-6 times until it turned into blue colour. This was 
followed by 5 minutes room temperature incubation. 
20. 10mL of chilled Buffer P3 was added. The addition of P3 buffer produced a fluffy 
white material. The suspension was mixed thoroughly and vigorously by inverting the 
tube 4-6 times, until the suspension turned colourless. The suspension was incubated 
on ice for 20 minutes. 
21. The suspension was mixed before centrifuging at 20,000g for 30 minutes at 4ºC. The 
supernatant was transferred into a fresh 50mL tube. 
22. The supernatant was centrifuged again at 20,000g for 15 minutes at 4ºC. The 
supernatant was transferred into a fresh 50mL tube. 
23. Meanwhile, a Qiagen-Tip 500 was equilibrated by flowing through 10mL of Buffer 
QBT. 
24. The supernatant was pipetted to the Qiagen-Tip 500 and allowed it to enter the resin 
by gravity flow. 
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25. The Qiagen-Tip 500 was washed twice with 30mL of Buffer QC by gravity flow. 
26. DNA was then eluted with 15mL of Buffer QF. The eluate was collected in a 50mL 
tube. 
27. The DNA was precipitated by the addition of 10.5mL isopropanol to the eluted DNA. 
The solution was immediately mixed and centrifuged at 15,000g for 30minutes at 4ºC. 
The supernatant was carefully decanted as the pellet is loosely attached. 
28. The DNA pellet was washed with 5mL of 70% ethanol and centrifuged at 15,000g for 
10minutes. The resulting supernatant was carefully decanted without disturbing the 
pellet 
29. The pellet was air-dried for 5-10 minutes. The DNA was then re-dissolve in 1mL TE 
buffer, pH8. 
30. The DNA concentration was determined at 260nm. 
 
A2.5. Plasmid Transfection 
Optimization was first performed using HCET cells and PSG5 vector to determine 
suitable voltage and amount of plasmid DNA used (Figure A4).  
1. Transient DNA plasmid transfection was done using electroporation. At least 1x106 
cells were needed per electroporation condition. 
2. The cells were washed once with PBS, followed by trypsinisation and neutralization 
as described in A1.3. 
3. The cells were then spun down at 1200rpm for 5 minutes. 
4. The pellet was rinsed once with PBS. 
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5. Cell count was performed as described in A1.3. 1x106 cells were aliquoted into 
1.5mL Eppendorf tube. 
6. The cells were spun at 1200rpm for 5 minutes. 
7. The cell pellet was resuspended in 110L of Solution R (Neon Transfection System 
100µL Kit, Invitrogen). 
8. One microgram of plasmid DNA was added and mixed gently with the re-suspended 
cells.  
9. 4mL of Solution E was added into the microporation tube. 
10. 100µL of cell suspension with added plasmid was taken up slowly avoiding bubbles 
using the Neon’s electroporation pipette.  
11. The MicroPorator-mini MP100 (DigitalBio, Seoul, Korea) was set up as follows:  
1300V, 30ms, 1 pulse 

























Figure A4. (A) Pictures showing optimization of electroporation conditions on 
immortalised human corneal epithelial (HCET) cells. Different parameters were tried: 
varied amount of plasmid DNA pSG5 were used (1-4µg), different electroporation timing 
(30 and 40ms) and different voltages (1000, 1300, 1350, 1400, 1500v) were used. The 
effectiveness of these electroporation parameters were determined by the amount of cell 
growth after 24 hours. After overnight incubation, 1300v, 30ms, 1 pulse with 1µg of 
plasmid DNA showed the highest cell survival of 85-90%. (B) To quantify the 
transfection efficiency, HCET cells were electroporated with 1µg of plasmid DNA pSG5 
and pSG5 TG-2 respectively. The electroporation parameters of 1300v, 30ms, 1 pulse 
were used. Reverse transcription and real time quantitative PCR was then performed. 









A2.6. SiRNA Transfection 
Short interfering (Si) RNA against TG-2 and fluorescein-conjugated SiRNA were used. 
The sense and anti-sense sequences (5’ to 3’) of the fluorescein-conjugated SiRNA were 
UUCUCCGAACGUGUCACGUdTdT and UUCUCCGAACGUGUCACGUdTdT 
respectively. Details of SiRNA transfection with the RNAiFect reagent have been 
previously described.(Chen et al 2005) Briefly, the ratio of siRNA to RNAifect used was 
1:8. The silencing or non-silencing (control fluorescein-conjugated siRNA) siRNA (1 μg 
per well in the case of a single well in a 12 well plate) was applied at a final 





A3. Use of Chemical Inhibitors, Hyperosmolar Stimulation and Fibronectin 
Coating 
A3.1. Caspase Inhibitor  
Z-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone), a 
cell-permeable pan caspase inhibitor, was added to the culture media at a concentration of 
20mM to inhibit caspases in cultured cells. 
 
A3.2. Hyperosmolar stimulation 
HCE-T cells were grown to 70-80% confluency before stimulation with hyperosmolar 
medium. The osmolarity suitable for experiment was determined through titration over a 
period of 24 hour (See Figure 2.1B). Sodium chloride was added to culture media to 
achieve osmolarity of 460mOsM (±5 mOsM), whereas control medium had osmolarity 
ranging from 290 to 305 mOsM. In every experiment, media osmolarity was determined 
and confirmed by VAPOR Pressure Osmometer 5520 (Wescor, UT).  
 
A3.3. Fibronectin Coating on Polystyrene Surface 
Fibronectin F0895 (Sigma stock 1mg/mL) was diluted to 1µg/mL in PBS.  An eight well 
plate was coated with 200uL diluted fibronectin for 3hr, 37C. The amount of fibronectin 
added can be changed depending on the size of the dish/well. The amount of fibronectin 
should be enough to cover the surface of the dish/well. After incubation, the surface was 
wash once with PBS. Cells were then seeded on the coated surface.   
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A4. Cell Lysis 
A4.1. Extraction of RNA and Quantification 
1. RNeasy Mini kit from Qiagen was used to extract RNA from cells. 
2. Cells were washed once with PBS. 
3. 350 μL of RLT buffer was added per well of a 6 well plate (for less than 5x106 cells). 
Cells were harvested using cell scraper. 
4. The cells were homogenized using a 22-gauge needle for at least 5 times. 
5. 350 μL (or the same volume as RLT buffer) of 70% ethanol was then added and 
mixed by pipetting.  
6. The mixture was then transferred to an RNeasy spin column with 2mL collection tube 
and centrifuged for 15 s, at >8000g. The flow-through was discarded. 
7. 700 μL of Buffer RW1 was added to the spin column and centrifuge for another 15s 
at >8000g. The flow through was discarded. 
8. 500 μL of Buffer RPE was again added to the spin column and re-centrifuged for 2 
minutes, at >8000g. 
9. After discarding the flow through, the spin column was placed in a new 2mL 
collection tube and centrifuged dry at full speed for 1 minute. 
10. After discarding the flow through, the column was placed in another new collection 
tube. 30 μL of RNase-free water was added and RNA was collected by centrifuging at 
>8000g, 1 minute.   
11.  30µL RNase-free water from step 9 was added back into the spin column and 
centrifuged again at >8000g for 1 minute. 
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12. After extraction, RNA quantification was performed using Nanodrop at 260/280 
(~1.8 is fine) and 260/230 (2.0-2.2 is fine). 
13. The purified RNA was then stored at -80ºC. 
 
A4.2. Total Proteins Extraction 
1. Cell lysis buffer was prepared by adding 2.5µL of protease inhibitor, 10µL 
phosphatase inhibitor to 65µL of Radioimmunoprecipitation assay (RIPA) buffer. 
2. Cells were washed once with cold PBS. 
3. Cell lysis buffer was added to the cells (around 200µL needed for a 10cm plate). This 
is followed by incubation on ice for 5 minutes. 
4. A sterile cell scrape was then used to harvest adherent cells. The cell suspension was 
then transferred to an eppendorf tube. 
5. The cell suspension was homogenized on ice with sonicator for 20 seconds.  
6. This is then followed by centrifugation at 10,000g for 15 minutes at 4ºC. 
7. The cell lysate was aliquoted, snap freeze in liquid nitrogen and stored at -80ºC. 
 
A4.3. Mitochondrial Protein Extraction 
1. HCE-T cells were grown to 70-80% confluency, washed with PBS and trypsinised as 
described in A1.3.  
2. The cells were pelleted down at 1,000 rpm for 5 minutes at 4ºC.  
3. The cell pellet was re-suspended in cold PBS and pelleted down again. 
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4. After removal of supernatant, 1mL of mitochondrial extraction buffer (MSHE) buffer 
A was added and incubated on ice for 2 minutes.  
Composition of MSHE buffer A: 
0.21M mannitol, 0.07M sucrose, 10mM HEPES (pH 7.4), 1mM EDTA, 1mM EGTA, 
0.15mM spermine, 0.75mM spermidine 
10µL of protease inhibitor was added freshly into 1mL of MSHE buffer A every time 
before use. 
5. The suspension was spun at 1,600 rpm for 5 minutes at 4ºC.  
6. After removal of supernatant, the pellet was re-suspended in 1mL of MSHE buffer A  
7. Viable cells were checked with trypan blue and homogenized using a 27G needle, 60 
times on ice, and verified by microscopy.  
8. To pellet unbroken cells and nuclei, the suspension was spun at 800g for 3 minutes. 
The supernatant was retained and spun again at 11,000g for 15 minutes at 4ºC.  
9. The resulting supernatant was the cytosolic fraction. The mitochondrial pellet was re-
suspended in 200mL of MSHE buffer A, and was further purified by centrifugation at 
1,000g for 5 minutes and at 11,000g for 15 minutes.  
10. The protein concentrations of the extracted total protein mitochondrial protein were 
determined using BCA protein Assay kit as described in A4.4. 
 
A4.4. Bicinchoninic Acid (BCA) Protein Assay 




2. Albumin standards provided by the BCA kit were diluted with nanopure water into 
concentrations from 1000μg/mL to 25μg/mL.  
3. 10L of standards and samples was pipetted into the microplate. Triplicates were 
done for each of them. 
4. Working Reagent was prepared by mixing 50parts of Reagent A with one part of 
Reagent B. 
5. 200µL of Working Reagent were added to every well containing either protein 
samples or standards. 
6. The plate was incubated for 30 minutes at 37ºC. 




A5. Western Blotting 
Protein concentration was determined using the BCA method as described in A4.3. 
A5.1. Preparation of Buffers 
1. The running buffer was a Tris/glycine/SDS running buffer from Biorad, CA, USA.  
2. The transfer buffer was Tris/glycine transfer buffer from the same company with 
addition of 20% methanol, kept chilled before use. 
3. TBST wash buffer is composed of 0.1% Tween 20 in Tris buffered saline. 
 
A5.2. Gel Electrophoresis 
1. The same mass of protein (40μg) was mixed with 4x loading dye containing 20% beta 
mercapethanol. 
2. The samples were denatured at 99ºC for 10 minutes. 
3. For identification of protein bands, 10µL of protein standard with known molecular 
masses was loaded in one lane. 
4. The gel electrophoresis was carried out at 100 volts for around 1 hour and 30 minutes. 
The machine was stop when the dye front reached the bottom of the gel. 
 
A5.3. Transfer and Blotting 
1. PVDF membrane was activated with 100% methanol for 15 seconds, followed by 
soaking in water for 2 minutes. The membrane was then submerged in transfer buffer 
until ready to make the western sandwich. 
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2. After the gel has finished running, the front glass plate was removed and the gel was 
carefully detached. The gel was equilibrated for 10 minutes in transfer buffer. 
3. The western sandwich was prepared in a tray containing the cold transfer solution. 
The sandwich was prepared in the following order: A fiber pad, a filter paper, the 
PVDF membrane, gel, a sheet of filter paper and a fiber pad. Bubbles were removed 
from the sandwich by rolling a pipette over the set-up. 
4. The sandwich was then placed inside a cassette, whereby the PVDF membrane was 
closest to the transparent side of the cassette. 
5. The sandwich was put in a transfer device.  The black side of the cassette was placed 
next to the black side of the transfer cassette. 
6. The transfer tank was filled the cold transfer buffer together with an ice and a stir bar. 
7. The transfer was carried out at 20v overnight or 110v for 75 minutes.  
8. After the run, the PVDF membrane was removed from the cassette. The PVDF 
membrane was washed 3x 5 minutes in TBST. 
9. The membrane was blocked was blocked in 5% Bovine Serum Albumin (BSA) in 
TBST for one hour at room temperature. 
10. This is followed by 3x 5 minutes washing in TBST at room temperature with shaking. 
11. Primary antibody was added into 1% BSA in TBST and incubated at for 1 hour at 
room temperature with shaking. Alternatively, the primary antibody incubation can be 
left overnight at 4ºC with shaking. 
12. This is followed by 3x 5 minutes washing in TBST at room temperature with shaking. 
13. Secondary antibody in 1% BSA in TBST was incubated for 45 minutes at room 
temperature with shaking. 
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14. This is followed by 3x 5 minutes washing in TBST at room temperature with shaking. 
15. Substrate was added to the membrane. The incubation time of the substrate depends 
on the strength of the substrate used. 
16. The PVDF membrane was placed in a plastic bag and put into a cassette. A piece of 
film was put over the PVDF membrane for 1 minute. 
17. Chemiluminescence captured by the film then detected using Kodak imaging system 
2000R (CT, USA). 
18. The image is then analysed by densitometry which evaluates the relative amount of 
protein staining.   
 
A5.4. Densitometry 
To prepare band image file: 
1. Image J was used to open the image file. 
2. The images were converted to 8 bit. 
3. The band of interest was enlarged using “Magnifying Glass” tool. 
4. The image was cropped by drawing a tight fitting rectangle around the band using the 
“Rectangle” tool. 
5. The images were cropped by selecting “Image > Crop”. 
6. All the cropped images were then pasted on Powerpoint and saved as a TIFF file. 
 
To measure band intensities: 
7. The saved TIFF file was opened in ImageJ. 
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8. The image was converted to 8 bit again. 
9. The image was enlarged using “Magnifying Glass” tool. 
10. The rectangle tool was used to create a vertical rectangle in the first lane. To indicate 
that this is the first lane of the gel, “Analyse > Gels > Select First lane” was selected. 
11. Using the mouse, click inside the rectangle and drag the box to the second lane. This 
lane was labeled as another lane by selecting “Analyse > Gels > Select next lanes”. 
12. After dragging the last rectangle over the last lane, “Analyse > Gels > Plot lanes” was 
selected. 
13. Image J will open a new window containing a mountain for each band. The mountain 
represents the density of the band.  
14. The area inside the mountains was calculated by clicking the “magic wand” inside a 
mountain to calculate the area inside the mountain.  
15. For loading control in western blot, the band intensity of each protein band was 
compared to the band intensity of its loading control.  
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A6.  Centricollation 
A6.1. Cell Lysis for Centricollation 
1. Cell lysis buffer was prepared by adding 2.5µL of protease inhibitor, 10µL 
phosphatase inhibitor to 65µL of Radioimmunoprecipitation assay (RIPA) buffer. 
2. Cells were washed once with cold PBS. 
3. Cell lysis buffer was added to the cells (around 200µL needed for a 10cm plate). This 
is followed by incubation on ice for 5 minutes. 
4. A sterile cell scrape was then used to harvest adherent cells. The cell suspension was 
then transferred to an eppendorf tube. 
5. The cell suspension was centrifuged at centrifuged at 1200rpm for 5 minutes at 4ºC. 
6. The cell pellet was re-suspended in homogenizing buffer (1mL of 8.5% GradiSpec 
with 2µL of 0.5M of Ethylenediaminetetraacetic acid (EDTA) and 10µL of protease 
inhibitor).  
7. The cells were then homogenized for approximately 25 times with a 27G needle and 
syringe. 
8. The homogenized suspension was centrifuged at 1000rpm for 5 minutes at 4ºC.  
9. BCA was then carried out as described in section A4.3. Higher protein concentrations 





Enhanced density gradient extraction (Edge™) 200 System (Prospect Biosystems) is a 
bench-top, air-driven temperature-controlled ultracentrifuge system driven by centrifugal 
force for a stepwise extraction of particles.  
 
1. As shown in Figure A5, 1 mL of samples with 8.5% GradiSpec solution was added 
into the SteriLiner.  
2. The SteriLiner was then inserted into the rotor of the Edge 200 machine and spun for 
5 minutes at 125,000g force. 
3. After spinning, the supernatant was removed with a fine tip pipette without disturbing 
the pellet at the walls of the SteriLiner. The supernatant was kept in Eppendorf tube. 
4. 100 uL of the next higher GradiSpec Sucrose Fraction (20%, 30%, 40%) was added 
into the same SteriLiner. 
5. The centre hole of the SteriLiner was covered using parafilm. It was then vortexed for 
1 minute until all the pelleted sample on the wall is re-suspended in the solution. 
6.  The parafilm was then removed and the same procedure from 2 to 4 was repeated 
until supernatants of the various sucrose fractions were obtained.  
7. Gross fractionations were first performed using sucrose density solution at 8.5%, 
20%, 30% and 40% (Figure A5). 
8. To narrow down the range of sucrose density solution containing the interacting 
proteins and organelles, an approximate organelle localisation chart provided by 
Prospect Biosystems was referred (Figure 3.5).  
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9. After the range of sucrose density solution was narrowed down, centricollation was 




















Figure A5. Diagram showing the process of centricollation. After homogenizing cell 
lysates with Density solution 1, samples were centrifuged and BCA was performed. 
Centricollation was carried out by adding 1 mL of sample to SteriLiner and rapidly spun 
at 125,000g for 5 minutes. After spinning, the sample was allowed to rest. The 
supernatant (Fraction 1) was carefully removed. The next higher Density Solution was 
added and the same procedure was repeated until supernatants of the various densities 
were obtained. This study mainly used Density Solution of 8.5%, 10%, 15% and 20%.  
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A7.  Immunoprecipitation  
A7.1. Co-Immunoprecipitation to Pull Down TG-2 Binding Partners 
1. Cell lysate was collected as described in A4.2. 
2. EZview Red ANTI-FLAG M2 affinity gel beads were mixed until uniformly 
suspended. 
3. 40µL of the affinity gel beads was aliquoted into a 1.5mL eppendorf tube on ice.  
4. 500µL of TBS buffer was added to the eppendorf tube with beads. The content was 
vortex and centrifuged for 30 seconds at 8200g. 
5. Supernatant was carefully removed and the tube with beads was placed on ice. 
6. 500µL of TBS buffer was again added to the beads. The content was vortex and 
centrifuged for 30 seconds at 8200g. 
7. Cell lysate was spun at 8200g for 10 minutes at 4ºC. 
8. 500 ug (200-1000µL) of cell lysate was added to the washed beads. The final volume 
was top-up to 1mL by adding lysis buffer. 
9. The beads were gently shaken overnight at 4ºC.  
10. This is followed by spinning down at 8200g for 30 seconds at 4ºC.  
11. Supernatant was removed. Tube with beads was place on ice. 
12. The beads were washed by adding 500µL TBS with brief vortexing. 
13. Incubation was done at 4ºC for 5 minutes, followed by centrifugation for 30 seconds 
at 8200g. 
14. Supernatant was carefully aspirated. 
15. The beads were washed 2x with 500µL of TBS and brief vortexing.  
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16. After removing the final wash supernatant, the bound antigens can be eluted and 
analysed. 
17. 3X FLAG peptide was dissolved in 0.5M tris HCl, pH 7.5, 1M NaCl to prepare stock 
solution at a concentration of 25µg/µL.  
18. To prepare 5µg/µL of 3X FLAG peptide, the stock concentration was diluted 5-fold 
with water. 
19. To prepare 3X FLAG Elution Solution at a concentration of 150ng/µL, 3µL of 
5µg/µL 3X FLAG peptide was added to 100µL of TBS. 
20. As a positive control, 1mL of TBS and 4µL of 50ng/µL FLAG-BAP fusion protein 
was added to a comparable tube of washed resin. 
21. As a negative control, a comparable lysate volume from a lysate of cells not 
expressing FLAG fusion protein was used. 
22. 100µL of 3X FLAG Elution Solution was added to each sample and control beads. 
23. Samples and controls were incubated with gentle shaking for 30 minutes at 4ºC. 
24. The beads were centrifuged at 8200g for 30 seconds. 
25. Without disturbing the beads, the resulting supernatant was transferred to fresh tube. 





A7.2. Co-Immunoprecipitation to Pull Down Paxillin Interacting Partners 
1. To pre-clear the lysate, 500ug lysate was incubated with 60ul of streptavidin agarose 
slurry for 1 hour by end-over-end mixing.  
2. The lysate and agarose mixture was then centrifuged at 1000g at 4°C, 1 minute.  
3. The supernatant was incubated with rabbit anti-paxillin conjugated to biotin (1:20), 
overnight at 4°C with end-over-end mixing.  
4. The lysate and antibody mixture was incubated with 60ul of streptavidin agarose 
slurry for 2 hours at 4°C, with end-over-end mixing.  
5. The lysate and agarose mixture was again centrifuged at 1000g at 4°C, 1 minute 
before the supernatant was removed and stored.  
6. The remaining beads with bound protein complex were washed 4 times with binding 
buffer solution. 
7. The washed agarose beads with the bound protein complex were boiled at 95°C, for 9 
minutes in 50ul of 2X protein loading dye containing 20% reducing agent, to denature 
and release the bound protein from the agarose beads. 
 
A7.3. Cell Free In Vitro Immunoprecipitation 
1. Recombinant human proteins TG-2 (R&D system), JNK (Santa Cruz) and paxillin 
(Biolegend) were pre-cleared in 1.5mL tubes by mixing with streptavidin agarose 
resin for 1 hr at 4˚C.  
2. The tubes were centrifuged at 1,000 g for 1 min at 4˚C. The supernatant was 
transferred to new tubes, and the streptavidin agarose beads were discarded.  
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3. JNK (5µg) and paxillin (1µg) were mixed with 1µg, 2.5 µg or 5 µg of TG-2 
respectively in 1.5mL tubes.  
4. Biotinylated anti-paxillin (10µg) was added to each tube, and PBS was added to make 
each tube to a final volume of 200µL.  
5. The tubes were incubated overnight at 4˚C with end-over-end mixing. 
6. The next day, the same amount of streptavidin agarose resin used for pre-clearing was 
added to each tube and the tubes were incubated at 4˚C for 2 hrs.  
7. The supernatant was removed from each tube and resin beads were washed 5x with 
500µL of cold PBS.  
8. Fifty microliter of 2x protein loading dye was added to each tube and the tubes were 
heated at 95˚C for 10 min. The same volume from different samples was used for 




A8.  Liquid chromatography-tandem mass spectrometry (LC-MS/MS)  
1. Protein digestion was performed using a trypsin digestion kit.  
2. The lyophilized IP samples were first re-dissolved in 25 μL Extraction Buffer 
followed by 25μL of Digest Buffer.  
3. Samples were reduced using 1.5μL of Tris (2-carboxyethyl)phosphine (TCEP), mixed 
and incubated for 20 minutes at 37ºC. Negative controls “immunoprecipitation” 
with pre-immune serum was also included 
4. Samples were brought to room temperature and 1.5 μl of iodoacetamide was added, 
mixed and incubated for another 20 minutes at room temperature.  
5. Trypsin digestion was then carried out by adding 1.5 μL of 1μg/μL Trypsin for 3 
hours at 37ºC.  
6. The digested samples were dried using speedvac.  
7. 10 μL of loading buffer was added to re-dissolve samples and analysis was performed 
using LC-MS/MS.  
8. Micro-capillary LC column (15 cm × 75 μm i.d.) was self-packed using PicoFrit 
(New Objectives, Woburn, MA) with integrated spray tip which was directly coupled 
with the nano-spray interface (Protana, Odense, Denmark) into ABI’s QSTAR mass 
spectrometer. The packing material was Luna C18, 3μm, 100 Å (Phenomenex 
Torrance, CA).  
9. Samples were loaded onto a trap column (C18, 0.3 x 5 mm, from Dionex, LC 
Packings) from Famos autosampler (Dionex, LC Packings) at 30 μL/min.  
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10. After a 5 min wash with acetonitrile/water (5/95, v/v with 0.1% formic acid), the 
system was switched (Switchos, Dionex, LC Packings) into line with the C18 
capillary column.  
11. Using an Ultimate solvent delivery system (Dionex, LC Packings), peptides were 
eluted by a linear gradient of acetonitrile (0.1% formic acid) from 5% to 55% over 35 
min at flow rate of 300 nL/min.  
12. Parameters for the nanospray and other instrumentation were set as follows: ionspray 
voltage (IS) = 1800 V, curtain gas (CUR) = 25, declustering potential (DP) = 60 V, 
focusing potential (FP) = 265 V, collision gas setting (CAD) = 5 for nitrogen gas, 
DP2=25. All data was acquired using information-dependent acquisition (IDA) mode 
with Analyst QS software (Applied Biosystems).  
13. TOF-MS survey scan parameters were set as follows: 1 sec TOF MS survery scan in 
the mass range of 350~1200 Da followed by two product ion scans of 3 sec each in 
the mass range of 100~1800 Da. The “enhance all” function was used in the IDA 
experiments. Switching criteria were set to ions greater than m/z = 350 and smaller 
than m/z = 1200 with charge state of 2 to 4 and an abundance threshold of > 8 
counts/s. Former target ions were excluded for 120s. IDA collision energy (CE) 
parameter script was used for automatically controlling the CE.  






Figure A6. Mass spectrogram showing the ion fragment with peptide sequence that 




A9.  Mapping of Protein Ligands to TG Domains 
1. Cells were lysed and immunoprecipitation was performed with anti-Flag antibodies as 
described in A7.  
2. Elutes were sent for tryptic digest and nano LC/LC MS/MS as described in A8.  
3. Using MASCOT protein database search, the potential binding partners of TG-2 was 
given a confidence level according to factors such as: not present in the negative 
control, not in a similar class as negative control proteins, a known protein, found 
with an antibody against TG-2, related to known TG-2 functions as documented in 
Gene Ontology, not repeated in different peptide fragments, and it is found in 
replicated experiments.  
4. Each of these factors contributed 1 point. Only level 3 and 4 (3 or more point) ligands 
were considered for mapping to TG domains.  
5. Proteins with functions clearly related to cell adhesion or trafficking were 
preferentially retained and the known relations of these proteins with TGM-2 plotted. 
6. The functional relationships of these potential binding partners were constructed and 
validated using Pathway Studio Version 5.0.  
7. Pathway Studio extracted related PubMed articles based on the mass-spectometry 
results. One article was limited to one intervening entity. To determine the 
relationships with TG-2, the abstracts of these published articles were manually 
chosen.  
8. After generating a list of TG-2 related ligands, a search on the PubMed gene database 
was performed to classify entities according to their biological process.  
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9. Western blots were then carried out with the corresponding antibodies against the 
suggested ligands.  
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A10. Immunostaining  
A10.1. Immunocytochemistry and Immunohistochemistry 
1. Fixation was performed with 4% paraformaldehyde (PFA) in PBS for 15 minutes. 
2. To make 50mL of 4% PFA: 
i. 2 gram of paraformaldehyde was added to 250 mL of conical flask or beaker. 
ii. 50 ml of water and a stirrer was added.  
iii. The mixture was heated at 100ºC until moisture was observed  at the side of 
the glass beaker. 
iv. The beaker was placed on a magnetic mixer.  
v. Add in drops of 5M NaOH until solution becomes clear.  
vi. The beaker was removed from heat. Same number of drops as step v of 5M 
HCl was added. 
vii. 2.5mL of 20x PBS was added. 
3. The slides were washed twice with PBS.  
4. The cells/tissues were then permeabilised with 0.1% of Triton X-100 in PBS for 10 
minutes.  
5. This is followed by 3x 5minutes washing with PBS.  
6. Blocking was performed with 1.5% BSA in PBS for 1hour in humidified chamber. 
7. Excess blocking buffer was tapped off from the slides.  
8. The slides were then incubated with primary antibody in 1.5% of BSA for 2 hours at 
room temperature in humidified chamber.  
9. Washing was done 3x 5minutes with PBS. 
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10. Secondary antibody in 1% BSA in PBS was added to the slides at room temp for 1 
hour in moist chamber. 
11. Washing was done 3x 5minutes with PBS. 
12. To stain the nucleus, the cells/tissues were incubated with Dapi in PBS (1:1000) for 
10 minutes. 
13. The slides were rinsed 3x with PBS 
14. The slides were then mounted with 10µL of mowiol.  
15. A coverslip was added on top of the glass slide. The side of the coverslip were sealed 
with transparent nail polish. 
16. Slides were then observed under a microscope and fluorescent images were captured  
 
A10.2. Immunofluorescence Staining with Phalloidin 
1. Cells were grown for 24 hours to produce a confluent monolayer of cells on glass 
coverslip coated with fibronectin. The cells were submerged in DMEM-F12 
supplemented with 5% FBS, at 37
o
C, 5% CO2 atmosphere.  
2. After removing the medium, the monolayer was washed once with PBS.  
3. Scratches were made with a 1 mL blue pipette tip.  
4. After scratching, the monolayer was washed twice with PBS to remove cell debris.  
5. Cells were incubated with fresh DMEM-F12 supplemented with 5% FBS, at 37oC, 
5% CO2 atmosphere, for 3 hours.  
17. The monolayer cells was washed with PBS and fixed with 4% paraformaldehyde 
(PFA) in PBS for 15 minutes 
18. The slides were washed twice with PBS.  
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19. The cells/tissues were then permeabilised with 0.1% of Triton X-100 in PBS for 10 
minutes.  
20. This is followed by 3x 5minutes washing with PBS.  
21. Blocking was performed with 1.5% BSA in PBS for 1hour in humidified chamber. 
22. Excess blocking buffer was tapped off from the slides.  
23. The slides were then incubated with phalloidin and DAPI in 1.5% of BSA for 30 min 
at room temperature in humidified chamber in the dark.  
24. Washing was done 3x 5minutes with PBS 
25. Excess liquid was removed from the coverslip by touching the corner on a paper 
towel. The coverslip was then inverted on a drop of mounting media on a glass slide 
26. The coverslip and glass slide was left for 20 min to dry followed by sealing of the 






A11. Polymerase Chain Reaction (PCR) 
A11.1. Reverse Transcription 
1. Reverse transcription was done to obtain cDNA from RNA (Figure A7). The RNA 
concentration was first measured using nanodrop. 
2. The following were added into a nuclease-free microcentrifuge tube: 
1µg of RNA 
1µL of 10mM dNTP Mix 
1µL of 50µM random hexamer  
Sterile water to 8µL  
3. The mixture was heated at 65°C for 5 minutes followed by incubation on ice for at 
least 1 minute. 
4. The content of the tube was collected by brief centrifugation and the following were 
added: 
2µL of 10x First-Strand Buffer 
2µl 0.1M DTT 
4 µl of 25mM MgCl2   
1 µl of RNaseOUT Recombinant RNase Inhibitor  
1µL of Superscript III RT 
5. The solution was mixed by pipetting gently up and down.  
6. The solution was incubated at 25°C for 10 minutes, then 50°C for 50 minutes.  

















Figure A7. Diagram showing a summary of reverse transcription to obtain cDNA from 
RNA. The whole process involved denaturation of RNA strands at 65ºC, annealing of 






A11.2.  Quantitative Real Time PCR (qPCR) 
Real-time PCR was performed using specific Taqman probes. GAPDH gene was used as 
an endogenous control which quantifies relative gene expression in cDNA samples. 
1. The sequences of the forward and reverse primers (50–30) to detect TG-2 were 
AGGGTGACAAGAGCGAGATG  
TGGTCATCCACGACTCCAC 
2. The following were pipetted into the two 1.5mL eppendorf tubes labelled TG-2 and 
GAPDH. 
Reagent Volume  
Water 17.1 
2x master mix 45 
Primer (Forward) 9 
Primer (Reverse) 9 
Taqman Probe 0.9 
Total vol in PCR tube 81 
 
3. 29.7µL of the mixed solution each was aliquot into 2 eppendorf tubes. 
4. 3.3µL of cDNA was added into the tubes. 
5. The solution was mixed by pipeting up and down followed by spinning down at 
1000rpm for 5 minutes. 
6. 10µL was pipetted into a well of the 384 PCR plate. Triplicates were done for each 
sample. 
7. The rest of the solution from step 2 was use as a Negative Control. 10µL of negative 
control was pipetted into the PCR plate. 
8. The plate was spun at 2000g for 3 minutes at 4ºC. 
9. The PCR machine was set with the following parameters 
Pre-incubation (1 cycle) 
95C None 10.01 min 
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Amplification (45 cycles) 
95C None 10 s 
54C None 10s 
72C Single 30s 
Cooling (1 cycle) 
40C None 1s 
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A12. Functional Assays 
A12.1. Caspase Assay  
Caspase-3 and -7 activities were measured using Caspase-Glo 3/7 assay while caspase-9 
activity was measured using Caspase-Glo 9 assay. The Caspase-Glo Assay is a 
luminescent assay that is able to measure caspase-3/7 or 9 activities in living cells. 
Addition of the Caspase-Glo 3/7 or 9 Reagent caused cell lysis, followed by caspase 
cleavage of the substrate, and production of luminescent signal. Pro-luminescent caspase-
3/7 or 9 substrate containing tetrapeptide sequence DEVD was provided. Once the 
substrate is cleaved, aminoluciferin is release and luminescent signal is generated.  
1. 100µL of complete media containing 1.1x105 cells/mL cells were grown in 96 wells 
white walled-plate. These are the sample wells.  
2. 20µM of caspase inhibitor Z-Vad-FMK, as described in A3.1, was added into three of 
the wells which contained cells and incubated for 24 hours. These are the inhibitor 
wells. 
3. The plate was equilibrated to room temperature. 
4. 100µL of Caspase-Glo 3/7 or Caspase-Glo 9 reagents were to each well (blank, 
samples, inhibitor wells). 
5. Plate was shake on a plate shaker for 30 seconds.  
6. The plate was then incubated at room temperature for 2 hours. 
7. Luminescent signal, which was proportional to the amount of caspase activity 




A12.2.  Mitochondrial Depolarisation Assay 
Mitochondrial membrane potential of various cells was studied by staining the cells with 
JC-1, a membrane permeable dye which exhibits membrane potential dependent 
accumulation in mitochondria. In live cells, JC-1 is a metachromatic probe which exists 
either as a green-fluorescent (~529 nm) monomer at depolarised membrane potentials, or 
as an orange-fluorescent (~590 nm) J-aggregate at hyperpolarized membrane potentials. 
 
1. Non-adherent cells in the media were collected and adherent cells were trypsinised. 
2. The cells were pelleted at 800rpm for 5 minutes. 
3. The pelleted cells were resuspended in 1mL of media and incubated with 10µL of 
200µM JC-1 dye for 30 minutes, at 37ºC and 5% CO2.  
4. As a positive control, 2µL of 2mM mitochondrial membrane disruptor CCCP was 
added.  
5. Cells were washed once with PBS and spun down at 800rpm for 5 minutes at room 
temperature. 
6. Cells were re-suspended by gently flicking the tubes. 
7. 500L of warm complete media was added. 
8. Samples were analysed by flow cytometry performed at 488nm.  
9. Healthy cells with intact mitochondria fluoresce red; while apoptotic cells fluoresce 
green. 
10. An ellipse was use to delineate a population of cells with healthy mitochondria. The 
percentage of depolarised cells was computed by measuring the amount of cells 
falling outside the ellipse. 
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A12.3. Transglutaminase Colorimetric Microassay Kit 
Cellular transglutaminase enzymes can catalyze the crosslinking of biotin cadaverine to 
CBZ-Gln-Gly peptides coated on 96-well plates. The greater the activity of the cellular 
transamidase enzymes, the more biotin will be cross-linked to these peptides.  
1. 150μL per well of 1X diluent buffer was added and the plate was incubated for at 
least 30 minutes at 37°C. 
2. Samples from cells or tissues were centrifuged before use. 
3. The 1X diluent buffer was removed from the plate. 
4. Per well, the following were dispensed:  
samples: 40 μL+10μL distilled water),  
positive control: 40μL TG (1/10 in NaCl 0.14M) + 10μL distilled water 
negative control: 40μL TG + 10μL of Negative control reagent 
one blank well for HRP substrate/chromogen solution only 
5. 50 μL per well of reconstituted biotin-cadaverine/CaCl2 was added. 
6. Incubation at 37°C for 15 minutes. 
7. The enzyme tracer solution was prepared at 1/2000. 
8. The wells were washed 3x with PBS containing 0.1% Tween 20 or TBS containing 
0.1% Tween 20. 
9. 100 μL per well of 1/2000 diluted enzyme tracer solution was added. 
10. The plate was incubated for 15 minutes at 37°C. 
11. HRP substrate/chromogen solution was prepared. 
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12. The wells three times were washed 3x with PBS containing 0.1% Tween 20 or TBS 
containing 0.1% Tween 20. 
13. 100μL per well of HRP substrate/chromogen solution was added. 
14. Incubation at room temperature for 2 to 10 minutes. 
15. 100μL per well of blocking reagent was dispensed. 
16. The optical density of each well at 450nm was measured. 
 
A12.4. G-LISA Kit 
Traditionally, the Rho family proteins such as RhoA, Rac or Cdc42 assays had been 
performed using a conventional agarose beads affinity pull-down method. However, this 
method have several drawbacks such as time consuming, requiring large amount of total 
protein, limited in the number of samples that can be handled simultaneously and 
generating semi-quantitative results. 
These G-LISA RhoA, Rac and Cdc42 kits from Cytoskeleton enabled Rho proteins to be 
measured in less than 3 hours, requires only 1-5% of the material needed for a 
conventional pull down assay, able to handle large number of samples and generated 
quantitative results. 
The G-LISA kit contained a Rho protein-GTP binding protein linked to the wells of a 96-
well plate. Active GTP-bound Rho present in cell lysates can bind to the wells. Specific 
antibody was then used to detect the bound active Rho proteins. The inactive GDP-bound 




A12.4.1. RhoA and Rac1/2/3 G-LISA Activation Assay 
1. Cells with confluency of 50% were lysed and collected using cold lysis buffer as 
described in A4.2. 
2. Total amount of proteins were quantified using BCA assay as described in A4.4. 
3. The cell extracts were equalized with cold lysis buffer. Concentration of equalized 
protein must not > 2mg/mL or <0.4mg/mL. 
[(A-B)/B]*(vol of A)=  ____  µL 
 A= higher concentration lysates (mg/mL) 
 B= most diluted lysates (mg/mL) 
4. For Rho A assay, 60µL of lysis buffer and 120µL of ice cold binding buffer was 
added into microfuge tube.  
For Rac assay, 60µL of lysis buffer and 60µL of ice cold binding buffer was added 
into microfuge tube.  
5. The tubes were vortexed for 3-5 seconds at high speed and then placed on ice. This is 
buffer blank sample. 
6. For Rho A assay, 24µL of Rho Control Protein, 96µL of cold lysis buffer and 120µL 
of binding buffer was added into the microfuge tub.  
For Rac assay, 5µL of Rac Control Protein, 55µL of cell lysis buffer and 60µL of 
binding buffer was added into the microfuge tub.  
7. The tubes were vortexed for 3-5 seconds at high speed and then placed on ice. This is 
positive control sample.  
8. Strips of wells were taken out from the plate and placed on ice. 100µL of cold water 
was added to dissolve the powder in the wells.  
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9. Frozen cell lysates were thawed in room temperature water bath. Lysis buffer was 
added to respective tubes based on calculations from the equation in step 3. 
10. 120µL of lysate for triplicate wells were aliquoted into fresh ice cold microfuge 
tubes. 
11. Equal volume of cold binding buffer was added to each tube on ice. 
12. Water was completely removed from the microplate wells by vigorously flicking the 
plate, followed by 5-7 hard and vigorous series of pats onto paper towels. 
13. Plate was placed back on ice. 
14. Each tube was immediately vortexed for 3-5 seconds with high speed.  
15. 50µL of equalized cell lysate, buffer blank control or RhoA/Rac positive control was 
pipetted to triplicate wells respectively. 
16. Plate was immediately placed on a cold orbital microplate shaker at 210rpm, 4ºC for 
exactly 30 minutes. 
17. During the incubation, anti-RhoA primary antibody was prepared by diluting to 1/250 
in Antibody Dilution Buffer. 
Anti-Rac primary antibody was prepared by diluting to 1/200 in Antibody Dilution 
Buffer. 
* Final volume of 500µL is enough for 1 strip (8 wells) 
18. After 30 min, the solution was flicked out from the wells followed by washing 2x 
with 200µL room temperature wash buffer using. Wash buffer was vigorously 
removed after each wash. 
19. The plate was placed on bench. 
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20. 200µL of room temperature Antigen Presenting Buffer was immediately pipetted into 
each well using a multi-channel pippettor. The wells were incubated at room 
temperature for exactly 2 minutes. 
21. Antigen Presenting Buffer was vigorously flicked out and the inverted plate was 
patted 5-7 times. 
22. The wells were then washed 3x with 200µL room temperature wash buffer and the 
wash buffer was vigorously removed. 
23. 50µL of diluted anti-RhoA/anti-Rac primary antibody was added to each well and the 
plate was placed on the shaker at 250 rpm for 45 minutes in room temperature. 
24. During the primary antibody incubation, for Rho A assay, secondary HRP labeled 
antibody was diluted to 1/62.5 in antibody dilution buffer; for Rac assay, secondary 
HRP labeled antibody was diluted to 1/100 in antibody dilution buffer. 
* The final vol of 500µL is enough for 1 strip of 8 wells. 
25. Primary antibody was vigorously flicked out and the inverted plate was pat 5-7 times. 
26. The wells were then washed 3x with 200µL room temp wash buffer and the wash 
buffer was vigorously removed every time. 
27. 50µL of diluted secondary antibody was added to each well and shook at 200-400 
rpm in room temperature for 45 minutes. 
28. HRP detection reagent was prepared by mixing equal volume of reagent A with B 
into a fresh tube (50µL per well). Mixture must be protected from light.  




30. The wells were washed 3x with 200µL room temperature wash buffer. The wash 
buffer was vigorously removed every time. 
31. 50µL of HRP detection reagent was added into each well and incubated at 37ºC for 
15 minutes in Rho A assay, but 20 minutes in Rac assay.  
32. 50µL of HRP stop Buffer was added to each well. 
33. Absorbance was measured at 490 nm using a microplate spectrophotometer.  
 
A12.4.2.  Cdc42 G-LISA Activation Assay 
1. Cells with confluency of 20-30% were lysed and collected using cold lysis buffer as 
described in A4.2. 
2. Total amount of proteins were quantified using BCA assay as described in A4.4. 
3. The cell extracts were equalized with cold lysis buffer. Concentration of equalized 
protein must not > 2mg/mL or <0.4mg/mL. 
[(A-B)/B]*(vol of A)=  ____  µL 
 A= higher concentration lysates (mg/mL) 
 B= most diluted lysates (mg/mL) 
4. 120µL of lysis buffer was aliquoted into a microcentrifuge tube. This is buffer blank 
sample. 
5. 12µL of Cdc42 Control Protein and 108µL of cold lysis buffer was added into the 
microfuge tub. The tubes were vortexed for 3-5 seconds at high speed and then placed 
on ice. This is positive control sample for 2 wells.  
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6. Strips of wells were taken out from the plate and placed on ice. 100µL of cold water 
was added to dissolve the powder in the wells.  
7. Frozen cell lysates were thawed on ice. Lysis buffer was added to respective tubes 
based on calculations from the equation in step 3. 
8. Water was completely removed from the microplate wells by vigorously flicking the 
plate, followed by 5-7 hard and vigorous series of pats onto paper towels. 
9. Plate was placed back on ice. 
10. 50µL of equalized cell lysate, buffer blank control or Cdc42 positive control was 
pipetted to triplicate wells respectively. 
11. Plate was immediately placed on a cold orbital microplate shaker at 210rpm, 4ºC for 
exactly 30 minutes. 
12. During the incubation, anti-Cdc42 primary antibody was prepared by diluting to 1/20 
in antibody dilution buffer. 
* Final volume of 500µL is enough for 1 strip (8 wells) 
13. After 30 min, the solution was flicked out from the wells followed by washing 2x 
with 200µL room temperature wash buffer using. Wash buffer was vigorously 
removed after each wash. 
14. 200µL of room temperature Antigen Presenting Buffer was immediately pipetted into 
each well using a multi-channel pippettor. The wells were incubated at room 
temperature for exactly 2 minutes. 
15. Antigen Presenting Buffer was vigorously flicked out and the inverted plate was 
patted 5-7 times. 
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16. The wells were then washed 3x with 200µL room temperature wash buffer and the 
wash buffer was vigorously removed. 
17. 50µL of diluted anti-Cdc42 primary antibody was added to each well and the plate 
was placed on the shaker at 250 rpm for 45 minutes in room temperature. 
18. During the primary antibody incubation, secondary HRP labeled antibody was diluted 
to 1/62.5 in antibody dilution buffer. 
* The final vol of 500µL is enough for 1 strip of 8 wells. 
19. Anti- Cdc42 primary antibody was vigorously flicked out and the inverted plate was 
pat 5-7 times. 
20. The wells were then washed 3x with 200µL room temp wash buffer and the wash 
buffer was vigorously removed every time. 
21. 50µL of diluted secondary antibody was added to each well and shook at 200-400 
rpm in room temperature for 45 minutes. 
22. HRP detection reagent was prepared by mixing equal volume of reagent A with B 
into a fresh tube (50µL per well). Mixture must be protected from light.  
23. Secondary antibody was vigorously flicked out and the plate was inverted and pat for 
5-7 times. 
24. The wells were washed 3x with 200µL room temperature wash buffer. The wash 
buffer was vigorously removed every time. 
25. 70µL of HRP detection reagent was added into each well and incubated at 37ºC for 
10 minutes. 
26. 140µL of stop Buffer was added to each well. 
27. Absorbance was measured at 490 nm using a microplate spectrophotometer.  
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A13.  Cell Viability/Proliferation Assay  
A13.1. Crystal Violet 
Crystal violet dye stains DNA. This assay is useful for obtaining quantitative information 
about the relative density of cells in multi-wells plate. Upon solubilisation of the dye, the 
amount of dye taken up by the cells can be quantitated in a plate reader. 
1. Cells were counted and 1x106 cells were transfected by electroporation as described 
in A2.5. 
2. The cells were seeded in a six-well culture plate, incubated for 24h at 37ºC and 5% 
CO2. 
3. The cells were washed with PBS prior to staining with crystal violet solution.  
4. One milliliter of crystal violet dye was added into each well and incubated in room 
temperature for 20 minutes.  
5. The cells were carefully washed three times with PBS.  
6. The crystal violet dye was then solubilised with 1ml of 1%SDS solution, followed by 
gentle shaking for 30minutes.  
7. The absorbance was then measured using microplate reader at 595 nm. 
 
A13.2. MTS Cell Proliferation Assay 
The CellTiter 96® AQueous One Solution Reagent from Promega contains a tetrazolium 
compound [MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] and an electron coupling reagent (PES: phenazine 
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ethosulfate). PES can combine with MTS to form an insoluble formazan product which 
has a purple color. The quantity of formazan product measured at 490nm absorbance is 
directly proportional to the number of living cells. 
1. 50µL of complete media was added to 96-well plate and equilibrated in 37ºC, 5% 
CO2 incubator for 30 minutes.  
2. 5000 cells in 50µL were seeded in complete medium to the equilibrated 96-well plate. 
3. The MTS colorimetric assay was performed by adding 20mL of the CellTiter 96 
AQueous One Solution Reagent directly to 96 wells plate containing 100µL of culture 
media. 
4. The cells were incubated for 3 hours in humidified, 37ºC, 5% CO2 atmosphere. 
5. Absorbance was measured at 492nm with the microplate reader. 
 
A13.3  Ki-67 Assay 
Ki-67 is a nuclear antigen that is expressed in the late G1, S, M, and G2 phases of the cell 
cycle, but is absent from non-proliferation cells (G0 phase). The expression of the Ki-67 
protein has been associated to cell proliferation. Hence, the fraction of cells that stain 
positive for the Ki-67 nuclear antigen is a highly accurate method of assessing the 
fraction of proliferating cells. 
1. A monolayer of scrambled shRNA and shTG cells were scratched as described in 
Appendix A14.4. 
2. After scratching the monolayer, the cells were washed twice with PBS. 
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3. Fresh DMEM-F12 media with 5% FBS was added to the wells containing the 
scratched monolayers. 
4. The cells were incubated in humidified chamber for 6 hours at 37oC, 5% CO2. 
7. As described in Appendix A10.1, cells were fixed with 4% paraformaldehyde (PFA) 
in PBS for 15 minutes. 
8. The slides were washed twice with PBS.  
9. The cells/tissues were then permeabilised with 0.1% of Triton X-100 in PBS for 10 
minutes.  
10. This is followed by 3x 5minutes washing with PBS.  
11. Blocking was performed with 1.5% BSA in PBS for 1hour in humidified chamber. 
12. Excess blocking buffer was tapped off from the slides.  
13. The slides were then incubated with anti-Ki-67 (1:40. Appendix B) in 1.5% of BSA 
for 2 hours at room temperature in humidified chamber.  
14. Washing was done 3x 5minutes with PBS. 
15. Secondary antibody in 1% BSA in PBS was added to the slides at room temp for 1 
hour in moist chamber. 
16. Washing was done 3x 5minutes with PBS. 
17. To stain the nucleus, the cells/tissues were incubated with Dapi in PBS (1:1000) for 
10 minutes. 
18. The slides were rinsed 3x with PBS 
19. The slides were then mounted with 10µL of mowiol.  
20. A coverslip was added on top of the glass slide. The side of the coverslip were sealed 
with transparent nail polish. 
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21. Slides were then observed under a microscope and fluorescent images were captured  
22. Positively-stained cells (green) within contiguous cells of a confluent area were 
counted 3 times in each cell type. 
 
A13.4  Cell Cycle Analysis 
1. 4×105 cells were cultured for 2 days.  
2. Non-adherent and trypsinised cells were pelleted as described in A1.3. 
3. Cells were re-suspended in 500μL PBS, transferred drop by drop to 4.5 mL of chilled 
70% ethanol while gently vortexing and incubated in ethanol overnigh at 4ºC. 
4. The cells were pelleted and resuspended in 5mL PBS at room temperature for 1 
minute. 
5. The cells were pelleted again by centrifugation and re-suspended in 200µL of 
GUAVA cell cycle reagent.  
6. This is followed by 30 minutes room temperature incubation before analysis by mini-




A14.  Cell Adhesion and Migration Assay 
A14.1.  Cell Impedance 
Xcelligence system (Roche Applied Science, Basel, Switzerland) measures cell 
proliferation by detecting the changes in impedance. The local ionic environment at the 
electrode/solution interface changes with the presence of cells on top of the electrodes. 
The impedance increased with increasing number of cells, displayed as cell index (CI) 
values. In addition, the quality of interaction between cells and electrodes can affect cell 
impedance. Hence, electrode impedance can be used to monitor cell viability, number, 
morphology, and adhesion degree in cell-based assays (Figure A8). 
 
 
Figure A8. Diagram showing the electrode impedance in the Xcelligence system 
increases with increasing cell numbers and cell adhesion strength. 
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1. Five thousand cells were seeded in 200µL of cell culture media in each well of a 96-
well plate, in quadruplicate.  
2. The cells requiring hyperosmolar stimulation were seeded in fresh hyperosmolar 
media as described in A3.2. 
3. Cell proliferation was monitored over 1 week. 
 
A14.2.  Trypsinisation Assay 
1. Adherent cells at confluency of 50-60% were washed once with PBS. 
2. The cells were incubated with PBS-diluted 0.005% Trypsin-EDTA at 37 °C, 5% CO2 
for 1 hour.  
3. Photographs were taken periodically without mechanical perturbation. 
 
A14.3. Real Time Cell Migration Assay 
1. Scrambled shRNA or shTG cells were seeded in a 6mm (inside diameter) x 8mm 
(outer diameter) x 5mm (height) detachable culture glass cylinder filled with 100µL 
5% DMEM-F12 supplemented medium.  
2. After overnight incubation, the culture cylinder was removed.  
3. The monolayer was washed with twice PBS to remove cell debris.  
4. Fresh medium was added and cell migration was recorded every 10 minutes for 100 
frames (around 16 hours).  
5. The centroid positions of 50 randomly selected contiguous cells at the advancing 
edge, tracked every 10 min over 16 h by live cell time-lapse microscopy.  
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6. Cell centroids were computed after manually outlining cells using ImageJ software. 
Initial cell positions were normalised to plot origin.  
7. The details of the ImageJ analysis is at Appendix A18.2 
 
A14.4. Scratched Wound Assay 
1. Scrambled shRNA or shTG cells were seeded in uncoated or fibronectin-coated 6-
well tissue culture plates and grown for 24 hours to produce a confluent monolayer of 
cells. The cells were submerged in DMEM-F12 supplemented with 5% FBS, at 37
o
C, 
5% CO2 atmosphere.  
2. After removing the medium, the monolayer was washed once with PBS.  
3. Straight scratches were made with a 1 mL blue pipette tip.  
4. After scratching, the monolayer was washed twice with PBS to remove cell debris.  
5. Re-epithelialization of the denuded area was determined using ImageJ software from 
images captured at fixed positions every 2 hour for 14 hours. 
6. The details of the ImageJ analysis is at Appendix A18.2 
 
A14.5. Cell Area Measurement 
1. shTG or scrambled shRNA cells were cultured on uncoated or fibronectin-coated 
dishes with serum supplemented medium until 80% confluency. 
2. The cells were washed twice with PBS. 
3. Serum-free medium was added and incubated overnight. 
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4. The cells were seeded into uncoated or fibronectin precoated 8-well chamber slides 
and incubated overnight.  
5. Using ImageJ software (National Institute of Health, USA), cell boundaries including 
cytoplasmic protrusions of non-overlapping cells were outlined manually on captured 
images (20× magnification, Axioplan 2 fluorescence microscope, Carl Zeiss, 
Oberkochen, Germany) and cell area was measured. Nuclear boundaries of the same 
cells were drawn to calculate nuclei areas. 






A15.  Animal Work 
A15.1. Mouse Model  
Mice were handled according to guidelines in the Association for Research in Vision and 
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research 
and protocols approved by the Institutional Animal Care and Use Committee of 
SingHealth. Heterozygous TG-2-deleted mice (Tgm2
tm1.1Rmgr
) originally on a mixed 
C57BL/6J-129S1/SvImJ strain background were established as previously described [46]. 
These heterozygous TG-2 deleted mice were backcrossed more than 12 generations to 
C57BL/6J to produce congenic heterozygote (TG-2
+/−
) mice. The heterozygous TG-2
+/-
 










A15.2.  Assessing Corneal Wound Healing in Mouse 
1. Mice were anesthetized by intra-peritoneal injection of ketamine hydrochloride 
(2mg/g body weight) and xylazine (0.4mg/g body weight).  
2. Hind limb toe pinching was done to monitor the depth of anesthesia.  
3. A trephine with diameter in 2mm was used to mark the central cornea.  
4. The epithelium was peeled off using a forcep under a dissecting microscope.  
5. Wound healing was accessed by instilling 10µL of fluorescein staining for 5 seconds 




6. Excess fluorescein dye was rinsed off with sterile saline for 1 minute.  
7. Digital camera photography was done in cobalt blue light with ultraviolet lightfilters.  
8. Wound area was determined by the fluorescein staining and expressed as a percentage 






A16.  In vitro Label Free Protein Interaction Assay 
1. Recombinant paxillin protein (Biolegend, 0.15ug/ul) was thawed on ice. 
2. PBS pH4.3 and PBS pH7.5 were prepared. 
3. 100uL of paxillin was mixed with 200uL of PBS pH7.5. 100uL of paxillin was mixed 
with 200uL of PBS pH4.3. The final concentration of paxillin in PBS is 0.05ug/uL. 
4. 12uL of Pax-PBS 7.5 and Pax-PBS 4.3 was aliquoted into designated well.  
5. Quick spin was performed on the micro plate. 
6. The plate was sealed with PCR plate seal, followed by overnight incubation at 4°C. 
7. The next day, vinculin (Abnova), TG-2 (R&D) and Integrin α5 β3 (R&D) 
recombinant protein were thawed. 
8. The proteins were dilute with PBS pH7.5 to designated concentration 
TG-2 at 0.1, 0.05 and 0.01ug/uL 
Integrin αV β3 at 0.1, 0.05 and 0.01ug/uL 
Vinculin at 0.07, 0.035, 0.01ug/uL 
9. Quick spin was performed on the micro plate. 
10. The solution in the micro plate was removed by gently tapping the plate on tissue 
papers. 
11. The micro plate was washed 3x with 30uL of PBS pH7.5. After every wash, the 
solution in the plate was removed by gently tapping the plate on tissue papers. 
12. 15uL of PBS pH7.4 was added into each well. The micro plate was then spinned 
down. 
13. This is then followed by incubation of the micro plate in the Enspire Multimode Plate 
Reader (Perkin Elmer, MA, USA) at 27°C for 2 hours. 
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14. 15uL of recombinant protein was added into each well. 
15. Quick spin was performed on the micro plate. 
16. The micro plate was read using the Enspire Multimode Plate Reader. 
17. 15uL of the next proteins was added to each well.  
TG-2 at 0.0067ug/uL 
Integrin αV β3 at 0.1ug/uL 
Vinculin at 0.0067ug/uL 
18. Quick spin was performed on the micro plate. 






A17.  In vitro Kinase Assay 
These experiments were outsourced to ProQinase GmbH, Freiburg, Germany. 
 
A17.1.  TG-2 Intrinsic Kinase Activity Assay 
The ability of the putative protein kinase TGM2 to phosphorylate Paxillin was 
determined in an in vitro kinase activity assay experiment in comparison to the protein 
kinase JNK1 and the phosphorylation of Histone H1 by CDK2-CyclinE1 complexes. 
1. The following buffers were prepared: 
Standard Assay Buffer (2.5x stock) 
125 mM HEPES-NaOH, pH 7.5  
7.5 mM MgCl2 
7.5 mM MnCl2 
7.5 µM Na-orthovanadate  
2.5 mM DTT 
 
Kinase Dilution Buffer (10x stock)  
500 mM HEPES-NaOH, pH 7.5  
2.5 mg/ml PEG20.000  
10 mM DTT 
 
2. Reaction mixture was pipetted into a 1.5ml Eppendorf cups in the following order:  
10 µL of 2.5x Standard Assay Buffer  
7.5µL Substrate in 50mM HEPES pH7.5 
5µL Recombinant kinase in 1x Kinase Dilution Buffer 
2.5µL ATP + tracer (
32
P-γ-ATP in H2O approx 4.5*10
6
 cpm/sample) 
Total volume is 25µL and the final assay concentration of ATP was 10µM. 
 
3. The samples were mixed and incubated at 30°C for 60 mins.  
4. The reaction was stopped by addition of 10µL 4x SDS sample-buffer and incubation 
at 95°C for 5 mins. 
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5. 20µL of the samples were loaded on a 4-12% Bis-Tris polyacrylamid gel and 
analysed by electrophoresis.  
6. The gel was stained with colloidal coomassie solution for visualisation of protein 
loading and dried. For visualisation of transferred radioactive phosphate the gel was 
exposed to X-ray film (Kodak BioMax MR) for various periods of time.   
 
A17.2.  In vitro Autoradiographic Kinase Assay 
1. A reaction cocktails was prepared as follows:  
60mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3mM MnCl2, 3μM Na-orthovanadate, 
1.2mM DTT, 50μg/ml PEG20000, 1μM ATP/[γ-33P]-ATP (8. x 1005 cpm per well), 
protein kinase (1-400 ng/50μl) and sample protein (5 μg/50 μl).  
2. The reaction cocktails were pipetted into a 96 well, V-shaped polypropylene plates in 
the following order:  
10 μl of kinase solution  
40 μl of buffer/ ATP/ test sample mixture  
3. One well of each plate was used for a control containing no enzyme.  
4. The assay plates were incubated at 30°C for 60 minutes.  
5. The reaction cocktails were stopped with 20 μl of 10% (v/v) H3PO4.  
6. The reaction cocktails were transferred into 96-well glass-fiber filter plates, pre-
wetted with 150 mM H3PO4, followed by 10 min incubation at room temperature.  
7. The filter plates were washed 3x with 250 μl of 150 mM H3PO4 and 1x with 20 μl of 
100% ethanol.  
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8. The plate was dried for 30 min at 40°C 
9. 50 μl of scintillator (Rotiszint Eco plus, Roth) were added to each well  
10. The incorporation of 33Pi (“counting of cpm”) was determined with a microplate 
scintillation counter (Microbeta, Perkin Elmer).  
11. The autophosphorylation activity of each kinase had previously been determined in 
two independent experiments  
12. The mean autophosphorylation values (in cpm) had been calculated for each kinase at 
a given input of radioactivity. These autophosphorylation values were normalised to 
the counts used in the current experiment and subtracted from the corresponding raw 
data obtained with each kinase.  
13. The background value of the protein sample (mean of two singlicate measurements) 





A18.  Analysis 
A18.1.  Statistical Analysis 
For continuous variables, all results shown are means ± SD. Statistical differences for cell 
areas were determined by ANOVA with post-hoc comparisons where the ANOVA is 
significant. The general linear model (GLM) procedure was used (SPSS, Inc.) for the 
evaluation of velocity of cell migration and gap width inin vitroscratch assays. The post 
hoc test option in the GLM procedure was used to evaluate for significant differences 
between the 4 conditions (cells with scrambled shRNA and shRNA targeting TG2, either 
with or withoutfibronectin), p values adjusted for multiple comparisons were evaluated 
for statisti-cal significance. For categorical variables, proportions (e.g.proportions of 
positively-labeled Ki-67 cells) were compared using the Chi square test, with p≤0.05 
being considered significant.  
 
A18.2.  ImageJ Analysis 
A.  Loading 
1. Image was loaded by clicking at: plugins > input-output > ICS/IDS 
2. Video was loaded by clicking: file > open > file is in .ics format 
3. Previous saved tracks were loaded by clicking:  plugins > MTrackJ > load tracks > 
tracks are in mdf format 




B.  Cell Area Measurement 
5. Before starting measurement, a scale bar was drawn to match the ruler in the image, 
followed by clicking: analyse > set scale > value came out in um 
6. Image properties were checked at: Image > properties > unit of length “um” > pixel 
width “0.6468750” > OK 
7. After changing the properties, each pixel was made sure to have 0.6468750um (for 
10x magnification) (20x magnification, 1 pixel= 0.323µm).  
8. Image properties need to be changed every time a new image was opened because the 
measurement by default is in pixel 
9. The tab “polygon selection” was selected, followed by outlining the border of the 
cells 
10. Measurement of cell area was done by clicking: Analyse > measure 
 
C.  Tracking cells 
11. The resolution of original picture is 1280 x 960 pixels 
12. Before starting tracking cells, the image properties need to be changed by clicking: 
Image > properties > unit of length “um” > pixel width “0.6468750” > frame interval 
“10 min” >OK 
13. After changing the image properties, each pixel is 0.6468750um. Each frame when 
tracking must be in 10 min interval, usually total frame is >= 145 frames.  
14. The cells were magnified before tracking. 
15. The centre of the cells was tracked instead of the dots in the cells. 
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16. New tracks were added by clicking: plugins > MTrackJ > add tracks 
17. To tracking setting was set as follows: check “move to next time index after adding 
points”, “finish track after adding point at last time index”.  
18. The display properties of the track at “configure displaying” can be changed. If there 
are multiple tracks which block the sight of next cells while tracking, the finished 
track can be hided: configure display > uncheck display finished track 
19. The width of line can be changed: configure display > track width > 0 
20. Different tracks can be assigned into the same cluster for future analysis. This will 
change the numbers and colour of the tracks. This is usually done after finishing all 
the tracks: cluster track > ctrl+ right click > right click > OK 
21. To continue previous track: Continue tracks > add tracks 
 
D.  Save Files 
22. File was saved by clicking: Save tracks 
23. For the track files, it is a small file. The track file was changed to “.mdf” format. 
 
E.  Measuring Cell Tracks 
24. Click “measure tracks” > display track, display points 
 
F.  Measure the Distance between First and Last Frame 
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25. Frame numbers was reduced by clicking: plugins > stacks > stack reducer (only first 
and last frame left). There are 2 ways to calculate length:  
26. A) Using line drawing method: draw a straight line > connect first and last frame with 
straight line > press “ctrl + m” to measure > move straight line down the picture > 
get 10 measurements > get average 
27. B) Plugin > analyse >grid > lines > 1000 pixels^2 > using multi tool, place dots on 
horizontal line > measure > On the same horizontal line, the corresponding points 







A18.3.  Cell Oscillation Analysis 
This cell oscillation analysis program was written by our collaborator Dr Earnest Mendoz 
from National University of Singapore. The cell track of a migrating cell was tracked 
using ImageJ as described in the Material and methods of Appendix A18.2C. The 
software will measure the cell oscillation by generating a directionality line that joins the 
origin of the cell track to its end point, the displacement of each cell from the 
directionality line was measured (Figure A9, green arrow). Mean of oscillation is the 
mean displacement of all the frames for each cell within certain time interval.  
 
 
Figure A9. Diagram illustrates the theory behind the cell oscillation analysis software.   
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number) Dilution Species Source
Transglutaminase-2 ab421 1: 50 (IF
a
) Rabbit Abcam









Phospho-β1 integrin (S785) ab5185 1: 200 (western) Rabbit Abcam








Phospho-FAK (Tyr576) #07-157 1: 150 (western) Rabbit Millipore
Phospho-FAK (Tyr925) #3284 1: 500 (western) Rabbit Cell Signaling
Integrin β3 ab34409 1: 400 (western) Mouse Abcam
Integrin β1 MAB1965 1: 200 (western) Mouse Millipore
Vinculin clone hVIN-1 V4505 1: 400 (western) Mouse Sigma
Paxillin P1093 1: 500 (western) Mouse Sigma
FAK 610087 1: 200 (western) Mouse BD Biosciences
Talin T3287 1: 500 (western) Mouse Sigma
β-Actin ab8227 1: 1000 (western) Rabbit Abcam
β-Actin A5441 1: 5000 (western) Mouse Sigma
Cytochrome C 556433 1: 1000 (western) Mouse BD Biosciences Pharmingen
Manganese superoxide dismutase (MnSOD) 611580 1: 500 (western) Mouse BD Biosciences Pharmingen
Anti-mitochondrial intramembrane cleaving protease (PARL) sc-98994 1: 200 (western) Rabbit Santa-Cruz Biotechnology
Anti-Trk C (NTRK3) sc-14025 1: 200 (western) Rabbit Santa-Cruz Biotechnology
Mesotrypsinogen (PRSS3) sc-47127 1: 200 (western) Goat Santa-Cruz Biotechnology
Rho GTPase activating protein (ARHGAP)-17 sc-160145 1: 200 (western) Goat Santa-Cruz Biotechnology
Desmin (DES) sc-34201 1: 200 (western) Goat Santa-Cruz Biotechnology
Unc 18-2 (STXBP2) sc-23014 1: 200 (western) Goat Santa-Cruz Biotechnology
Glutamate receptor ionotropic kainate (GRIK)2 sc-26478 1: 200 (western) Goat Santa-Cruz Biotechnology
ELKS/RAB6 interacting/CAST family member (ERC)2 sc-70271 1: 200 (western) Goat Santa-Cruz Biotechnology
Golgi-associated protein (GOLGA)2 sc-16268 1: 200 (western) Goat Santa-Cruz Biotechnology
GLI family zinc finger (GLI)-1 sc-6153 1: 200 (western) Goat Santa-Cruz Biotechnology
Golgin 160 (GOLGA3) sc-79966 1: 200 (western) Goat Santa-Cruz Biotechnology
Integrin beta (ITGB) 4 sc-6629 1: 200 (western) Goat Santa-Cruz Biotechnology
Human immunodeficiency virus type I enhancer binding protein (HIVEP)2 sc-10682 1: 200 (western) Goat Santa-Cruz Biotechnology
Anti-human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2) sc-68482 1: 200 (western) Rabbit Santa-Cruz Biotechnology
Centrosome-associated protein (CEP) 350 NB-100-59811 1: 200 (western) Rabbit Novus Biological 
Anti-mouse IgG (whole molecule) FITC F2012 1: 800 (western) Goat Sigma
Anti-rabbit Alexa Fluor 488 A11070 1: 800 (western) Goat Invitrogen
Anti-mouse HRP A9044 1: 5000 (western) Goat Sigma
Anti-rabbit HRP A0545 1: 5000 (western) Goat Sigma
Anti-goat IgG F7367 1: 400 (western) Mouse Sigma
Anti-MAP3K12 mAb LS-C158096 1: 800 (western) Mouse LSBio
Protein disulphide isomerase (PDI) (F-11) sc-166474 1: 200 (western) Mouse Santa-Cruz Biotechnology
Lysosomal associated membrane protein (LAMP)-1 (H5G11) sc-18821 1: 200 (western) Mouse Santa-Cruz Biotechnology
Early endosome antigen (EEA)1 E3906-200UL 1: 200 (western) Rabbit Santa-Cruz Biotechnology
RAB7 R4779-200UL 1: 200 (western) Rabbit Santa-Cruz Biotechnology




 Although called integrin beta 3-phospho-Y773 antibody in manufacturer's catalog, it refers to the same tyrosine residue because amino acid counting from 
N terminus of propeptide.
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Appendix C. List of Reagents and Chemicals 
Item Product Number Company Country of Origin
SuperScript® III Reverse Transcriptase 18080051 Life Technologies CA, USA
Random Hexamers N8080127
Dulbecco’s modified Eagle medium: nutrient mixture F12 (DMEM-F12)1320-033
Fetal bovine serum (FBS) 16000-044
Puromycin A1113802
Penicillin-Streptomycin 15140148
Lipofectamine Plus Reagent 15338-100
MitoProbe™ JC-1 Assay Kit for Flow Cytometry M34152
Neon 100 μL Transfection Kit MPK10096
GUAVA cell cycle reagent 4500-0220 Millipore MA, USA
Culture glass cylinder Bioptechs PA, USA
Phosphate Buffered Saline (PBS) SH30256.01 GE Healthcare NJ, USA
Dimethyl sulfoxide (DMSO) 472301 Sigma MO, USA
RIPA buffer R0278-50ML
Protease inhibitor cocktail S8820
Trypsin–EDTA T4174-100ML
Tryphan blue T8154-20ML
Pan-caspase inhibitor Z-VAD-FMK V116-2MG
Mitochondrial extraction buffer (MSHE) A MITOISO1-1KT
Polybrene 107689
Purified pig liver TG-2 T5398-1UN
Bovine Serum Albumin A9418-500G
Paraformaldehyde P6148-500G
pSG5 vector 216201 Stratagene CA, USA
phrGFPII-N plasmids 240145
Sodium chloride (NaCl) 1.16224.9011 Merck Darmstadt, Germany
ProteoExtract-All-In-One Trypsin Digestion Kit 650212
BCA protein assay kit 23225 Pierce Biotechnology IL, USA
Supersignal West Pico chemiluminescent substrate 34077
Supersignal West Dura chemiluminescent substrate 34075
Supersignal West Femto chemiluminescent substrate 34094
Nitrocellulose membrane 162-0115 Bio-Rad Laboratories CA, USA
Non-fat milk powder 170-6404XTU
Beta-mercaptoethanol 161-0710
4–20% pre-cast SDS-polyacrylamide gel 456-1096
Triton X-100 161-0407 
Tween 20 170-6531
LB Agar powder 166-0472EDU
LB broth pellet 166-0412
CellTiter 961 AQueous Non-Radioactive Cell Proliferation Assay G3582 Promega WI, USA
Caspase-Glo 3/7 caspase activity kits G8090
Caspase-Glo 9 caspase activity kits G8210
TG colorimetric assay kit opr0001 CovaLab Lyon, France
Crystal violet staining solution C581-25 Fisher Scientific NJ, USA
10x Tris-buffered saline BUF-3030-10X4L 1st Base Singapore
0.1M EDTA BUF-1051-500ml-pH7.4
Water, DEPC treated BUF-1170-1L
GradiSpec Discovery Reagent Kits PB
‐
203D Prospect Biosystem NJ, USA
Fibronectin precoated 8-well chamber slides EW-13004-28 BD Bioscience MA, USA
Phosphatase inhibitors 4906845001 Roche Basel, Switzerland
Rac1 G-LISA Activation Assay BK126 Cytoskeleton Denver, USA
RhoA G-LISA Activation Assay BK121
Cdc42 G-LISA Activation Assay BK127
Phalloidin, Alexa Fluor 568 A12380 Molecular Probes Basel, Switzerland
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Figure A10. β3 integrin is expressed in cultured human corneal epithelial cell (HCE-T) 
and primary human limbal epithelial cells. (A) Representative western blots images of 
cultured HCE-T and primary human limbal epithelial cell lysate probed with primary 
antibodies against β3 integrin phosphorylated at Tyr747 (pTyr747 β3 integrin) and total 
β3 integrin. (B) Bar chart showing normalised values of β3 integrin transcript detected by 
gene chip. This intensity had been normalised to the median probe signal of all transcripts 
(> 23,000 genes) in Affymetrix microarray chip U133A for human genes (n =14 
independent samples of cultured HCE-T cells and primary limbal epithelial cells grown 
from different donors).   
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Figure A11. 190 Ser/Thr kinase assays showing activity values (in cpm) with 5µg of 
paxillin. Yellow: Kinase with substrate; blue: Kinase autophosphorylation.   
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